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ABSTRACT 
 
Structural-functional diversity of proteoglycans is the pivot of their biological importance during 
the embryonic development, in the adult and also in pathological conditions such as cancer. 
proteoglycans may be involved in different cell behavior by binding and modulating a broad 
spectrum of growth factors. In particular, among proteoglycans, glypicans are listed as both tumor-
inhibitors and promoters and seems to be closely tumor-type specific. Our study on glypican 5 in a 
particular soft tissue sarcoma, human osteosarcoma, support the hypothesis that this molecule may 
be considered as a tumor-suppressor, inhibiting cancer cell growth and motility. 
Glycosaminoglycans participate to many of the proteoglycan biological processes and their 
functional complexity is in part due to their structural and chemical characteristics. For this reason 
we decided to investigate two particular glycosaminoglycan chains, highly sulfated heparan sulfate 
moieties and a specific keratan sulfate structure, using the monoclonal antibody technique. Our goal 
is to understand the correlation between the chemical structures of these moieties and their 
distribution in the human adult tissues. These may be the first steps in the comprehension of  the 
structural-functional relationship of proteoglycans that could be considered as an attractive target 
for therapeutic intervention in different pathological conditions. 
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ABBREVIATIONS 
AchR acetylcholine receptor 
ADAM A disintegrin and metalloproteinase 
AIS axonal initial segment 
APC antigen presenting cells 
BBB blood brain barrier 
b FGF basic fibroblast growth factor 
BMP bone morphogenic protein 
BMPR bone morphogenic protein receptor 
BKHS bovine kidney heparan sulfate 
BSA bovine serum albumin 
BWS Beckwith Wiedermann Syndrome 
C4-BP C4-binding protein 
CHO Chinese Hamsted ovary 
CS chondroitin sulfate 
Dlp Dally-like protein 
DMEM Dulbecco’s modified Eagle’s 
medium 
DS dermatan sulfate 
ECM extracellular matrix 
EGF epidermal growth factor 
EGFR epidermal growth factor receptor 
ERM ezrin/radixin/moesin 
FAK focal adhesion kinase 
FBS fetal bovine serum 
FGF fibroblast growth factor 
FGF-BP fibroblast growth factor-binding 
ptotein 
FGFR fibroblast growth factor receptor 
FITC fluorescin isothiocyanate 
Fz Frizzled 
GAG glycosaminoglycan 
GDF growth differentiation factor 
GM-CSF granulocyte macrophage-colony 
stimulating factor 
GPC glypican 
GPI glycosyl phosphatidyl inositol 
Ha hyaluronan 
HA hemagglutinin 
HB-GAM heparin-binding growth-associated 
molecule 
Hep heparin 
HGF hepatocyte growth factor 
HGFR hepatocyte growth factor receptor 
HGF/SF hepatocyte growth factor/scatter 
factor 
HNSCC head and neck squamous cell 
carcinoma 
HRP horseradish peroxidise 
HS heparan sulfate 
IGF insulin-like growth factor 
IGFR insulin-like growth factor receptor 
IL-8 interleukin-8 
KS keratan sulfate 
LDL low density lipoprotein 
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LRR leucine rich region 
MAPK mitogen-activated protein kinase 
MASC myotube-associated specificity 
component 
MMP metalloprotease 
MuSK muscle-specific tyrosin kinase 
NFkB nuclear transcription factor-kappa B 
NGS normal goat serum 
NMJ neuromuscular junction 
PG proteoglycan 
PDGF platelet-derived growth factor 
PDGFR platelet-derived growth factor 
receptor 
PE phycoerythrin 
PIHS porcine instinal heparan sulfate 
PKC protein kinase C 
SD syndecan 
SGBS Simpson-Golabi-Behemel Syndrome 
Shh Sonic hedgehog 
ShS sheep serum 
SMC smooth muscle cell 
TAFI thrombin activatable fibrinolysis 
inhibitor 
TGFβ transforming growth factor β 
TGFβR transforming growth factor β receptor 
TMA tissue macroarray 
TNF tumor necrosis factor 
TRITC tetrametyl rhodamine isothiocyanate 
VEGF Vascular endothelial growth factor 
VEGFR Vascular endothelial growth factor 
receptor 
VLDL very low density lipoprotein 
WISP-1 Wnt1 inducible signaling pathway 
protein 
Wg Wingless 
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Proteoglycans are macromolecules composed of a central protein structure substituted with 
covalently attached glycosaminoglycan chains. GAGs may be divided in three main families: 
heparin/heparan sulfate, chondroitin sulfate and its epimerized homolog dermatan sulfate and 
keratan sulfate. Inside these families there are different subtypes on the basis of the chemical 
structure and the tissue localization (Tab.1). All GAGs are characterized by disaccharide 
units repetition, in particular acetylated hexosamine (N-acetyl-galactosamine or N-acetyl-
glucosamine) and uronic acids (D-glucuronic acid or L-iduronic-acid). Only keratan sulfate 
is comprised of N-acetyl-glucosamine and galactose unit [Theocharis et al., 2010]. The 
linkage of GAGs to the core protein involves a specific tetrasaccharide of two Galactose 
residues and a Xylose residue, coupled to the core protein through an O-glycosidic bond to a 
serine residue except for KS type I that is linked to the core protein through an N-asparagine 
bond. GAGs may be modified at various positions by  sulfation, epimerization and 
acetylation. Size and ratio of the GAG chains may change with development, aging or during 
particular pathological conditions [Hardingham and Fosand, 1992]. There is no an unifying 
structural feature to form a unique and knowable PG family. This is due to the fact that many 
PGs have structural forms and sequences similar to those found in other protein families. In 
the past different PG classifications were done, on the basis of their localization and the type 
and number of GAG chains attached, the size, the modular composition or the gene 
homology. A new classification is here proposed on the basis of PG structural characteristics 
(Tab.2). PGs function as coreceptor for different ligands and at first it was believed that PG 
functions could be related exclusively to the presence of the GAG chains. The capacity of 
GAG chains to differently bind molecules involved in cell-cell and cell-matrix adhesion, cell 
proliferation and cell motility, appears to be charge-dependent because it is determined by 
the degree of sulfation of the chain. Another important parameter that influences PG binding 
capacity is the number and the size of the GAG chains attached to the core protein 
[Ruoslahti, 1989]. Now the PG family includes different molecules that may exist in 
glycosylated or unglycosylated isoforms, or moleculs that are considered as PG also if they 
are free of any glycosylation. For this reason the attention of researcher now become to move 
toward a new way of visualization of this macromolecule family. It becomes increasingly 
important to focus also the structural and functional characteristics of the core protein. In the 
next section it will follow a large study on the PG ligands and the related functions with a 
particular attention to the sites which are directly responsible for the binding.  
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GAG Size range Core protein linkage Disaccharide structure 
Heparin 10-17 disaccharide 
units 
 
  
HS 10-17 disaccharide 
units 
 
 
CS-A More than 100 
disaccharide units 
 
 
CS-B/DS 
 
More than 100 
disaccharide units 
 
 
CS-C More than 100 
disaccharide units 
 
 
CS-D More than 100 
disaccharide units 
 
 
CS-E More than 100 
disaccharide units 
 
 
KS-I 8-9 disaccharide units 
  
KS-II 5-11 disaccharide units 
 
 
KSIII 5-11 disaccharide units 
 
 
Table 1. GAG species and their structural characteristics 
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PG class 
 
PG name 
Core 
protein size 
(kDa) 
Chromosomal location 
Number and type of 
GAG chain  
Human gene 
designation Human mouse 
Matrix-associated       
Basement membrane Perlecan 400 1p36.1-p34 4 3 HS/CS HSPG2 
 Agrin 220 1p36.33 4 3-6 HS AGRN 
 Leprecan 82 1p34.1 4 1-2 CS LEPRE1 
 Bamacan 138 10q25 19 3 CS SMC3 
Hyaluronan-binding Versican 74-370 5q14.3 13 no GAGs/ 5-17 CS CSPG2 
 Neurocan 135 19p12 8 1-2 CS NCAN 
 Aggrecan 250 15q26.1 7 50-100 CS/KS ACAN 
 Brevican 96 1q31 3 no GAGs/  1-3 CS BCAN 
Collagen-binding  Opticin 90 1q32.1 1 HS/CS OPTC 
 Lumican 38 12q21.3-q22 10 2-3 KS  LUM 
 Decorin 42 12q21.3-q23 10 1 DS/CS DCN 
 Biglycan 38 Xq28 X 1-2 DS/CS BGN 
Table 2. Rivisited PG nomenclature based upon combined GAG and core protein structural-functional traits 
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 Epiphycan 36 12q21 10 2 CS/DS EPYC 
 Keratocan 37 12q22 10 KS KERA 
 Fibromodulin 42 1q32 1 4 KS  FMOD 
 Mimecan/ 
osteoglycin 
34 9q22 13 KS  OGN 
 Osteoadheri/osteomo
dulin 
47 9q22.31 13 KS  OMD 
 Asporin 45 9q22 13 no GAGs ASPN 
 PRELP 58 1q32 1 no GAGs PRELP 
Interstitial Chondro-adherin 36 17q21.33 11 no GAGs  CHAD 
 Bikunin 25 9q32-q33 n.d. 1 CS AMBP 
 Testican1/ 
osteonectin 
44 5q31.2 13 1-2 HS/CS SPOCK1 
 Testican2/ 
osteonectin 
44 10pter-q25.3 10 1-2 HS/CS SPOCK2 
 Testican3/ 
osteonectin 
44 4q32.3 8 1-2 HS/CS SPOCK3 
 Endocan 20 5q11.2 13 1 DS ESM1 
Neural  Interphoto receptor1 135 6q14.2-q15 9 N.D. IMPG1 
 Interphoto receptor2 135 3q12.2-q12.3 16 N.D. IMPG2 
11 
 
 Neuroglycan C 60 3p21.3 9 no GAGs/ 1CS      CSPG5 
 Phosphacan 175 7q31.3 6 2-5 CS PTPRZ1 
Cell surface anchored  Glypican 1 57-69 2q35-q37 1 1-3 HS GPC1 
 Glypican 2 57-69 7q22.1 5 1-3 HS GPC2 
 Glypican 3 60 Xq26.1 X 1-3 HS GPC3 
 Glypican 4 57-69 Xq26.1 X 1-3 HS GPC4 
 Glypican 5 65 13q32 14 1-3 HS/CS GPC5 
 Glypican 6 60 13q32 14 1-3 HS GPC6 
Transmembrane  Syndecan 1  33 2p24.1 12 1-2 HS/1-3 CS SDC1 
 Syndecan 2  23 8q22-q23 15 1-2 HS/1-3 CS SDC2 
 Syndecan 3 43 1pter-p22.3 4 1-2 HS/1-3 CS SDC3 
 Syndecan 4 22 20q12 2 1-2 HS/1-3 CS SDC4 
 CD44 90-250 11p13 2 no GAGs/ HS/CS CD44 molecule 
 NG2/CSPG4 300 15q24.2 9 1 CS NG2 
 SV2 80 1q21.2 N.D. KS  SV2A 
 Betaglycan 110 1p33-p32 5 1 HS/CS/ DS TGFBR3 
Intracellular  Serglycin 18 10q22.1 10 10-15 Hep or HS/CS SRGN 
Hybrid Collagen type IX 65 6q12-q14 1 no GAGs/ 1CS COL9A1 
12 
 
 Collagen type XV 225-250 9q21-q22 4 1-4 HS/CS COL15A1 
 Collagen type XVIII 180-200 21q22.3 10 3 HS COL18A1 
 Thrombomodulin 57 20p11.2 2 no GAGs/ 1CS THBD 
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PG GAG Core Protein 
Perlecan FGFs, PRELP, VEGF, PDGF, 
FGFR3, bFGF 
Laminin, collagen type IV, collagen type 
XVIII, fibronectin, thrombomodulin, 
fibrillin-1, PRELP, FGF7, FGF18, FGF-
BP, N-CAM, nidogens, fibulin 2, α2β1 
integrin,  α-dystroglycan, LDL, VLDL 
Agrin N.D. α-dystroglycan, laminins 1,2 and 4, 
PDGF, TGFβ, MASC, acetylcholine 
receptor 
Leprecan N.D. Collagens 
Bamacan N.D. Histone deacetylases, acetyltransferases 
Versican P-selectin, L-selectins, chemokines, 
CD44, β1 integrin, EGFR, toll-like 
receptor 2 
Hyaluronan, lectins, fibronectin, collagen 
type I, β1 integrin, tenascin R, fibulin 1, 
fibulin 2, fibrillin 1 
Neurocan HB-GAM, amphoterin Hyaluronan. lectins, tenascins C and R, 
Ng-CAM, N-CAM, TAG1/axonin1, 
heparin, FGF2 
Aggrecan collagens Hyaluronan, lectins, collagen type II, 
collagen type IX, collagen type XI, 
COMP, matrilin, CMP 
Brevican N.D. Hyaluronan, lectins, tenascins, EGFR, 
fibulin 2, Bral2, neurofascin 186 
Opticin Collagens type IX, collagen type 
XVIII 
N.D. 
Lumican N.D. Collagens, citokynes, α2β1 integrin 
receptor, cytokines 
Decorin TNF-β, WISP-1, FGF-2, collagen 
type I, collagen type VI 
TGFβs, TNF-b, WISP-1, collagens type 
I, collagen type II, MMPs, EGFR, IGFR, 
EGF, IGF 
Biglycan BMP2, BMP4, WISP-1 Collagen type VI 
Epiphycan N.D. Collagens 
Keratocan N.D. Collagens 
Fibromodulin N.D. Collagen type I, collagen type II 
Mimecan//osteoglycin N.D. BMP2, BMP3, TGFβ1, TGFβ2 
Osteoadherin/osteomodulin N.D. αvβ3 integrin, EGFR 
Asporin N.A. TGFβ1, BMP2, collagen type II 
PRELP N.A. Perlecan, collagen type I, collagen type 
II, C4-BP, C9 
Table 3. GAG chain- versus core protein-mediated interactions of PGs  
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Chondroadherin N.A. α2β1 integrins, collagen type II 
Bikunin N.D. Cathepsin G, acrosin, chymotrypsin, 
trypsin, granulocyte elastase, plasmin 
Testicans 1-3 N.D. Protease, cathepsin L 
Endocan Cytokines, fibronectin, collagens, 
HGF/SF 
VEGF-A, VEGFR2, FGF2, TGFβ, IGF2, 
EGF, integrins 
Interphoto receptors 1-2 N.D. N.D. 
Neuroglycan C N.D. ErbB3 
Phosphacan N.D. CAMs, pleiothropin 
Glypicans 1-6 FGFs, FGFR, Wnt, BMPs, IGF-2, 
TGFβ 
Wnt, bFGF 
Syndecams 1-4 MMP7, ADAM, fibronectin, 
laminin, vitronectin, plasma 
protein, anti thrombin 1, FGFs, 
VEGF, PDGF, HGF, TGFβ, 
thrombospondin, chemokine, IL8, 
pathogens, integrins, collagens, 
Wnt 
MMP7, integrins,  PDZ proteins, FGF2, 
TGFβ, anti-elastase, α1-antitrypsin 
CD44 N.D. Hyaluronan, collagens type I and IV, 
laminin, fibronectin, osteopontin, 
integrins, HGF, EGF, FGFs, VEGF-A, 
TGFβ, MMPs, VEGFR2, ErbB family 
receptors, ezrin, radixin, moesin, merlin 
NG2/CSPG4 N.D. Collagens type V and VI, FGF2, PDGF-
AA, PDGFRα, FGFR1, FGFR3, laminin 
2, α3β1 integrin 
SV2 N.D. N.D. 
Betaglycan FGFs, TGF-β TGFβ1, TGFβ2, TGFβ3, TGFβRs, 
inhibin A, inhibin B, BMP2, BMP4, 
BMP7, BMPRs, endoglin, β-arrestin 2, 
GAIP-protein 
Serglycin CD44, granzyme B, proteases N.D. 
Collagens N.D. Integrins, MMPs, MT1-MMP, FGF2, 
VEGF, C4-BP, factor H, thrombomyosin 
Thrombomodulin Antithrombin, thrombin Anti-thrombin, anti-coagulant protein C, 
thrombin, TAFI 
  N.D.: not detected; N.A.: not applicable 
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PG GAG Core protein Context 
Perlecan Cell proliferation, cell 
motility, matrix assembly, 
angiogenesis 
Cell proliferation, cell-
matrix interaction 
NIH-3T3 fibroblasts, SMCs, 
engineered human skin  
model, Zebrafish model, null 
mice models 
Agrin N.D. Cell-matrix interaction, 
neurite outgrowth, immune 
response 
Mutant mice models 
Leprecan N.D. Cell proliferation NIH-3T3 fibroblasts 
Bamacan N.D. Cell proliferation  
Versican Cell-cell adhesion Cell proliferation, cell-
matrix interaction, cell 
motility  
NIH-3T3 fibroblasts 
Neurocan N.D. Cell-matrix interaction, 
neurite outgrowth, matrix 
assembly 
 
Aggrecan Matrix assembly Cell-matrix interaction, 
matrix assembly 
Nanomelic chicken model, 
mutant mice models 
Brevican N.D. Cell motility, matrix 
assembly 
 
Opticin Matrix assembly, 
angiogenesis 
N.D.  
Lumican Matrix assembly Cell motility CHO cells 
Decorin Matrix assembly Cell proliferation, matrix 
assembly 
CHO cell line, SMCs, null 
mice models 
Biglycan Cell proliferation, cell 
differentiation 
Matrix assembly  C2C12 cells, knockout mice 
models 
Epiphycan N.D. N.D.  
Keratocan N.D. N.D.  
Fibromodulin N.D. Matrix assembly Null mouse models 
Mimecan/osteoglycin N.D. Matrix assembly Knockout mouse models 
Osteoadherin/osteomodulin N.D. Cell-matrix interaction MC3T3E1 cells 
Asporin N.A. Matrix assembly  
PRELP N.A. Cell proliferation, cell-
matrix interaction, immune 
response 
Mouse osteoblasts, mouse 
osteoblasts, in vivo mouse 
models 
Chondroadherin N.A. Cell-matrix interaction K9 cells 
Bikunin N.D. Cell motility, coagulation  
Table 4. GAG chain- versus core protein-mediated function of PGs  
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Testicans 1-3 N.D. Cell motility, neurite 
outgrowth 
 
Endocan Cell proliferation, cell-
matrix adhesion 
Cell-matrix interaction, 
angiogenesis 
HEK-293 cells 
Interphoto receptor 1-2 N.D. N.D.  
Neuroglycan C N.D. Cell proliferation MDA-MB 453 cells, CHO 
cells, Escherichia Coli model 
Phosphacan N.D. Neurite outgrowth  
Glypicans 1-6 Cell proliferation, 
apoptosis 
Cell proliferation, 
apoptosis 
Drosophila model, Xenopus 
model, mutant mouse models 
Syndecans 1-4 Cell proliferation, cell-cell 
adhesion, cell-matrix 
interaction, cell motility, 
matrix assembly, cell 
differentiation, 
angiogenesis, immune 
response 
Cell-cell adhesion, matrix 
assembly, cell 
differentiation, 
angiogenesis 
CHO cell line, syndecans null 
fibroblasts, Huh7 cells, 
HT1080 cells,  mutant mice 
models, Zebrafish model, 
quail model 
CD44 N.D. Cell proliferation, cell-
matrix interaction, cell 
motility, cell differentiation  
 
NG2/CSPG4 N.D. Cell-matrix interaction, cell 
motility, neurite outgrowth, 
apoptosis, angiogenesis 
Glioma cells, C57Bl/6 mice 
models 
SV2 N.D. N.D.  
Betaglycan Cell motility Cell proliferation MCF10A and MDA-MB-231 
cell lines, 3T3 fibroblasts, in 
vivo xenograft mice model, 
null mice model 
Serglycin Cell-cell adhesion, cell 
motility, immune 
response 
N.D. Serglycin deficient mast cells, 
monocyte-like THP-1 cells, 
knockout mouse models, 
NDST-2 knockout mouse 
models 
Collagens N.D. Cell motility, apoptosis, 
angiogenesis, immune 
response 
Umbilical vein endothelial 
cells, chick chorioallantoic 
membranes 
Thrombomodulin Coagulation Cell proliferation, 
coagulation, immune 
response 
Mutant mouse models 
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PG GAG Core protein Context 
Perlecan Cell proliferation, cell 
motility, angiogenesis 
Angiogenesis Tumor cells 
Agrin Matrix assembly N.D. Alzheimer’s disease 
Leprecan N.D. N.D.  
Bamacan N.D. Tumor progression  
Versican N.D. Cell proliferation, cell-
matrix interaction, cell 
motility, metastasis 
NIH-3T3 fibroblasts, tumor 
cells 
Neurocan N.D. N.D.  
Aggrecan Matrix assembly Matrix assembly Nanomelic chicken model, 
mutant mice models 
Brevican N.D. Cell motility 9L cells 
Opticin Angiogenesis N.D. CAM assay 
Lumican Tumor progression Cell motility, metastasis A375 cells, B16F1 cells 
Decorin N.D. Tumor progression, 
angiogenesis, metastasis 
Colon carcinoma cells, 
HT1080 cells, Saos2 cells, 
breast cancer animal models 
Biglycan Tumor progression N.D.  
Epiphycan N.D. N.D.  
Keratocan N.D. N.D.  
Fibromodulin N.D. N.D.  
Mimecan/osteoglycin N.D. N.D.  
Osteoadherin/osteomodulin N.D. Cell proliferation, cell 
migration 
 
Asporin N.A. Matrix assembly Osteoarthritis 
PRELP N.A. Immune response Rheumatoid arthritis 
Chondroadherin N.A. N.D.  
Bikunin N.D. Cell motility, metastasis Bladder carcinoma 
Testicans 1-3 N.D. Cell motility  
Endocan Tumor progression Angiogenesis Bladder cancer, vascular 
endothelial cells, transgenic 
mice mdels 
Interphoto receptor 1-2 N.D. N.D.  
Table 5. GAG- chain versus core protein- involvement in disease  
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Neuroglycan C N.D. Cell proliferation T47D cells, MDAMB-453 
cells 
Phosphacan N.D. N.D.  
Glypicans 1-6 Cell proliferation N.D.  
Syndecans 1-4 Cell proliferation, cell-
matrix interaction 
Tumor progression, 
angiogenesis 
Tumor cells 
CD44 N.D. Tumor progression, cell 
motility, angiogenesis 
SCC25 cells, CAL 27 cells, 
MCF7 cells, B-CCL cells, in 
vivo models 
NG2/CSPG4 N.D. Tumor progression, cell-
matrix interaction, cell 
motility, apoptosis, 
angiogenesis 
 
SV2 N.D. N.D.  
Betaglycan N.D. Tumor progression  
Serglycin Cell motility, metastasis, 
immune response 
N.D.  
Collagens N.D. Angiogenesis  
Thrombomodulin Coagulation N.D.  
 
 
 
1.1. Cell proliferation 
ONLY CORE PROTEIN 
In CHO cells decorin directly inhibits cell proliferation and this function depends on its 
capacity to bind TGF-β1, β2 and β3 with the same efficiency, via its core protein [Baghy et al., 
2012; Hardingham and Foseng, 1992; Iozzo and Murdoch, 1996; Iozzo, 1998]. Decorin is up-
regulated when cells reach quiescence and it has been identified as one of the genes, named 
quiescins, that are overexpressed by lung fibroblasts during the stationary phase of contact 
inhibition and quiescence [Iozzo and Murdoch, 1996]. Decorin may also inhibit cell proliferation in 
a directly way independent of TGFβ. In fact when decorin is ectopically expressed into colon 
carcinoma cells which do not synthesize decorin, the cells become quiescent, form small colonies in 
soft agar and do not generate tumors in immunocompromised hosts. Overexpression of decorin or 
its addition in culture media has been shown to cause a severe cytostatic effect on many cancer cells 
including glioma, ovarian and colon cancer cells. Increased decorin expression in vivo, achieved 
19 
 
with gene transfer techniques, causes growth inhibition in various tumors and it prevents metastasis 
in particular in breast cancer animal models. It is shown that a number of clones are arrested in G1 
phase of the cell cycle and their growth suppression can be restored by treatment with decorin 
antisense oligodeoxynucleotides [Iozzo, 1998]. A tumor xenograft approach using decorin-
expressing cell lines, such as HT1080 and Saos2, showed a significant reduction of growth and 
neovascularization, in particular at the tumor invasive front compaired to the decorin expressing 
counterpart. De novo expression of decorin or exogenous recombinant decorin, down-regulated the 
endogenous expression of the pro-angiogenic factor VEGF and suppressed the tumorigenicity of 
human colon carcinoma cells both in vitro and in vivo. Another mechanism of cell growth 
modulation by decorin is through interaction with growth factor receptors such as EGFR and IGFR. 
The decorin-induced growth arrest is associated with an induction of p21, a potent inhibitor of 
cyclin-dependent kinase activity. Ectopic expression of decorin proteoglycan or decorin core 
protein fraction, a mutated form lacking any GAG side chains, induces growth suppression in 
neoplastic cells of various histogenetic origins [Iozzo, 1998]. The induction of p21 occurs due to a 
rapid phosphorylation of the EGF  receptor and a concurrent activation of the MAP kinase signal 
pathway. This leads to a protracted induction of endogenous p21 and ultimate cell cycle arrest 
[Iozzo, 1998]. The ability of secreted decorin to induce growth suppression gives furthers support to 
the concept that abnormal production of this PG around invading carcinomas represents a 
specialized biological response of the host designed to counterbalance the invading tumor cells 
[Iozzo, 1998]. Decorin is also essential for smooth muscle cells proliferation and synthetic 
functions. In particular the effect of decorin on SMCs is mediated via inhibition of TGFβ activity 
and leading to decreased proliferation and less synthetic activity of these cells [Singla et al., 2011]. 
Decorin also has an important effect on the vascular calcification and it increases calcium 
deposition in cultured bovine arterial SMCs [Fischer et al. 2004].  
A subpopulation of 3T3 fibroblasts that express a form of betaglycan lacking the GAG 
chains binds different growth factors with equal affinity compared with the fully glycosylated 
species [Couchman, 2010; Hardingham and Fosang, 1992]. Betaglycan ectodomain may be 
regulated by shedding via proteolytic cleavage, producing a soluble form that is proposed to 
sequester growth factors from their signaling receptors, antagonizing the signaling [Bilandzic and 
Stenvers, 2011]. The C-terminal of the betaglycan cytoplasmic domain may bind the C-terminal 
domain of the protein GAIP, an inducible phosphoprotein, and this interaction stabilizes the PG 
molecule at the cell membrane and increase TGFβ responsiveness in Mv1Lu mink lung epithelial 
cells and L6 myoblasts [Bilandzic and Stenvers, 2011]. TβR2 null mice die at embryonic stages by 
heart and liver defects caused by an altered TGFβ2-induced mesenchymal transformation process 
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and the incidence of apoptotic events. Betaglycan orchestrates the TGFβ, BMP and inhibin-
mediated signals in different cell types enhancing the binding of all the TGFβ isoforms with their 
receptors, in particular the TGFβ2. On the other hand, betaglycan enhances the binding of BMP2, 4, 
7 and GDF5 to BMPR1 leading to an increase in Smad1 phosphorylation. The capacity of this PG 
to bind TGFβ may be the reason of its tumor suppressor function in different cell types. In 
particular its loss is related with the loss of sensitivity to TGFβ and inhibin-mediated control of 
cancer cell growth and migration. It is demonstrated that cancer cells show a downregulation  or 
loss of betaglycan expression at the mRNA and/or protein levels which correlates with increasing 
tumor progression [Bilandzic and Stenvers, 2011]. Betaglycan also binds β-arrestin2 in a GAG-
independent manner. Arrestin is a regulator of G protein-coupled receptors which bind to activated 
receptor, targeting them for internalization and desensitization. Arrestin requires betaglycan to be 
phosphorylated by the TGFβR2. As result of betaglycan-arrestin association, betaglycan and the 
TGFβR2 are co-internalized via a clathrin-independent/lipid raft pathway and TGFβ signaling is 
suppressed. The association of betaglycan with β-arrestin2 also results in the internalization of 
ALK6 type I BMP receptor, conversely, enhancing BMP signaling [Bilandzic and Stenvers, 2011].   
Thrombomodulin EGF-like repeats in the extracellular part of the core protein, has 
mitogenic effects on cultured fibroblasts and vascular smooth muscle cells mediated via activation 
of protein kinase C and MAPKs [Anastasiou et al., 2012]. 
N-terminal domain of PRELP is a type-specific NFkB inhibitor, in particular in the bone 
tissues [Happonen et al., 2001]. Studies on in vitro cultures of mouse osteoblasts and osteoclasts 
and in vivo mouse models of bone loss confirm that PRELP involvement in osteogenesis requires 
its internalization and its inhibition of the transcription nuclear factor NFkB [Rucci et al., 2009]. 
The binding of PRELP inhibits the p65NFkB transcriptional activity and blocks osteoclasts 
formation by a direct mechanism affecting perfusion osteoclasts. In this way it becomes an active 
regulator of bone resorption [Rucci et al., 2009]. 
Versican structurally consists of N- and C-terminal globular domains and two chondroitin 
sulfate domains (CS-α and CS-β), which are encoded by differential splicing exons. Alternative 
splicing generates at least four isoforms of versican known as V0, V1, V2, and V3. V0 contains 
both CS-α and CS-β; V1 and V2 possess only CS-β and CS-α, respectively; and V3 solely has the 
globular domains. Versican isoforms V0/V1 are mainly expressed in the late stage of embryonic 
development, whereas versican V2 is one of the main constituents of the mature neural ECM. The 
different versican isoforms show different function in enhancing or inhibiting cell proliferation. In 
particular the V1 isoform has been shown to enhance cell proliferation and protect NIH-3T3 
fibroblasts from apoptosis [Ricciardelli et al., 2009]. In fact in vivo studies on V1-induced NIH-3T3 
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tumor formation in nude mice is associated with apoptotic resistance and down-regulated Fas 
mRNA and protein levels and unexpectedly, sensitization to a wide range of cytotoxic agents 
[Ricciardelli et al., 2009]. Both the G1 and G3 versican domains have been shown to promote cell 
proliferation of NIH-3T3 fibroblasts and tumor cells. The G1 domain of versican is thought to 
stimulate proliferation by destabilizing cell adhesion whilst the G3 induced proliferation is 
mediated, at least in part, by the action of EGF-like motifs in the G3 domain activating EGF 
receptors [Ricciardelli e3t al., 2009]. By contrast, the V2 isoform exhibits opposing biological 
activities by inhibiting cell proliferation and lacking any association with apoptotic resistance 
[Ricciardelli et al., 2009]. The smallest splice variant, V3, consisting only of the amino- and 
carboxy-terminal G1 and G3 domains and lacking CS chains, was found to be expressed in primary 
endothelial cell cultures only following activation by pro-inflammatory cytokines or growth factors. 
The role of V3 in activated endothelium is not yet known. The overexpression of V3 in arterial 
SMCs resulted in their increased adhesion to culture flasks but reduced proliferation and slower 
migration in scratch wound assays [Ricciardelli et al., 2009]. In the same way, the overexpression 
of the V3 isoform in melanoma cancer cells markedly reduces cell growth in vitro and in vivo and 
promotes metastasis to the lung. These findings suggest that the V3 isoform may have a dual role as 
an inhibitor of tumor growth and a stimulator of metastasis [Ricciardelli et al., 2009]. Elevated 
levels of versican have been reported in most malignancies to date, including; brain tumors, 
melanomas, osteosarcomas, lymphomas, breast, prostate, colon, lung, pancreatic, endometrial, oral, 
and ovarian cancers. Even non-solid cancers, such as human acute monocytic leukemia cells, 
express and secrete V0 and V1 isoforms [Ricciardelli et al., 2009]. In all of these cases versican 
expression is related with poor prognosis. Epithelial versican expression has also been described in 
endometrial cancer and ovarian cancer. In ovarian cancer, high stromal versican levels correlated 
with serous cancers and were associated with reduced overall survival, while high versican levels in 
the epithelial cancer cells correlated with clear cell histology and increased recurrence-free survival 
[Ricciardelli et al., 2009]. The knockdown of versican expression in A549 lung cancer cells by 
RNA interference significantly inhibited tumor growth in vivo but not in vitro.  
Neuroglycan C is expressed predominantly in the brain where it can directly bind and 
activate ErbB tyrosine kinase, one of the component of the EGF receptor family. This is confirmed 
also in in vitro studies on MDA-MB-453 cells, where the treatment with an anti ErbB3 antibody 
completely block neuroglycan C activity. This PG is not able to bind ErbB 1, 2 and 4. It was 
demonstrated that recombinant extracellular domains of NGC produced in Escherichia coli and 
CHO cells induce cell proliferation of the human breast cancer cell lines, T47D and MDAMB-453, 
via direct binding to ErbB3 and transactivation of ErbB2 [Kinugasa et al., 2004]. 
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NIH-3T3 fibroblastst were trasfected with mouse leprecan cDNA or with a truncated form 
encoding only the N terminal region of leprecan core protein or with an antisense construct. Clones 
expressing high level of both the isoforms and the antisense derivatives that showed negligible 
expression of the endogenous leprecan transcript, show an elevated capacity to form colonies and 
the clones transfected with the truncated form, lacking the carboxy-terminus, exhibited colony 
forming efficiencies comparable to that of vector transfected clones. These data suggest a growth 
suppressive function of leprecan attributable to its core protein portion [Kaul et al., 2000]. 
Bamacan is important in the formation of cohesin complexes that stabilize the cell during 
the cell cycle. During the S phase of cell cycle, bamacan bind the other components of cohesin 
complex such histone deacetylases or acetyltransferases via its core protein. In vitro studies show 
that histone deacetylases can directly deacetylate bamacan. Overexpression of deacetylases leads to 
under-acetylation of bamacan and cohesion defects, consistent with the idea that acetylation 
promotes cohesion and deacetylation reduces it cohesion. The ATPase activity of the bamacan 
subunits is critical for chromosome cohesion and it has been suggested that acetylation of bamacan 
by acetyltransferases modulates its ATPase activity [Xiong et al., 2010]. The involvement of this 
proteoglycan in chromatide cohesion during metaphase play an important role also in tumorigenesis 
and in tumor progression. Increased levels of bamacan have been reported in human tumors, 
primarily those of epithelial origin, such as breast, colon and lung. Moreover during tumor 
formation, extracellular bamacan forms abnormal accumulation, also if its exact extracellular 
function is not yet known. 
NG2 proteoglycan binds to FGF2 and PDGF-AA with high affinity. The core protein of 
NG2, rather than the chondroitin sulfate chain, serves as a co receptor for FGF family members, 
with putative binding sites scattered throughout the D2 and D3 domains. Both FGF2 and PDGF-AA 
are critical for expansion of the oligodendrocyte progenitor population. In addition, phosphorylation 
of NG2 plays a role in cell proliferation. Extracellular signal-regulated kinase catalyzes the 
phosphorylation of NG2 at Thr2314, stimulating cell proliferation. Interestingly, α3β1 integrin 
activation is also required for this NG2-dependent increase in proliferation. NG2 phosphorylated at 
Thr2314 is co-localized with α3β1 integrin on microprojections on the apical cell surface. The 
integrin interacts with a set of signaling molecules, different from those needed in the motility 
mechanism [Xu et al., 2011]. Under non-stimulatory conditions, NG2-transfected U251 glioma 
cells are more proliferative than parental U251 cells due to basal levels of NG2 phosphorylation at 
Thr2314. Thr2314-Glutamine mutants exhibit even higher rates of proliferation, while Thr2314-
Valine mutants are indistinguishable from non-transfected U251 cells [Stallcup and Huang, 2008]. 
In in vivo studies it was induce glioma formation via injection of a PDGF-B expressing 
23 
 
retrovirus into the white matter of adult wild type C57Bl/6 mice and NG2 null C57Bl/6 mice. The 
study underlines the important effect of NG2 in promoting glioma progression [Stallcup and Huang, 
2008]. In a second in vivo assay it was utilized microinjection of CT2A mouse glioma cells into the 
white matter of five adult wild type and five adult NG2 null C57Bl/6 mice [Stallcup and Huang, 
2008]. It was shows a dramatic difference in the size of the tumors that develop in the two mouse 
lines after three weeks. Tumors in wild type mice are on average 10-fold larger than tumors in NG2 
null mice [Stallcup and Huang, 2008]. Since CT2A cells express NG2, the differential effects of 
NG2 on tumor progression in wild type and NG2 null mice must come from elements of the host 
stroma, possibly including pericytes in the tumor vasculature and oligodendrocyte progenitors 
recruited to the tumor mass [Stallcup and Huang, 2008]. 
CD44 extracellular region interacts with hyaluronan and different ErbB family members, 
representing a pathway to EGFR inhibitor resistance by cross-activation of related pathways. 
Togheter with its ability to bind different citoskeletal elements, such as ezrin, radixin, moesin and 
merlin, by its cytoplasmic domain, CD44 acts as a promoting of tumor cell proliferation and 
motility. CD44 role is evaluated in particular in head and neck squamous cell carcinomas. The 
trasfection of CD44 low cell line SCC25 with CD44 gene, induces aggressive tumor morphology 
and appear to enhance tumor initiation. In these cells, CD44 complexes with RhoA-specific guanine 
nucleoside exchange factor to induce RhoA signaling, phospholipase C epsilon activity and cancer 
cell migration. The complex also interact with EGFR to stimulate Ras-mediated signaling and 
HSNCC cell growth. This interaction may be related with the chemotherapy resistance that is 
characteristics of this tumor type. Knockdown of CD44 in the overexpressing cell line CAL 27, 
validates these data by reducing tumor growth. The interaction between CD44 and ErbB2 has been 
shown in other tumors and could potentially provide a mechanism to bypass EGFR inhibition.  
It has been shown that the core protein of endocan interacts in vitro with lymphocyte and 
monocyte LFA-1 and inhibits the LFA-1/ICAM-1 interaction, thereby regulating leukocyte 
recruitment and adhesion into inflammatory sites. Endocan is over expressed in a number of 
malignant tumors, including non small cell lung cancer, glioblastoma and hepatocellular carcinoma, 
with the expression level positively correlating with the severity of the disease. Within such tissues, 
endocan has been detected in endothelial cells at the tumor periphery. In severe combined 
immunodeficiency mice, injection of nontumorigenic HEK-293 cells, which have been engineered 
to express endocan, forms tumors, whereas HEK-293 cells expressing the S137A mutant form of 
endocan did not. This suggests that the tumor-promoting activity of endocan is, at least partly, 
caused by the GAG chain, presumably through promoting the activity of growth factors, including 
HGF/SF. 
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ONLY GAG CHAINS 
HS chains of glypicans can bind both FGF2 and its receptor, promoting the receptor 
dimerization and increasing the growth factor mitogenic activity [Filmus, 2001]. The use of 
heparin-sulfate degrading enzymes reduces the FGFs binding of more than 95%, and this confirms 
the involvement of the GAG chains in the FGF binding of glypicans [Midorikawa et al., 2003]. 
Glypicans are also involved in BMP binding and regulation. The same studies in Drosophila with 
dally mutants, showed also that glypican regulates the signaling of dpp, the Drosophila 
corresponding form of BMP [Filmus, 2001]. In particular glypican 3 seems to be involved in the 
negative control of cellular proliferation [Midorikawa et al., 2003]. For this function, IGF2 and 
FGFs in general are suggested as putative GPC3 ligands. More deeply this PG seems to inhibit 
IGF2 signaling pathway, by competing for IGF2 binding with the signaling receptor [Midorikawa et 
al., 2003] The existance of diseases due to GPC3 mutations and characterized by cell growth 
disorders, validates the important role of glypican 3 expression as cell proliferation modulator. In 
fact mutations in GPC3 are associated with the Simpson-Golabi-Behmel syndrome characterized by 
pre- and post-natal overgrowth. SGBS is caused by a nonfunctional GPC3 protein and its study is 
supported by the generation of GPC3-deficient mice [Filmus, 2001]. In these mice there is an 
increase in the proliferation rate of epithelial cells in the ureteric bud/collecting system. This 
support the idea that GPC3 is involved negatively in the regulation of cell proliferation and it can 
induce apoptosis in a cell type-specific manner [Filmus, 2001]. The same clinical evidence of SGBS 
are present also in Beckwith-Wiedemann syndrome, that is related to an overexpression of IGF2 
factor. The loss-of-function mutation of GPC3 is equivalent to overexpression of IGF2 [Filmus, 
2001]. To validate this data mice overexpressiong IGF2 were generated and they showed together 
with the phenotypic features of BWS, also the skeletal defects that are typical of SGBS. An elegant 
in vivo study with a double mutant mice lacking the IGFR and H19 locus was generated to clarify 
the GPC3 function in the IGF signaling pathway. IGFR is a negative regulator of IGF2 and, binding 
the growth factor, it is able to downregulate its endocytosis and degradation. H19 locus regulates 
IGF2 imprinting. The double mutant mice show developmental growth typical of SGBS, caused by 
the mutation of the glypican-3 gene on the X chromosome. IGF2R-deficient mice  display a degree 
of developmental overgrowth similar to the GPC3
-/-
 mice and this support the hypothesis of a direct 
cooperation between the glypican and IGF2 [Yan et al., 2009].    
Syndecans bind different growth factors involved in the cell proliferation, like FGFs, 
VEGFs, PDGF, via their HS chains. CS chains may cooperate with HS for the binding. Post-
translation HS chain modification or modification of the enzymes involved in HS modification, may 
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deeply influence the syndecan-mediated growth factors signaling [Tkachenko et al., 2005]. For 
example, in quail, Qsulf1, the avian homolog of Sulf1 and Sulf2, has been shown to remodel HS on 
the cell surface promoting Wnt1 signaling. In human cancer cell lines, Hsulf1 expression inhibited 
HGF stimulation of cell proliferation [Tkachenko et al., 2005]. The inhibition of HS formation 
attributable to mutations of EXT1 and EXT2 genes, results in hereditary multiple exostoses, an 
autosomal skeletal disorder characterized by inappropriate chondrocyte proliferation and bone 
growth due to an abnormal diffusion of hedgehog proteins [Tkachenko et al., 2005]. Also in 
pathological conditions, GAG modification result really foundamental for syndecans functions. For 
example during liver fibrosis and carcinogenesis, the degree of 3-O-sulfation of syndecans heparan 
sulfate is increased [Choi et al., 2011]. Also if structural modifications of heparan sulfate chains 
make an important contribution to the ability of syndecans to encode such enormous molecular and 
functional diversity, this structural diversity can be further increased through structural variability 
of chondroitin sulfate chains covalently attached to syndecan1, 3, and 4 [Choi et al., 2011]. 
syndecan 1 is known to associate with HGF and promote activation of phosphoinoside 3-kinase and 
mitogen-activated protein kinase pathways in multiple myeloma [Choi et al., 2011]. The 
involvement of the interaction of syndecans with their ligands in cell proliferation are well studied 
in different in vivo mutant mice models. For example homozygous disruption of syndecans 1 gene 
in mice determines an abnormally slow re-epithelialization after injury and an increased leukocyte 
adhesion involving the Wnt 1 signaling pathway; in syndecans 1 knockout mice mammary gland 
specific expression of Wnt1 do not lead to development of tumor as happens in wild type mice 
[Tkachenko et al., 2005].  
Biglycan GAG chains are essential for its capacity to modulate cell proliferation and tumor 
progression. In facts this PG binds WISP-1 through its chains, in particular DS and CS-4 sulfated 
chains. In vitro solid phase assays demonstrate that the use of dermatan sulfate or chondroitin-4 
sulfate moieties abolishes the binding of biglycan with WISP-1 demonstrating that a sulfate group 
is only required at position 4 of the N-acetylgalactosamine. By binding to biglycan, WISP-1 
prevents its inhibitory activity on tumor cell proliferation favouring the tumor progression 
[Desnoyers et al., 2001]. 
COOPERATION 
Perlecan functions as a gatekeeper to limit access of growth factors to subjacent target cells 
controlling cell replication and proliferation, as happens for the smooth muscle cells in 
vasculogenesis. So perlecan could modify the behavior of replicative cells by controlling the 
amount of growth factors involved in vascular morphogenesis [Iozzo, 1998]. Murine perlecan is 
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capable of downregulating Oct-1, a transcription factor involved in vascular smooth cell growth 
control, in in vitro experiments. Because the addition of soluble heparin does not elicit the same 
response, it is plausible that the ability of perlecan to alter smooth muscle cell function resides in 
the coordinated binding of the N-terminal domain of the protein core (SEA module and three SGD 
tripeptides) and HS chains [Iozzo, 1998]. In particular the function of HS chains seem to be the 
binding of FGF2 and its protection from proteolytic degradation [Bix and Iozzo, 2008]. The role of 
HS in smooth muscle cell proliferation has been shown to be important, when it is removed by a 
combination of bacterial heparinase digestions, the cells at a site of injury no longer respond to 
introduced FGF2 [Whiterlock et al., 2008]. It has been shown that the HS chains are responsible for 
the binding of other components of FGF family, like FGF1, 7, 9, 10, 18 and such interactions may 
lead to enhanced angiogenesis and chondrogenesis [Iozzo, 1998; Whitelock et al., 2008]. Different 
in vivo studies show the importance of perlecan-FGFs binding. For example colon carcinoma cells, 
in which the perlecan gene is disrupted by targeted homologous recombination, grow slowly, fail to 
respond to exogenous FGF7 with or without heparin and are less tumorigenic when injected in 
immunocompromised mice. In an engineered human skin model, perlecan-deficient keratinocytes 
form a poorly-organized epidermis which is partially restored by exogenous FGF7 [Whiterlock et 
al., 2008]. The protein core of perlecan binds to FGF18, a key factor for chondrogenesis, and alters 
the mitogenic effect of FGF18 on growth plate chondrocytes. This finding is also supported by the 
similarity in cartilage phenotype between perlecan null and the FGF18 null mice which both exhibit 
a defect in endochondral ossification [Whiterlock et al., 2008]. Finally, Perlecan HS is also involved 
in branching morphogenesis of the submandibular salivary gland by specifically interacting with 
FGF10. In ex vivo models, heparanase co-localizes with perlecan in the glandular basement 
membrane and liberates FGF10 that is bound to the heparan sulfate. This chains leads to a signaling 
cascade which activates MAPK, stimulates the formation of epithelial clefts and ultimately 
enhances branching morphogenesis. The specificity of this interaction was demonstrated by surface 
plasmon resonance studies showing that FGF10 and FGF10/FGFR2b complexes bound to HS 
chains on perlecan, and that these complexes could be liberated by heparanase [Whiterlock et al., 
2008]. Interestingly, perlecan is also able to act on the PDGF signaling pathway. In fact PDGF has 
been shown to contain an alternatively spliced exon that contains “heparin-binding” or matrix 
localization sequences. Both PDGF homodimers bind to perlecan HS derived from endothelial cells, 
and the inhibition of smooth muscle cell growth by perlecan may involve the inhibition of PDGF 
signaling which has downstream effects on FGF2 signaling [Whiterlock et al., 2008]. 
It is well known, also in in vivo studies, that glypicans bind Wnt and, like in the FGF2 
binding, also in this case the HS chains are involved. Studies on dally-like, a Drosophila glypican, 
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show that dally mutation or the use of siRNA is associated with segment polarity defects similar to 
the ones caused by the loss of Wnt activity [Filmus, 2001; Yan et al, in 2009]. In these studies are 
investigated the interactions of dally-like with the Drosophila corresponding wingless morphogen, 
Wingless. It is shown that dally like may have a biphasic activity in the binding of Wg and that this 
behaviour is due to the ratio of dally-like and Fz2 (the Wg signalling receptor) on the cells. More 
deeply while a low ratio of Dlp:Fz2 can help Fz2 to bind Wg activating the signal cascade, a high 
ratio of Dlp:Fz2 prevents Fz2 from capturing Wg while Dlp may bind and sequester the morphogen 
factor. Also if previous studied showed that mutant models for the HS chains biosynthesis enzymes, 
have a defective Wg signalling, Yan demonstrates that Dlp core protein is involved in Wg binding, 
so it is possible to say that the specificity of Dlp in Wg signaling and biphasic activity results from 
its core protein. In particular the N terminal domain of core protein is essential for Wg binding. 
These conclusions are consistent with previous ones indicating that Xenopus GPC4 interacts with 
Wnt11 via N-terminal region of its core protein, and that GPC3 core protein binds directly Wnt and 
Shh without GAG chains interaction. As well as if Dlp core protein is responsible for Wg 
signalling, HS chains are also important for the binding affinity. Wg Dlp shows significantly 
stronger binding for Wg than the core protein alone [Yan et al., 2009].    
To better study the domains involved in the interaction of syndecans with FGF2, different in 
vivo mouse models were generated. Expression of a full-length SDC4, SDC1 and GPC1 or of 
chimera constructs consisting of the ectoplasmic domain of GPC1 linked to the 
transmembrane/cytoplasmic domain of SDC4 (G1-S4c) or of the ectoplasmic domain of SDC4 
linked to the GPC1 GPI anchor (S4-GPI), significantly increases cell associated HS mass and the 
number of FGF2-binding sites. However only cells expressing SDC4 and G1-S4c construct but not 
GPC1, SDC1 or S4-GPI cells demonstrated enhanced responsiveness to FGF2. Through this in vivo 
evidences, it is possible to conclude that the presence of SDC4 cytoplasmic domain and not simply 
an increase in the cell surface HS mass, that correspond to an increase in FGF-binding site number, 
is required for signaling. The cleavage of syndecans-4 HS chains also blocked enhanced FGF2 
responsiveness, demonstrating that both SDC4 HS chains and SDC4 cytoplasmic domain  are 
required for FGF2 signaling [Tkachenko et al., 2005].  
1.2. Cell-cell adhesion 
ONLY GAG CHAINS 
Serglycin is proposed to be one of the most important PG essential in cell-cell interaction 
during the immune response. It is released by immune cells and binds to CD44 expressed on 
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lymphoid cells. This interaction is mediated by both serglycin CS-4 sulfated and CS-6 sulfated 
chains, but it is not dependent on the presence of heparin or HS chains. The interaction of serglycin  
with its extracellular ligands determines lymphoid cells activation [Kolset and Tveit, 2008; Kolset 
and Pejler, 2011]. 
Also in the case of versican, CS chains are identified as the principal binding sites for 
different cell surface molecules, such as P- and L-selectin, β1 integrin, EGFR, CD44 and other 
ligands like chemokines that may be down regulated by versican binding [Ricciardelli et al., 2009]. 
COOPERATION 
Syndecans, in particular syndecans 4, binds of different cell membrane proteins, such as 
integrins, happens via both GAG chains and core protein. For example, in vitro studies show that 
syndecans 4 expressing cells are able to bind specifically human foreskin fibroblasts and mouse 
aortic endothelial cells [Tkachenko et al., 2005]. 
1.3. Cell-matrix interaction 
ONLY CORE PROTEIN 
The adhesion of cells to the matrix is mainly mediated by the PG core protein. For example, 
the extracellular domain of the CD44 core protein binds different matrix component, like 
hyaluronan, collagens type I and II, laminin, fibronectin and osteopontin [Hardingham and Fosang, 
1992; Hertweck et al., 2011; Louderbough and Schroeder, 2011]. The N-terminal domain of core 
protein is involved in hyaluronan binding giving it a different binding affinity for hyaluronan. The 
different glycosylation of the core protein and the molecular weight of Ha, in particular during 
inflammation seem to be implicated in the variation of the hyaluronan-binding affinity [Hardingham 
and Fosang, 1992]. In particular, while low molecular weight Ha stimulates cell growth, high 
molecular weight Ha inhibits proliferation [Hertweck et al., 2011]. This binding activates several 
pathway involved in cell proliferation, adhesion and migration. More precisely, it activates Rho and 
Rac1 GTPase that cause a reorganization of the actin cytoskeleton, ErbB2 tyrosine kinases, which 
lead to cell proliferation, and nuclear factot NFkB [Wu et al., 2005]. Osteopontin selectively binds 
to CD44 isoforms v6 and v7 and triggers signaling that promotes cell survival, migration and 
invasion and angiogenesis. 
Versican binds hyaluronan molecules via its N-terminal globular domain and lectins via the 
C terminal region and it may also interact with fibronectin, tenascin R, fibulin 1 and 2, fibrillin 1and 
collagen type I reducing cell adhesion [Iozzo and Murdoch, 1996; Iozzo, 1998; Wight, 2002; Wu et 
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al., 2005; Ricciardelli et al., 2009]. The versican C-terminal G3 domain is involved in the binding 
of β1 i ntegrins increasing phosphorylation of FAK and reducing H2O2-induced apoptosis [Wu et 
al., 2005]. The increased FAK phosphorilation causes an increased cell adhesion and spreading and 
a reduced migratory capacity [Wu et al., 2005]. In vitro experiments on NIH-3T3 fibroblasts and 
canecr cells show that soluble versican may reduce prostate cancer and melanoma cells adhesion to 
fibronectin-coated surfaces, promoting cancer cell proliferation and motility [Theocharis et al., 
2010]. 
Also aggrecan, neurocan and brevican bind hyaluronan via their N-terminal globular domain 
I, in particular the G1 region, that binds lectins via the C-terminal region [Hardingham and Fosang, 
1992; Iozzo and Murdoch, 1996; Iozzo, 1998]. Brevican upregulation and proteolytic cleavage 
affect cancer cell adhesion and promote cancer cell motility and its core protein is also involved in 
EGFR activation that determins an increasing in cell-adhesion molecules expression and secrection 
of fibronectin fibrils on the cell surface [Theocharis et al., 2010]. 
Perlecan may have different functions in the cell-matrix adhesion on the basis of the type of 
cell involved. In fact cells like endothelial cells or chondrocytes are urged by perlecan expression to 
adhere to the ECM while other cell types like that of the hematopoietic system may be rejected by 
the presence of the perlecan [Iozzo and Murdoch, 1996]. Some adhesive properties described for 
perlecan can be attributed to N-terminal domain [Iozzo and Murdoch, 1996]. For example perlecan 
N-terminal SEA module and the SGD tripeptides may bind laminin 111, collagen type IV, 
fibronectin, thrombomodulin, fibrillin 1 and PRELP [Bix and Iozzo, 2008]. The domain II contain 
the LDL attachment sites and the domain III, that is present in mouse but not conserved in human, 
contain an RGDS region that binds FGF7 and FGF-BP [Bix and Iozzo, 2008], whereas the domain 
IV of perlecan core protein is involved in neural cell adhesion via contact with N-CAM molecules 
[Iozzo, 1998] and it also binds nidogens, fibuli 2, fibronectin and collagen type IV [Bix and Iozzo, 
2008]. The C-terminal domain V contains EGF repeats and binds nidogen 1, fibulin 2, β1 integrin, 
α2 integrin, FGF7, collagen XVIII, PRELP and α-dystroglycan [Bix and Iozzo, 2008]. To support 
the core protein functions, also GAG chains of perlecan are involved with the core protein in the 
binding of FGF7 and PRELP stabilizing the binding. 
The LG2 region of core protein C-terminus of agrin is responsible of the binding with α-
dystroglycan, a component of dystrophin glycoprotein complex, [Bezakova et al., 2003] that cross 
the plasma membrane and become a structural link between cell cytoskeleton and extracellular 
matrix binding laminin. In the basal lamina of the brain microvasculature and in the muscle 
basement membranes, agrin core protein binds the laminin 1, 2 and 4 throughout its N-terminal 
domain [Bezakova et al., 2003; Iozzo, 1998; Jury and Kabouridis, 2010]. Agrin is present in two 
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different isoforms, the secreted form and the transmembrane one, that takes a non cleaved signal 
peptide. While the secreted agrin isoform is able to bind laminin, the transmembrane agrin isoform 
is not able to do it. The presence or not of this signal peptide influences the localization of agrin in 
tissues that do or do not contain a basal laminin [Bezakova et al., 2003]. Agrin is essential in 
motoneurons and in the brain; in the first it pays an important role in the formation of 
neuromuscular junctions, while in the second it is essential for the integrity of the blood brain 
barrier. Mutant mice deficient in agrin show non-functional NMJs and an uncontrolled immune cell 
infiltration in the brain throughout the BBB and they die before or shortly after birth [Jury and 
Kabouridis, 2010]. 
NG2/CSPG4 extended central D2 domain binds to type V and VI collagen, acting as a 
linkage between the cell surface and the extracellular matrix. Similar results have been achieved on 
laminin 2-coated surfaces. The roles of collagen VI and laminin 2 in brain vasculature and their 
association with axonal processes provide a means for migration of NG2-positive glioma cells 
along blood vessels and nerve fiber tracts [Couchman, 2010; Xu et al., 2011]. 
Also for syndecans, the core proteins is involved in integrins binding, in particular 
unglycosylated syndecan 1, 2 and 4 ectodomains can promote integrins-mediated adhesion. In the 
case of syndecan-1, a specific region approximately in the middle of the ectodomain interacts 
directly with β3 or β5 integrins, instead syndecan 2 and 4 ectodomains are able to activate β1 
integrins in an indirect way [Couchman, 2010]. Syndecan 1 is responsible for the impaired cell 
spreading on vitronectin but not on fibronectin thanks to its ability to modulate vitronectin 
interaction with α5β3 integrin receptors [Tkachenko et al., 2005]. The region of the syndecan 1 
ectodomain that interacts with integrin has been identified, it is termed synstatin and located 
between the heparan sulfate substitution sites and the transmembrane domain. Synstatin is so called 
for its ability to act as a competitor of intact proteoglycans and inhibitor of angiogenesis and tumor 
progression [Choi et al., 2011]. Syndecans not only bind their ligands thorough their extracellular 
domain, but they can influence integrins-mediated adhesion also through the intracellular signaling 
routes [Couchman, 2010]. In this way syndecans can modulate different integrin-dependent 
processes like fibronectin matrix assembly.  
Chondroadherin is mainly found in the territorial matrix of articular cartilage where it binds 
the α2β1 integrins on the cell surface of chondrocytes and induces cells to remain round. Studies on 
a chondrosarcoma cell line, K9 cells, show that these cells are able to bind both native and unfolded 
chondroadherin, suggesting that the binding is due to a linear amino acid segment of the 
chondroadherin molecule [Haglund et al., 2011]. This segment is shown to be located in one of the 
two cysteine loops in the C terminus of chondroadherin [Haglund et al., 2011]. The binding induces 
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ERK phosphorylation in human articular cartilage chondrocytes, mediating signals between the 
chondrocytes and the cartilage matrix. Chondroadherin also interact with collagen type II 
influencing the collagen fibrillogenesis [Haglund et al., 2011]. It is demonstrated that complexes of 
monomeric collagen type II and chondroadherin can be released from articular cartilage to activate 
resident matrix metalloproteinases. Both chondroadherin and collagen interact with chondrocytes, 
partly via the same receptor, but give rise to different cellular responses. By also interacting with 
each other, a complex system is created which may be of functional importance for the 
communication between the cells and its surrounding matrix and/or in the regulation of collagen 
fibril assembly. 
PRELP is present in or close to several basement membranes. This structure is found as a 
thin sheet of extracellular matrix separating epithelial cells from the underlying connective tissue. 
PRELP binds the HS chains of perlecan and bridges the collagens type I and II fibres of matrix with 
these HSPGs at the cell surface, showing an important role in cell-matrix adhesion [Happonen et al., 
2011; Rucci et al., 2009]. This binding occurs via N-terminal region of PRELP, because full-length 
PRELP, but not truncated PRELP lacking the amino-terminal domain, bound perlecan, while the 
bind with collagen occurs via its LRR domain and truncation of PRELP had not disturbed the 
protein conformation. By binding to perlecan HS chains in the basement membrane via its amino-
terminal part and to collagen in the connective tissue via its LRR domain, PRELP is a likely 
candidate as one of the anchoring molecules at basement membrane-connective tissue junctions. 
Osteoadherin/osteomodulin was firstly extracted from bovine cartilage and then it was 
discovered also in human cartilage and bone matrices, where it seems to be osteoblasts-specific. It 
binds to hydroxyapatite and its potential function is to bind cells, since it is showed to be as 
efficient as fibronectin in promoting osteoblasts attachment in vitro. Its involvement in osteoblasts 
attachment is due to its interaction with α5β1 integrin [Bleicher et al., 2000]. In vitro experiments 
on rat osteosarcoma cells suggest that the integrins-binding is due to the core protein RGD region of 
osteoadherin. Moreover in vitro experiments on MC3T3E1 osteoblasts show that osteoadherin 
overexpression in these cells increase the cell differentiation and mineralization and reduces their 
proliferation and migration. Probably this anti-motility function may berelated with the 
osteoadherin capacity to bind and blocking EGFR. EGFR deficient mice demonstrate a reduced 
osteoblasts migration and proliferation and EGFR expression is upregulated in bone metastatic 
cancers. LRR domain of the OSD core protein is indicated as the EGFR-binding site. 
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ONLY GAG CHAINS 
In some cases GAG chains binding capacity may play a pivotal role in cell-matrix adhesion. 
In particular cel surface syndecans may interact with different ECM molecules like fibronectin, 
vitronectin, laminin, collagens, plasma protein and antithrombin 1 and with different growth factors 
and morphogens. The binding is due to their GAG chains that are able to recognizes and binds the 
heparin-binding sites of these molecules. More deeply, in myeloma cells syndecan 1 binds tenascin 
with different affinities depending on its degree of glycosylation and modification of its GAG 
chains [Choi et al., 2011]. In focal adhesions both integrins and proteoglycans are present together 
and it is well-known that focal adhesion formation during cell spreading on fibronectin depends 
upon engagement of an integrin and a cell-surface proteoglycan [Choi et al., 2011]. So the 
cooperation between integrins and syndecans became really crucial for cell adhesion to different 
matrices. In particular syndecan 1-mediated signaling promotes cell spreading in human mammary 
carcinoma cells, a process that requires cooperation with α5β3 integrin, and it supports α2β1 
integrin-mediated adhesion on collagen type I and type II. It is shown that syndecan 1 and β1 
integrin cooperatively regulate adhesion and MMPs production by human salivary gland tumors on 
the laminin α1-derived peptide AG73 [Choi et al., 2011]. Syndecan 2 cooperates with α5β1 integrin 
in cell adhesion to fibronectin and regulates actin cytoskeletal organization in Lewis lung carcinoma 
cells. In human colon cancer cells, syndecan 2 regulates adhesion and migration through 
cooperation with α2β1 integrin. Moreover syndecan 4 binds through its GAG chains to the heparin-
binding domain of fibronectin and promotes the formation of focal adhesions and stress fibers. 
Some studies suggest that CS chains may cooperate with HSs in binding to extracellular matrix 
protein laminin but they have not a principle role in the binding [Tkachenko et al., 2005]. 
Fibronectin interactions with heparan sulfate that mediate proteoglycan-based cell adhesion both in 
vitro and in vivo require N-sulfation, but not 2-O-sulfation, of the chains [Choi et al., 2011]. More 
deeply, integrin α5β1, but not α4β1 integrin or its close relative α9β1, requires syndecan 4 as a co-
receptor and can signal to induce focal adhesion formation and migration by increasing PKCα 
activation. Syndecan 4 is involved also in the regulation of astrocyte adhesion through a cooperative 
interaction with α5β3 integrin, and clustering of syndecan 4 and β1 integrin by laminin α3 chain-
derived peptide promotes keratinocyte migration [Choi et al., 2011]. RNAi knockdown and 
mutagenesis studies have subsequently revealed cooperation of α5β3 integrin and α5β5 integrin 
with syndecan 1 during adhesion to vitronectin 7, 8, and α2β1 integrin and α6β4 integrin with 
syndecans during adhesion to laminin [Morgan et al., 2007]. So the role of the complexes syndecan-
integrin became really foundamental in the process of matrix assembly. 
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COOPERATION 
The cooperation of GAG chains and core protein is the basis of endocan functions. In 
particular it binds fibronectin, collagens and cytokines via its GAG chain. Instead the EGF-like 
domain of core protein is involved in the binding of integrins, in particular of α5β3 integrins, a cell 
surface receptor that is present on the apical side of endothelial cells. This bind occurs in the 
presence of divalent cations. So endocan may cooperate with integrins to promote focal adhesion 
complexes assembly and disassembly influencing cell adhesion and migration that are really 
important during the endothelial-mesencymal transition [Carrillo et al., 2011]. 
1.4. Cell motility 
ONLY CORE PROTEIN 
V0 and V1 isoforms of versican are mainly expressed in embryonic tissues, where they act 
as barriers to neural crest cell migration and axonal outgrowth. In these tissues, it interferes with the 
attachment of embryonic fibroblasts to various substrata like fibronectin, laminin and collagen. The 
expression of versican core protein domain G1 within barrier tissues may be linked to guidance of 
migratory neural crest cells and outgrowth axons [Iozzo, 1998]. Versican is important in promoting 
also cancer cell motility and invasion. This hypothesis is supported by functional studies 
demonstrating that versican can increase cancer cell motility, proliferation and metastasis. In 
addition, purified versican is able to reduce attachment of prostate cancer cells and melanoma to 
fibronectin-coated surfaces in vitro [Ricciardelli et al., 2009]. Versican was selectively excluded 
from podosomes of human osteosarcoma cells and that inhibition of versican biosynthesis by an 
antisense method suppresses a malignant cell-adhesive phenotype [Ricciardelli et al., 2009]. Stable 
transfection of G1 versican into the H460M lung cancer cell line did not alter tumor growth rate in 
vivo, and interestingly clones expressing low or high levels of G1 versican had opposing effects on 
cancer cell motility in vitro and the incidence of metastasis in nude mice [Ricciardelli et al., 2009]. 
Only the cells expressing low levels of G1 versican demonstrated increased motility and metastasis 
to the lung. Interestingly, in MT-1 human breast cancer cells, overexpression of G3 versican 
resulted in larger tumors and the promotion of metastasis to bones and soft tissues [Ricciardelli et 
al., 2009]. Studies in astrocytoma cancer cell lines have demonstrated that the G1 domain, but not 
the G3 domain, of versican could enhance migration. Overexpression of G3 versican in astrocytoma 
cells enhances colony growth in soft agarose gel as well as tumor growth and blood vessel 
formation in nude mice. Both G1- and G3-overexpressing osteosarcoma cells exhibited enhanced in 
vitro growth when cultured on ECM substrates and in the absence of ECM anchorage [Ricciardelli 
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et al., 2009]. G1-overproducing sarcoma cells were more invasive than the corresponding G3 
transfectants and, upon subcutaneously inoculation into nude mice, the G1 transfectants formed 
larger tumor masses than vector transfected cells [Ricciardelli et al., 2009]. 
Testicans play as proteinase inhibitors modulating cell motility and tumor invasion. Human 
testicans 1 and 3 bind and inhibit MT1-MMP in in vitro assays, so that glioma cells show a more 
metastatic phenotype in the absence of testican 3. On the contrary testican 2 seems to abrogate the 
MMP inhibitions, but much more needs to deeply understand the role of these PGs [Roll et al., 
2006].  
Via its extracellular domain, CD44 binds TGFβ, HGF and VEGF, respectively activating 
ankyrin-CD44 interaction, that leads to Smad-dependent invasion, c-Met and VEGFR2, that 
activate endothelial cell migration, sprouting and tubule formation [Hertweck et al., 2011; 
Lounderbough and Schroeder, 2011]. In vivo studies on rat pancreatic carcinoma showed that 
transfection of CD44 variants into a nonmetastatic rat pancreatic carcinoma cell line conferred 
metastatic potential in these cells when injected into rats, which could be blocked by treatment with 
anti-CD44 v6 monoclonal antibody. The same results have been obtained from studies on breast 
cancer. It has been developed a tetracycline-inducible CD44s isoform in the weakly metastatic 
MCF7 breast cancer cell line and found that induction of CD44s in these cells  promotes aggressive 
characteristics in vitro and metastasis to the liver when injected into immunodeficient mice, 
although it did not affect growth rate and local invasion [Lounderbough and Schroeder, 2011]. 
Moreover CD44 can modulate matrix remodeling influencing the expression of different proteases 
like MMP2, MMP8, MMP13. In particular in chronic lymphocytic leukemia cells CD44 binds 
gelatinase B/MMP9 and α4β1 integrin, modulating the anchoring of B-CCL cells and mediating 
migration capacity and invasiveness [Hertweck et al., 2011]. Osteopontin interacts with the 
extracellular domain of CD44 and binds selectively the isoforms v6 and v7. This interaction 
promotes cell survival, migration and invasion, cancer growth and metastasis [Lounderbough and 
Schroeder, 2011].  The same effect is due to the interaction of CD44 extracellular portion with both 
high and low molecular weight Ha in in vitro cell culture. The binding activates the Rho family of 
GTPases and induces cell invasion and migration [Lounderbough and Schroeder, 2011]. The 
intracellular domain of CD44 may interact indirectly with the ERM proteins via the actin of 
cytoskeleton. This protein promote cytoskeletal remodeling and invasion. ERM compete with 
merlin for CD44 binding: merlin is an ERM-related protein that function as a tumor suppressor so 
the binding competition can lead to both tumor suppression and stimulation. High molecular weight 
Ha and an high cellular density promote merlin binding to CD44 and inhibit Ras-activated cell 
growth. Conversely the phosphorilation of merlin inhibits its binding to CD44 and leads ERM 
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proteins to bind it, promoting tumor growth and invasion [Lounderbough and Schroeder, 2011]. 
This is one of the antithetic effect showed by CD44 on cancer growth and invasion. For this reason 
it is important to investigate on the dual role of CD44 in tumor progression [Lounderbough and 
Schroeder, 2011]. Different studies have shown that variability in CD44 function may be due to the 
expression of its different isoforms. For example CD44v3 isoform interacts with Rac and Rho to 
promote cell migration and invasion whereas the standard isoform is upregulated and required for 
epithelial-mesenchymal transitions.  
Consistent results were observed in cell migration and related assays about the involvement 
of collagens molecules in cell motility modulation. Experiments on umbilical vein endothelial cells 
through a collagen filter show that cell migration could be inhibited by low doses of endostatin-
XVIII and NC1, two domains of collagen type XVIII core protein. Inhibiting invasion of the same 
cells into a basement membrane-like structure, required higher doses of endostatin and presumably 
interfered with MMP activation [Sasaki et al., 2002]. Migration inhibition by endostatin was also 
observed for endothelial cells under maximal growth in high serum conditions, and seems to be 
partly mediated through the early response of c-myc gene. Such high-serum conditions, however, 
abrogated endostatin’s effects on apoptosis and growth [Sasaki et al., 2002]. 
Several informations suggest that NG2 plays a role in effective cell migration. Early work 
on NG2 showed that melanoma cell attachment and spreading could be inhibited by NG2 
antibodies, and that NG2 was capable of triggering rearrangement of the actin cytoskeleton 
[Stallcup and Huang, 2008]. The first demonstration that NG2 can be important for cell motility 
came as a result of the finding that NG2 is a cell surface ligand for collagen type VI. Collagen type 
VI binds to the extended central D2 domain of NG2, as shown not only by solid phase binding 
assays with purified NG2 fragments, but also by studies in which recombinant deletion mutants of 
NG2 were expressed in rat B28 glioma cells [Stallcup and Huang, 2008]. NG2 transfectants lacking 
the D2 domain showed unchanged motility in the presence of collagen type VI, whereas full-length 
transfectants and transfectants that included D2 exhibited increased motility when exposed to 
collagen type VI (compared to parental B28 cells). Similar results were also obtained with human 
U251 glioma cells transfected with NG2. Moreover, oligodendrocyte progenitors from wild type 
mice migrate very well on collagen type VI-coated surfaces. In contrast, progenitors from NG2 null 
mice are much less motile on these same surfaces, emphasizing the importance of NG2 for cell 
motility in response to collagen type VI. Comparable results have been achieved on laminin 2-
coated surfaces [Stallcup and Huang, 2008]. The significance of these experiments may be 
questioned on the grounds that collagen type VI and laminin-2 are not major components of the 
brain parenchyma. However, their association with brain vasculature and with axonal processes 
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could provide a means for migration of NG2-positive glioma cells along blood vessels and nerve 
fiber tracts [Stallcup and Huang, 2008]. 
In vitro studies on different tumor types show that lumican core protein is an inhibitor of cell 
motility affecting the interaction between cell and matrix. In particular melanoma A375 cells 
cultured on collagen type I and fibronectin matrices demonstrate reorganization of the actin fibers 
and a reduction in vinculin expression. This is due to a reduction in the β1 integrin-vinculin link 
that is affected by the binding of lumican with β1 integrin. In these cells it is possible also to 
observe a reduction in the ratio between focal adhesion kinases and the phosphorilated form 
pFAKs. Also in CHO cells transfected with the α2 integrin subunit it is possible to appreciate such a 
decrease, that is related with a decreased chemotactic migratory capacity of these cells.  The use of 
siRNA directed against α2β1 integrins on A375 cells determins an abrogation of the anti-migratory 
effect of lumican, suggesting that the binding of the PG with these integrins has a pivotal role in its 
biological function. Whene B16F1 melanoma cells stably transfected with lumican are injected 
syngenically, number and size of lung metastasis nodules are decreased and there are an increasing 
in tumor cell apoptosis within metastasis. The nodules maintain a constant cell proliferation rate 
with a number of blood vessels decreased. This suggests that lumican acts also on the angiogenetic 
aspect of tumorigenesis [Iozzo and Sanderson, 2011; Theocharis et al., 2010]. 
Brevican expression was seen to be upregulated in different invasive tumors of the brain, 
such as astrocytoma, oligodendroglioma or glioblastoma. In these tumors, the PG appears to be 
related with the migratory and invasive cell capacity. In vitro and in vivo studies on non-invasive 9L 
gliosarcoma cell line, that does not express brevican, underlain the important role of the molecule in 
tumor invasion. In particular transfection of these cells with the brevican gene determines an 
invasive cell phenotype and cells become able to clusters extending well beyond the main tumor 
mass. 
A study demonstrated that proteins isolated from the culture medium of human hepatoma 
cells had the capacity to sustain human endothelial cells growth. The N-terminal of one of these 
proteins was discovered to have an amino sequence identical to that of bikunin, more deeply it 
corresponds to the truncated form of bikunin. This PG is suggested to be anti-inflammatory and anti 
metastatic both in animal and human, so that a bikunin therapy has been investigated in patients 
with sepsis, pancreatitis, lung injury and advanced cancer. Studies on bladder carcinomas 
demonstrated that bikunin may block tumor cell invasion by inhibiting tumor cell associated 
plasmin activity and u-PA. The plasminogen activator u-PA, is capable of catalyzing the conversion 
of the inactive zymogen plasminogen to the active proteinase plasmin, that can degrade most 
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extracellular proteins. Bikunin acts also inhibiting proteolytic enzymes, that are implicated in cancer 
metastasis.   
ONLY GAG CHAINS 
The GAG chains are essential for some of betaglycan’s functions, in particular they are 
involved in the binding of FGFs, that reduces PG-mediated inhibition of cell migration [Bilandzic 
and Stenvers, 2011]. Silencing betaglycan gene expression in MCF10A breast epithelial and MDA-
MB-231 breast cancer cells results in IkB degradation and NFkB mediated transcriptional activation 
by a β-arrestin2-dependent mechanism. Betaglycan can block NFkB signaling in a direct way or by 
binding TGFβ, that act on NFkB signaling [Bilandzic and Stenvers, 2011]. Similarly, silencing 
betaglycan in nontumorigenic NMuMG mouse cells increased cell motility and proliferation in an 
in vivo xenograft mouse model, which was associated with increased NFkB-mediated gene 
transcription and downregulation of E-cadherin [Bilandzic and Stenvers, 2011]. 
Syndecan 4 HS chains are responsible for the binding of fibronectin and the regulation of 
cell adhesion and spreading. In vitro experiments show that the overexpression of SDC4 in CHO 
cells promotes focal adhesion formation and decrease cell migration. On the other hand SDC4 null 
fibroblasts plated on fibronectin show enhanced lamellipodia formation and an increased level of 
Rac1 and low level of Rho.  In vascular smooth muscle cells, shear stress causes SDC4 dissociation 
from the focal adhesions. Overexpression of SDC4 blocks this dissociations and also results in 
reduced mechanical stress-induced cell migration. It is suggested that SDC4 is involved in the same 
way in the regulation of smooth muscle migration during arteriogenesis [Tkachenko et al., 2005]. 
Syndecans also modulate cytoskeletal organization. Expression of syndecan 2 or 3 induces filopodia 
formation in COS-1 and CHO-K1 cells. Moreover, syndecan 2, in cooperation with integrin α5β1, 
regulates actin cytoskeletal organization in an expression level-dependent manner: Lewis lung 
carcinoma-derived P29 cells expressing high levels of syndecan 2 form stress fibers, whereas low-
expressing LM66-H11 cells derived from the same tumor form cortical actin [Choi et al., 2011].  
For its capacity of capturing and storing growth factors by entrapping them within both the 
basement membrane and the tumor stroma, perlecan is involved in promoting the growth and 
invasion of tumor cells. Its mRNA and protein levels are notably increased in the metastatic 
neoplasms [Iozzo, 1998]. Purified perlecan enhances invasiveness of human melanoma cells 
whereas contact with basement membrane perlecan augments the growth of transformed endothelial 
cells but suppresses that of their normal counterparts [Iozzo, 1998]. Stable overexpression of an 
antisense perlecan cDNA in NIH-3T3 cells as well as in human metastatic melanomas leads to 
reduced levels of perlecan and concurrent suppression of cellular responses to FGF2. The binding 
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of perlecan to FGF2 factor occurses via HS chains [Iozzo, 1998]. In contrast, in fibrosarcoma cells, 
antisense expression of perlecan cDNA causes enhanced tumorigenesis characterized by heightened 
growth in vitro and in soft agar, increased cellular invasion into a collagenous matrix, and faster 
appearance of tumor xenografts in nude mice. Thus the cellular context is important in mediating 
perlecan’s function [Iozzo, 1998]. Large deposits of immunoreactive perlecan are present in the 
newly vascularized stroma of colon, breast and prostate carcinomas. In tumor xenografts induced by 
subcutaneous injection of human prostate carcinoma PC3 cells into nude mice, perlecan was 
actively synthesized by the human tumor cells and it was clearly deposited along the newly formed 
blood vessels of murine origin [Iozzo, 1998]. Another function of perlecan is the regulation of the 
permeability in the glomerular basement membrane. In fact removal of HS chains increases 
glomerular permeability to proteins and leads to proteinuria [Iozzo, 1998]. In various 
glomeruonephrities it was seen an alteration in both core protein and chains, indicating that perlecan 
is involved in several renal pathologies [Iozzo, 1998]. 
Nasopharyngeal carcinoma cells express high levels of serglycin and its expression is 
correlated with the metastatic potential of different tumor cell clones [Kolset and Pejler, 2011]. 
Serglycin's function of promoting cancer cell metastasis depends on glycosylation of its core 
protein. RNAi-mediated inhibition of serglycin expression blocked serglycin secretion and the 
invasive motility of highly metastatic cells, reducing metastatic capacity in vivo. Conversely, 
serglycin over expression in poorly metastatic cells increased their motile behaviour and metastatic 
capacity in vivo. Growth rate was not influenced by serglycin in either highly or poorly metastatic 
cells. Secreted but not bacterial recombinant serglycin promoted motile behaviour, suggesting a 
critical role for glycosylation in serglycin activity.  
1.5. Neurite outgrowth 
ONLY CORE PROTEIN 
Agrin induces acetylcholine receptor aggregation in cultured myotubes and binds also the 
acetylcoline esterase that limits the action of acetylcoline. It is suggested also a role for agrin in 
postsynaptic cleft organization and it may also play a key role in the regeneration of synapses 
during reinnervation of damaged sites by providing a template of the location of the original 
synaptic site [Iozzo and Murdoch, 1996; Iozzo, 1998]. The C-terminal modules of agrin core 
protein binds and sequester locally the PDGF and TGF-β factors, perhaps contributing to motor 
neuron survival [Iozzo and Murdoch, 1996]. Agrin binds the coreceptor MASC and indirectly acts 
on the receptor MuSK. These binds are essential for agrin-dependent synaptogenesis. Agrin, alone 
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or in combination with MuSK, act as a stop signal for neurite outgrowth. It is important in 
neuromuscular junctions formation, in fact agrin binds AchRs throughout the LG3 region of core 
protein C-terminal domain [Bezakova et al., 2003; Iozzo, 1998]. In in vivo null models the absence 
of agrin has no effect on brain development, but in in vitro cultures of hippocampal neurons isolated 
from agrin null mice the synapse formation seems to be disrupted.  
To investigate the role of NG2/CSPG4 in the nuerite outgrowth, NG2 was purified in a 
native state from B49 cells, the neural tumour cell line in which NG2 was first identified. Neurons 
do not attach to NG2-coated surfaces unless provided with adhesive molecules such poly-L-lysine, 
laminin or the L1 cell adhesion molecule [Tan et al., 2005]. These cell adhesion molecules all 
promote the growth of neuritic processes; however, when NG2 is a component of the substrate, the 
extent of neurite outgrowth is reduced by 40–45%. Removal of the chondroitin sulphate GAG 
chains from the NG2 core protein by digestion with chondroitinase ABC did not alter the ability of 
substrate-bound NG2 to inhibit neurite extension. On the other hand, treatment of the substrate with 
polyclonal antibodies against NG2 reduces the extent of growth inhibition [Tan et al., 2005]. When 
neurons were grown on growth-promoting substrates with either stripes or spots of NG2, the axons 
avoided the NG2-coated regions but grew extensively on the permissive surfaces [Tan et al., 2005]. 
Same portions of NG2 core protein, when added to cultures of newborn rat dorsal root ganglion 
neurons, induce the collapse of growth cones; this demonstrates that NG2 has all the properties 
associated with repulsive axon guidance cues and suggests that the dense accumulation of NG2 at 
glial scars could contribute to the creation of a barrier against successful axon growth [Tan et al., 
2005]. To study the NG2 domain involved in these functions, Tan et al. prepared a series of Fc and 
myc/his fusion proteins encoding individual domains of the NG2 core protein and combinations of 
adjacent domains. Each fusion protein was tested for its ability to induce growth cone collapse of 
newborn neurons and to inhibit the growth of axons from neonatal cerebellar granule neurons. The 
fusion proteins containing either domains 1 or 3 are inhibitory in both of these assays [Tan et al., 
2005]. The domain 2, which contains the sites of GAG attachment, is modestly inhibitory only 
when the GAG chains were present. Removal of the chondroitin sulphate GAG chains with 
chondroitinase ABC renders domain 2 inactive [Tan et al., 2005]. Curiously, chondroitinase 
digestion has no effect on the activity of a domain 1 and 2 Fc-fusion protein that also contains 
chondroitin sulphate GAG chains. Clearly, the GAG chains are not required for the inhibitory 
activity of large fragments of NG2 containing either domains 1 or 3 in these in vitro assays. The 
presence of inhibitory chondroitin sulphate GAG chains at glial scars in association with 
chondroitin sulfate-PGs other than NG2 may by one reason why chondroitinase ABC is effective in 
stimulating axon regeneration [Tan et al., 2005]. When NG2 is present as an integral membrane 
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protein, domain 1, which extends away from the plasma membrane, may be available to interact 
with the growth cones of damaged and sprouting neurons. Domain 3 lies close to the plasma 
membrane and may be inaccessible. When cleaved from the membrane and incorporated into the 
ECM, domains 1 and 3 would both be accessible. Thus, secretion or shedding of NG2 at glial scars 
could amplify the inhibitory signals transmitted by NG2 [Tan et al., 2005]. 
In the adult mouse, testicans are detected only in the brain, instead the human expression is 
more broader, and they are found also in prostate, testicles, heart, blood and cartilage. They show an 
anti-adhesive function, in particular testican 1 can block substrate attachment and neurite outgrowth 
of neuronal cells. This function is due to its capacity of binding and inhibition of proteases via the 
core protein portion of testican 1 [Roll et al., 2006]. 
No specific ligands for phosphacan has been reported, but several binding partners have 
been described and can be grouped according to the portion of the extracellular domain that they 
recognize. The growth factor pleiotrophin and the Ig superfamily CAMs L1/Ng-CAM, N-CAM, Nr-
CAM associate with the posphacan spacer region and the IgCAM protein contactin 1 binds to the C-
terminal domain. Importantly, the association between phosphacan on glia and contactin 1 on 
neurons promotes the outgrowth of neurites and induces bidirectional signaling between glia and 
neurons suggesting that this interaction plays a role in nervous system development [Bouyain and 
Watkins, 2010]. 
ONLY GAG CHAINS 
Considerable evidence indicates that versican actively regulates neuronal differentiation, 
maturation, neurite outgrowth, and synaptic transmission. Due to the difference in CS domains, 
versican V1 or V2 show distinct roles in cell function. It was demonstrated that V1 could induce 
mature neuronal differentiation. In contrast, V2, which is the predominant form of versican in the 
mature brain, exerts an inhibitory effect on neurite outgrowth. Through activating EGFR expression 
and modulating the downstream ERK signaling pathway, V1 could enhance cell proliferation and 
protect cells from apoptosis. 
Agrin plays an important role also in brain diseases like Alzheimer. The PG augment the 
rate of formation of fibrillar β amiloid  in the diseased brain and protects the proteolytic degredation 
of the β amiloid fibrils by binding them via its GAG chains. This means that agrin plays a crucial 
role in the formation of senile plaques and togheter with other extracellularmatrix components 
which are known to bind to agrin such as laminin and thrombospondin, stimulate the bundling of 
fibrillar β amiloid into larger aggregates. 
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COOPERATION 
The neurocan C-terminal domain may mediate the binding of neurocan to a variety of neural 
cell adhesion molecules including Ng-CAM, N-CAM and TAG-1/axonin-1, inhibiting their 
hemophilic interaction, and blocks neurite outgrowth [Iozzo, 1998]. Different studies show that also 
if both CS chains and core protein are involved in N-CAM binding with neurocan, the core protein 
retains binding activity also in absence of GAG chains. Similar binding characteristic are observed 
for Ng-CAM [Rauch, 2001]. Moreover neurocan interacts with tenascin and axonin-1 [Iozzo, 1998]. 
It may also bind heparin through the C terminal globular domain and this interaction has the 
important function of stabilizing the interaction of neurocan with its ligands [Rauch et al., 2001]. 
For example heparin stabilizes the binding of neurocan with FGF2, the heparin binding growth 
associated molecule HB-GAM and amphoterin. HB-GAM is a neurite-promoting matrix-associated 
protein lining growing axons in the brain. Amphoterin is a protein found in the leading edge and in 
substrate-attached material of growth axon cones and migrating cells. Not only the neurocan core 
protein but also CS chains bind FGF2 and the treatment of the PG with chondroitinase reduce the 
interaction by 35% [Rauch et al., 2001]. In contrast to the interaction with FGF2, the interaction of 
neurocan with HB-GAM and amphoterin appears to occur in a mainly CS chain-dependent manner. 
In fact chondroitinase treatment of neurocan reduces its binding capacity by 80%. It is interesting to 
note that HB-GAM-induced migration of neurons could be inhibited by addition of CS-6 sulfated 
chains but not by addition of CS-4 sulfated [Rauch et al., 2001].  
1.6. Matrix assembly 
ONLY CORE PROTEIN 
Decorin binds collagen type I and II in in vitro and in vivo assays  and it has an important 
role in organizing the extracellular matrix. The interaction is due to the LRR region of the core 
protein [Hardingham and Fosang, 1992; Iozzo and Murdoch, 1996]. In vivo experiments with 
decorin null animals models give the opportunity of studying the genetic evidence for a role of 
decorin in maintaining collagen fibrillogenesis. Mice carrying a homozygous disruption of the 
decorin gene grow normally to adulthood; however, they manifest a phenotype characterized by 
increased skin fragility. When sample of skin from the wild type and decorin null animals were 
subjected to biochemical testing, the latter samples exhibited a markedly reduced tensile strength 
that could be associated with an abnormal collagen fiber formation. Ultrastructural analysis of skin 
revealed bizarre and irregular collagen morphology with coarser and irregular fiber outlines in the 
decorin null speciments [Iozzo, 1998]. The comparison of matrix production wild type and decorin-
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null Dcn -/- mouse livers, shows strong evidence about the role of decorin in protection against 
fibrogenesis. The chemical induction of matrix deposition was higher in the liver from Dcn -/- mice. 
This response correlated well with the enhancement of collagen type I, III and IV proteins in the 
decorin deficient mice. Moreover the relative decrease in two major matrix metalloproteases, 
MMP2 and MMP9, and the concurrent increase in the hepatic levels of two major MMP inhibitors, 
TIMP-1 and PAI-1, indicated an involvement of decorin in the matrix regulation and remodelling 
[Baghy et al., 2012]. The functions of the decorin core protein as a matrix proteoglycan are well 
studied. It binds to collagen fibrils at the ‘‘d’’ or ‘‘e’’ bands and ‘‘decorates’’ the fibrils. One 
consequence of this interaction is a delay in triple helix formation and a reduction in the final 
diameter of the collagen fibrils in vitro [Seidler and Dreier, 2008]. The effect of irregular and 
heterogeneous diameter of collagen fibrils could be reproduced in vitro using decorin deficient 
fibroblasts and this phenotype could be rescued by exogenous decorin. However, in vivo, decorin 
was detected preferentially associated with a population of thicker fibrils in the interterritorial 
regions of articular cartilage, and was absent on the thinner fibrils in the territorial matrix around the 
chondrocytes, where collagen type IX was detected in greater amounts [Seidler and Dreier, 2008]. 
The decorin core protein was described to function as a signaling mediator. Decorin acts as a ligand 
for both the EGFR and the insulin-like growth factor receptor [Seidler and Dreier, 2008]. The 
importance of decorin role in matrix assembly process is highlighted in different pathological 
situation. For example in Marfan Syndrome there is a reduction in decorin gene transcription in 
fibroblasts and this is related with the connective tissue disorder that is characteristic of this 
syndrome [Hardingham and Fosang, 1992]. In Lyme disease, decorin binds Borrelia burgdorferi 
spirochete, that is the responsible of the tick-borne disease. The spirochete is not able to bind 
collagens type I and III directly, but it contains two decorin-binding proteins that act as adherins 
mediating the attachment of the organism to derman collagen via decorin. Decorin is involved not 
only in the initial colonization of the dermis, but it binds and inactivate the complement component 
C1q and it is involved in he further steps involving cytokine-controlled mediators of inflammation 
and immunological response [Iozzo and Murdoch, 1996]. Decorin is involved in the formation of 
atherosclerotic plaques and this is confermed also by different in vivo studies. For example systemic 
decorin overexpression resulted in a significant decrease in atherosclerotic plaque formation in 
Apo-E null mice. This was associated with a decrease in macrophage and collagen accumulation 
and decrease in gelatinase activity. In addition, serum triglyceride levels were also decreased 
suggesting a possible role for systemic decorin expression in the modulation of lipid profile [Singla 
et al., 2011]. 
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The LRR region of fibromodulin core protein contains the sequences for the biniding of 
fibril like collagens type I and II and for this reason, fibromodulin has an important role in 
organizing the extracellular matrix [Hardingham and Fosang, 1992; Iozzo and Murdoch, 1996]. 
Different in vivo studies on fibromodulin null mice Fmod -/- show that in absence of this PG there 
is a significant reduction in tendon stiffness and the ECM show particular characteristics like 
irregulat contour of fibrils and a higher concentration of small fibrils [Chakravarti, 2002]. It is 
possible to conclude that in particular tissues like tendon, fibromodulin is essential early in collagen 
fibrillogenesis to stabilize small-diameter fibrils.  
The C-terminal domain of neurocan core protein binds tenacin C and R, two related 
oligomeric extracellular matrix proteins. In particular tenascin C is the perfect partner of neurocan 
for the formation of the foundamental system of matrix organization: the complex 
glycoprotein/proteoglycan/hyaluronan, while tenascin R show a different behaviour. This protein 
expression seems to be inversely related to the neurocan one, in fact while the first increases during 
development, neurocan expression decline postnatal [Rauch et al., 2001]. 
Brevican is present in two different isoforms, one secreted and one anchored. The secreted 
isoform contain a C-terminal region that binds tenascin and other ECM molecules such as fibulin 2, 
hyaluronan and the link protein Bral2. The GPI-anchored isoform lacks this domain [Gary et al., 
1998] The secreted isoform is expressed only by neurons instead the GPI-anchored one is expressed 
only by glial cells [Gary et al., 1998]. It is also present at the axonal initial segment and takes place 
prior to the formation of the mature form of the ECM. The link between brevican and AIS accours 
via neurofascin 186, a glycoprotein from the Ig superfamily that is enriched at the AIS. 
The core protein of different syndecans is directly involved in the matrix assembly. For 
example deglycosylated syndecans 1 core protein, but not the glycosylated form, is able to bind 
anti-elastase and α1 antitrypsin [Choi et al., 2011]. The core protein of syndecans 2 is able to bind 
TGFβ directly and a truncated syndecans 2 cytoplasmic domain results in a dereased TGF-response 
and in an inability of cells to assemble laminin or fibronectin into a fibril matrix [Tkachenko et al., 
2005]. Moreover, syndecan 2 core protein appears to directly bind the pro form of matrix MMP7 
independent of GAG chains [Choi et al., 2011]. In vitro studies on different engineered cell types, 
like syndecan 2 knockdown HT1080 or CHO transfected with syndecans 2 lacking the C-terminal 
14 aminoacids of the cytoplasmic domain, show that these cells can not assemble laminin and 
fibronectin ECMs. The same effects are shown in Zebrafish models. In vivo studies on syndecans 4 
kockout mice demonstrate that also syndecans 4 core protein is essential for the formation of a 
correct matrix, expecially during the fibrin-fibronectin matrix contraction, in fact in these mutant 
mice fibroblasts have defects in this particular process of the matrix assembly [Choi et al., 2011].   
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Asporin directly binds to TGFβ1 and inhibits Smad signaling in chondrocytes; this lead to 
the suppression of TGFβ-mediated expression of different PGs like aggrecan that accumulate in the 
matrix. Also if the asporin-TGFβ binding is not yet well known, competition assays suggest that 
amino acids 159-205 of aspirin mediate its interaction with TGF-β1and effectively repress TGF-β1-
induced cartilage matrix gene expressions. Asporin also bind and decreases the concentration of 
BMP2 via its LRR domain, becaming a negative regulator of osteoblasts differentiation [Duval et 
al., 2011]. Throughout the same domain, asporin can bind also collagen type II, competing with 
decorin and playing an important role in osteoblast-driven collagen biomineralization activity. It is 
abundant in osteoarthritis articular cartilage and its expression is regulated by different cytokines 
such TGFβ, IL-1β, TNFα. In vitro experiments on cells treated with cytokines to reproduce the 
increased levels of proinflammatory stimuli observed in osteoarthritis synovial fluid, show a 
decreased asporin expression [Duval et al., 2011]. Moreover it was demonstrated that osteoarthritis 
susceptibility is affected by the number of aspartic acid residues in the aminoterminal extremity of 
the asporin protein. 
Mimecan/osteoglycin is essential in bone matrix formation because it can bind directly via 
its core protein different growth factors such as BMP2 and 3 and TGFβ1 and β2. Osteoglycin 
knockout mice show reduced tensile strength of the skin, caused by alterations in the diameters of 
collagen fibrils, thereby supporting a role for this proteoglycan in determining elasticity and tensile 
strength [Kampmann et al., 2009].  
The core protein plays the major role in the interaction between biglycan and collagen type 
VI and treatment with chondroitinase ABC does not affect the binding. This was supported by 
experiments demonstrating that the isolated chains were not able to inhibit the interaction in vitro. 
Collagen type VI have a role in the development of the matrix supramolecular structure as well as 
in tissue homeostasis by mediating interactions of cells with the extracellular matrix and its closely 
interaction with biglycan suggests that PG also may be of crucial importance in the matrix assembly 
and interaction with cells. 
ONLY GAG CHAINS 
Interestingly, the GAG chain of decorin had a reducing effect on collagen fibril diameter at 
early stages of fibrillogenesis [Seidler and Dreier, 2008]. In patients with a variant of Ehlers Danlos 
Syndrome, about half of the secreted decorin lack the GAG chain. These patients show a ß4 
galactosyltransferase I deficiency resulting in a reduced amount of L-IdoA in decorin. Notably, 
some of these patients have a skin fragility phenotype that resembles that of the decorin null mice 
[Seidler and Dreier, 2008]. Decorin not only regulates collagen fibril formation, but it also acts as a 
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bridging molecule between type I and type VI collagen. Decorin interacts with both collagens via 
different binding sites [Seidler and Dreier, 2008]. Although banded fibril-forming and filamentous 
beaded collagens form independent networks, they intermingle with each other in vivo, providing 
mechanical stabilization of tissues [Seidler and Dreier, 2008]. More recently, a complex formation 
between the globular domains of collagen type VI and a decorin/matrilin-1 complex has been 
described which can act as a bridge between collagen type VI and type II in cartilage, where decorin 
binds to the globular N-terminal domain of type VI collagen.  
Lumican play a pivotal role in the organization and maturation of a particular type of 
structure, that is the cornea. It is shown that in developing cornea, during the acquisition of cornea 
transparency, there is a marked upregulation of lumican mRNA and a concurrent switch from the 
nonsulfated to the KS sulfated isoform. This seems to underly the importance of KS GAG chains in 
the lumican biological function. [Iozzo and Murdoch, 1996] This conclusion is supported also from 
in vivo studies on lumican null-mice models Lum -/-. Lum -/- mice show a reduced cornea 
transparency and a marked skin fragility. In these animals skin, cornea and tendon show irregular 
collagen fibrils contours and the fibers show an increased diameter. Lumican seems to be 
foundamental in the binding of collagen fibers,  in limiting lateral growth of fibrils during the later 
stage of fibril formation [Chakravarti, 2002]. Lumican expression is increased in breast cancer, 
especially in the tumour stroma, and this correlates with higher tumour grade. Lumican expression 
has also been reported to be altered in various types of human malignancies, including melanomas, 
osteosarcomas, pulmonary, pancreatic and colorectal carcinomas. However, there are a lot of 
contrastant opinions regarding the role of this PG as pro- or anti-tumorigenic molecule and 
regarding its role as a prognostic tumor marker. For example, lumican overexpression correlates 
with poor prognosis in advanced colorectal, pancreatic cancers, in lung adenocarcinomas and 
squamous cell carcinomas [Iozzo and Sanderson, 2011; Theocharis et al., 2010].  
Opticin is present expecially in the ECM of vitreous humors where it play an important role 
in binding different matrix component. The presence of the GAG chains allow it to bind the CS 
chains of collagen type IX, stabilizing vitreous gel structure and manteining vitreous adhesion to the 
retina. The GAG chains also bind the HSPGs like the collagen type XVIII and in this way it link 
vitreous collagen fibrils to the inner limiting lamina. Opticin functions as an adhesive at the 
vitroretinal interface [Le Goff and Bishop, 2006]. 
The chondrodystplasia observed in the perlecan null mice is due to the fact that perlecan is 
involved in matrix assembly through its CS chains. In particular in cartilage matrix, CS perlecan 
chains binds and inhibits FGF2 binding to its receptor FGFR3 [Whiterlock et al., 2008]. 
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COOPERATION 
Changes in the expression of aggrecan CS epitopes are detected in mature canine articular cartilage 
after the experimental induction of joint instability leading to osteoarthritis. The aggrecan expressed 
in the experimental osteoarthritic cartilage contained CS that consistently had a longer chain and 
contained more of at least three different CS-epitopes detected by mAb [Hardingham and Fosang, 
1992]. It is suggested that the altered CS chains may contain special properties, such as an increased 
affinity for GFs or other cytokines that may facilitate matrix repair by the chondrocytes 
[Hardingham and Fosang, 1992]. Different studies underline that also the core protein may play an 
essential role in matrix assembly and composition. In particular, the function of aggrecan in matrix 
structure like cartilage is demonstrated by the phenotype of two different mutant animals: the 
nanomelic chicken, a useful model to elucidate intracellular trafficking of proteoglycans,.and the 
cartilage matrix-deficient (cmd) mouse [Iozzo, 1998]. In nanomelic chicken a single base mutation 
leads to a premature truncation of the aggrecan protein core, which lacks the C terminal globular G3 
domain. This gene mutation determins a recessively inherited connective tissue disorder. In the cmd 
mice phenotype is due to a deletion in exon 5 of the aggrecan gene. The delection occurs in the G1 
domain, resulting in a truncated polypeptide. Although heterozygous cmd mice appear normal, the 
homozygous mice die soon after birth due to respiratory failure [Iozzo, 1998]. These data highlight 
the importance of aggrecan in destructive diseases such as osteoarthrosis and underline its pivotal 
role in skeletal formation and maturation. 
Different control systems are involved in syndecan matrix assembly properties, and it is 
proposed that the cooperation between GAG chains and core protein may favour syndecan capacity 
of matrix modulation. Syndecan-2, for example, interact with MMP7 via its core protein and this 
binding potentiates the enzyme activation  with subsequent cleavage and shedding of the syndecan 
2 itself. Probably heparin and HS are also involved in the binding and activation of MMP7 
[Couchman, 2010]. Another syndecans capable to bind and modulate proteases is the syndecans 1 
and in the case of the interaction between syndecan 1 and MMP2, HS chains are involved and the 
interaction inhibit the catalytic activity of the MMP [Couchman, 2010]. In vivo experiments show 
that syndecan 4 can bind ADAMTS5, a member of the peptidase family ADAM, and it regulates its 
activity in a HS-mediated way [Couchman, 2010]. Syndecan 4 may interact also with ADAM12 via 
HS chains [Couchman, 2010]. 
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1.7. Apoptosis 
ONLY CORE PROTEIN 
Within the glypicans family, glypican-3 is an important apoptosis regulator: its loss 
determines the overgrowth characteristic of SGBS. For this function, GAG chains are not required. 
In fact GPC3 core protein is able to directly binds bFGF and inducing apoptosis.  
The binding of endostatin-XVIII to the surface of endothelial cells may lead to its rapid 
internalization and subsequent degradation. Intracellular forms, as well as signals transduced after 
engagement of specific endostatin receptors, could be responsible for the modulation of cell 
apoptosis and gene expression [Sasaki et al., 2002]. An increase in apoptosis was particularly 
prominent in FGF2 treated exponentially growing cells and was accompanied by the 
downregulation of anti-apoptotic proteins such as Bcl-2 and increased caspase-3 activity. Promotion 
of apoptosis was accompanied by the induction of tyrosine kinase signalling through the Shb 
adaptor protein and could be prevented by mutation of the heparin binding site of endostatin [Sasaki 
et al., 2002]. 
Chemoresistance is an important and problematic characteristic of many gliomas. 
Interestingly, in addition to its effects on cell proliferation and migration, NG2-dependent activation 
of α3β1 integrin also has effects on cell survival due to increased signaling through the PI3K/AKT 
pathway [Stallcup and Huang, 2008]. NG2-transfected U251 glioma cells are resistant to treatment 
with TNFα and chemotherapeutic drugs such as doxorubicin, vincristine and etoposide that 
effectively trigger apoptosis in parental U251 cells. siRNA-mediated knockdown of NG2 
expression effectively restores apoptosis sensitivity in U251/NG2 cells, further demonstrating the 
cause and effect relationship between NG2 expression and apoptosis resistance [Stallcup and 
Huang, 2008]. NG2 knockdown is also effective in increasing apoptosis sensitivity in endogenous 
NG2 expressing glioma lines such as U87 and A172, as well as in the A375 melanoma line, 
demonstrating that NG2-dependent apoptosis resistance is a widespread phenomenon in several 
tumor types. In all cases, there was a direct correlation of NG2 expression level with both β1 
integrin activation and the level of AKT phosphorylation. Two types of evidence indicate that the 
phenomenon operates in vivo as well as in vitro [Stallcup and Huang, 2008]. First, U87 cells 
produce significantly larger, faster growing tumors in NOD-SCID mice than U87 cells treated with 
NG2 siRNA to knock down expression of the proteoglycan in vivo. Growth of the siRNA-treated 
tumors is further inhibited by administration of TNFα, a phenomenon not seen in U87 tumors 
without siRNA treatment [Stallcup and Huang, 2008]. This demonstrates the increased apoptosis 
sensitivity provided by NG2 knockdown. The TNFα-independent decrease in tumor growth 
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provided by NG2 knockdown is likely due to the effects of NG2 on other parameters such as cell 
proliferation, reinforcing the idea that NG2 affects multiple aspects of glioma progression. Human 
glioma biopsy samples grown in spheroid cultures were tested for sensitivity to the chemotherapy 
drugs doxorubicin, etoposide and carboplatin. There was an excellent correlation between apoptosis 
resistance and the level of NG2 expression in these tumor samples [Stallcup and Huang, 2008]. 
1.8. Cell differentiation  
ONLY CORE PROTEIN 
CD44 mediate the binding of hematopoietic progenitor cells with Ha via its extracellular portion. In 
this way progenitor cells may interact with their respective niche in the bone marrow, proliferate 
and differentiate by regulation of local cytokine secretion [Hertweck et al. 2011]. CD44 play an 
important role also in T cell maturation. The v6 isoform mediates homing of progenitor cells from 
the bone marrow to the thymus where T-cells differentiation and selection takes place [Hertweck et 
al., 2011]. 
ONLY GAG CHAINS 
In the family of syndecans, syndecans 3 plays an important role in the skeletal muscle cell 
differentiation. Syndecan 3 is able to bind and control FGF2, the HGF/scatter factor and the TGFβ 
factor, controlling all these signal pathways via its GAG chains. When the syndecans 3 expression 
is suppressed, the myogenin is expressed. Myogenin is a transcription factor for muscle 
differentiation and its expression accelerates skeletal muscle differentiation and myoblast fusion 
[Tkachenko et al., 2005]. Also several BMPs may bind the syndecans GAG chains, stimulating 
chondrogenesis and chondrogenic differentiation of limb mesenchimal cells. Pretreatment of 
micromasses culture with heparinases, enhances the chondrogenic activity of BMP2, and reduces 
the concentration of BMP2 needed to promote chondrogenesis. 
In vivo studies suggest that also biglycan GAG chains may play a pivotal role in the 
formation of bone matrix and in controlling skeletal cell differentiation by binding BMPs 2 and 4. 
Knockout mice for biglycan show diminished bone mass progressively with age and they are 
defective in their capacity to form bone. The osteoporosis-like phenotype that is characteristic of 
this mouse model, is due to defects in cells critical to the process of bone formation. These data 
shows that biglycan deficient mice have diminished capacity to produce marrow stromal cells, the 
bone cell precursors, and that this deficiency increases with age. The cells also have reduced 
response to TGFβ, reduced collagen synthesis and relatively more apoptosis than cells from normal 
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littermates. In addition, calvaria cells isolated from biglycan deficient mice have reduced expression 
of late differentiation markers such as bone sialoprotein and osteocalcin and diminished ability to 
accumulate calcium judged by alizerin red staining. We propose that any one of these defects in 
osteogenic cells alone, or in combination, could contribute to the osteoporosis observed in the 
biglycan knockout mice [Young et al., 2002]. C2C12 myogenic cells were treated or untreated with 
BMP2 alone or in combination with glycanated, partially glycanated or de-glycanated BGN and it is 
shown that BMP signaling and function were increased when BMP2 was combined with de-
glycanated BGN among the groups tested. 
1.9. Angiogenesis 
ONLY CORE PROTEIN 
The C-terminal fragment of collagens type XVIII core protein is suggested to play a key role 
in angiogenesis. Angiogenesis is dependent on several integrin receptors, the activation of 
proteases, in particular matrix MMPs, and cytoskeletal changes required for cellular migration. 
Several of these components have been examined as potential targets of endostatin XVIII [Sasaki et 
al.,2002]. Several in vivo studies have consistently demonstrated that endostatin reduces the growth 
of various primary tumors as well as metastases because selectively decreases blood flow and size 
of tumor vessels and enhances apoptosis of tumor cells [Sasaki et al., 2002]. Endostatin treatment 
did not interfere with vessel density in the granulation tissue, wound contraction, or the final stage 
of repair. During the peak of angiogenesis, however, endostatin interferes with vessel maturation, as 
indicated by massive hemorrhages and pathological changes in the ultrastructure of vessel walls 
[Sasaki et al., 2002]. These findings are consistent with a higher sensitivity of tumor vessels, which 
are known to have a chaotic and leaky architecture and also integrate tumor cells into their 
endothelial lining [Sasaki et al., 2002]. Different studies underline the capacity of endostatin to bind 
and inhibit MMP2 and MT1-MMP, reducing endothelial cell invasion into a basement membane 
matrix [Sasaki et al., 2002]. Endostatin was also found to bind α5β1 and some other RGD-
dependent integrins, modulating cell spreading, focal adhesions formation and cell migration, in 
particular cell types like the endothelial cells. Endostatins do not have a cell adhesive RGD 
sequence, however the binding of these integrins may involve other sites similar to those also 
involved in the binding of MMP2 [Sasaki et al., 2002] There is also some evidence that endostatin 
binds weakly to tropomyosin and to disassemble focal cell adhesion plaques containing 
plasminogen activator. Whether endostatin can directly bind to cytoskeletal proteins remains an 
open question and would require its uptake by cells, for which phenomenon there are some 
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evidence exists [Sasaki et al., 2002]. Endostatin-XVIII and -XV are also present in the circulation, 
as shown by their isolation from large volumes of human plasma hemofiltrate and in immunological 
studies [Sasaki et al., 2002]. Endostatin-XVIII concentrations comparable with that present in 
mouse and human serum, were shown in in vitro assays to inhibit migration and other properties of 
cultured endothelial cells suggesting that circulating endostatin is involved in the control of vessel 
stability by counteracting local angiogenic stimuli [Sasaki et al., 2002]. Besides being involved in 
the early stages of the angiogenesis, endostatin is involved also in the mature vessel. In fact 
endothelial cells grown in contact with collagen fibrils readily form tube-like structures similar to 
vessels during early angiogenesis an these tubes were apparently stabilized by endostatin-XVIII. A 
core protein domain of collagen type XVIII, different from endostatin and called NC1, show a 
different function in angiogenesis. A more comprehensive study demonstrated that trimeric NC1-
XVIII caused a disassembly of these tubes into scattered cells, a process that was antagonized by 
monomeric endostatin [Sasaki et al., 2002]. Vascularization of embryonic chick chorioallantoic 
membranes is one of the standard models to study collagens involvement in angiogenesis in situ. 
Microgram amounts of endostatin-XVIII were shown to inhibit chick chorioallantoic membranes 
angiogenesis prior to or after stimulation with FGF2 or VEGF [Sasaki et al., 2002]. The major 
effect was a reduced capillary sprouting that in most studies was evaluated by a non quantitative 
scoring of vessel branching. Mutations of endostatin indicated that heparin, is essential for the 
inhibitory activity [Sasaki et al., 2002]. 
Endocan mainly expressed by endothelial cells and its expression is regulated in vivo by 
different inflammatory cytokines such VEGF, FGF2, TNFα. A marked expression of endocan is 
shown in brast, brain, lung, liver, kidney, suggesting that this PG may perhaps be important in the 
angiogenesis and endothelial-mesencymal transition processes, modulating the presence of different 
growth factors like FGF2, TGFβ, IGF2 via its N-terminal and EGF-like domains [Carrillo et al., 
2011]. Endocan is also associated with filopodia of angiogenic endothelial tip cells in invasive 
bladder cancer. Notably, endocan expression on tumor vessels correlated strongly with staging and 
invasiveness, predicting a shorter recurrence-free survival time in non-invasive bladder cancers. 
Both endocan and VEGF-A levels were higher in plasma of patients with invasive bladder cancer 
than in healthy individuals. Investigations in cultured blood vascular endothelial cells or transgenic 
mice revealed that endocan expression was stimulated by VEGF-A through the phosphorylation and 
activation of VEGFR-2, which was required to promote cell migration and tube formation by 
VEGF-A. Taken together, these data suggest that endocan interaction with VEGFR-2 or VEGF-A 
could stimulate tumor angiogenesis. 
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Syndecan core protein may play an important role in the angiogenesis process. For example, 
the core protein ectodomain is involved in the binding of different pro-angiogenic factors. Syndecan 
1 ectodomain is seen to bind integrins, VEGF and their respective receptors, stimulating endothelial 
cells to initiate endothelial invasion and budding. Short inhibitory peptide that mimic syndecan 1 
ectodomain, called synstatin, abrogate PG interactions and inhibits endothelial cell invasion and 
tumor growth in vivo [Morgan et al., 2007; Teng et al., 2012]. An in vivo model provided the use of 
anti-syndecan 2 morpholino oligonucleotides in Zebrafish shows that this syndecans may modulate 
VEGF signalling. Syndecan 2 knockout Zebrafish have the suppression of intersegmental vessels, 
whereas dorsal vessel formation is not affected. The overexpression of VEGF 165aa in syndecans 
2-morphans was not able to induce ectopic vessel formation whereas coexpression of syndecans 2 
and VEGF 165aa resulted in an increase of vessel formation compared with VEGF alone 
[Tkachenko et al., 2005].  
It was shown that domain V of the perlecan core protein, renamed endorepellin, harbored a 
powerful angiostatic activity as demonstrated by various in vitro and in vivo angiogenic assays 
[Whiterlock et al., 2008]. Endorepellin is composed of three laminin-like globular domains (LG1–
LG3) interspersed by four EGF-like modules, and interacts specifically with the α2β1 integrin, an 
established receptor for collagen type I, in platelets and endothelial cells. In the latter, endorepellin 
triggers a signaling cascade that leads to disruption of the endothelial actin cytoskeleton and thus to 
cytostasis [Whiterlock et al., 2008]. Importantly, systemic delivery of human recombinant 
endorepellin to tumor xenograft-bearing mice causes a marked suppression of tumor growth and 
metabolic rate mediated by a sustained down-regulation of the tumor angiogenic network 
[Whiterlock et al., 2008]. Genetic analysis using siRNA-mediated block of endogenous α2β1 
integrin or animals lacking the α2β1 integrin receptor have definitively shown that this is a key 
receptor for endorepellin and have further demonstrated that endorepellin targets the tumor 
xenograft vasculature in an α2β1 integrin-dependent manner [Whiterlock et al., 2008]. The last 
laminin-like globular domain, LG3, possesses most of the biological activity and can be released 
from the parent molecule by BMP1/Tolloid-like metalloproteinases which recognize a dipeptide 
that is highly conserved across species including human, mouse, Drosophila and Zebrafish 
[Whiterlock et al., 2008]. This highly conserved region within the perlecan core protein together 
with the high conservation of BMP1/Tolloid-like metalloproteinases suggests that liberation of LG3 
might be of physiological importance. Mutations in LG3 molecules displaying lower or no affinity 
for calcium disrupt LG3 angiostatic activity [Whiterlock et al., 2008]. LG3 fragments with identical 
N-terminal residues (i.e., cleaved by BMP1/Tolloid-like metalloproteinases) have been found in the 
urine of patients with end-stage renal failure and chronic allograft nephropathy, and in the amniotic 
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fluid of pregnant women with a marked increase in women with symptoms of premature rupture of 
fetal membranes and those carrying trisomy 21, Down Syndrome, fetuses. In addition, endorepellin 
fragments have been found in the media conditioned by apoptotic endothelial cells. In this case, the 
secreted LG3 interacts with the α2β1 integrin receptor of fibroblasts and triggers a signaling 
cascade that leads to activation of an anti-apoptotic pathway and potentially to a fibrogenic response 
[Whiterlock et al., 2008]. 
 CD44 promotes angiogenesis in tumor environment by binding TGFβ and promoting MMP9 
activity. CD44 v6 isoform has been shown to activate endothelial cell migration, sprouting and 
tubule formation thought activation of c-Met and VEGFR-2 in response to HGF and VEGF-A 
binding to the extracellular domain of CD44 [Louferbough and Schroeder, 2011]. 
NG2 may be an important linker between endothelial cells and pericytes. Vascular 
endothelial cells do not express NG2 proteoglycan, but exposure to NG2 stimulates the motility of 
glioma cells. This trans effect is due to the interaction of the proteoglycan with the galectin-3/α3β1 
integrin complex on the endothelial cell surface, resulting in enhanced β1 integrin signaling, greater 
endothelial cell motility and enhanced endothelial tube formation in vitro, and dramatically 
increased blood vessel development in vivo [Xu et al., 2011]. These phenomena are significant 
because of the intimate interaction that exists in blood vessels between endothelial cells and NG2-
positive pericytes. NG2 may be important as one element of the crosstalk that occurs between 
endothelial cells and pericytes. The significance of this will become more apparent when we discuss 
on neovascularization [Stallcup and Huang, 2008]. The role of NG2 in blood vessel development is 
extremely relevant in glioma progression. While the majority of vascularization studies focus on the 
endothelial component of blood vessels, it is now clear that pericytes are also an early and critical 
component of microvascular development [Stallcup and Huang, 2008]. NG2 also has an important 
role in pericyte development and function, as demonstrated by the decreased post-natal 
neovascularization observed in the NG2 null mouse. In ischemic retinal vascularization and in 
corneal vascularization induced by FGF2, blood vessels development is decreased more than 2-fold 
by genetic ablation of NG2 [Stallcup and Huang, 2008]. The NG2-deficient vasculature that forms 
in these pathological eye models is characterized by a diminished pericyte:endothelial cell ratio 
(dropping from 1:1 to as low as 1:4). The most obvious cause of this change is the reduced 
proliferation of pericytes in the absence of NG2, as detected by BrdU incorporation [Stallcup and 
Huang, 2008]. 
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ONLY GAG CHAINS 
Syndecans GAG chains composition is directly involved in the PGs control of angiogenesis. 
In mouse mammary cells the treatment with TGFβ determines an increased expression of syndecans 
chondroitin sulfate chains with the synthesis of longer chains as well as the increase in CS number 
attached to the core protein. CS-rich syndecan bounds specifically to thrombospondin, an 
antiangiogenic protein which failes to bind syndecan with a regular complement of CS and HS 
[Hardingham and Fosang, 1992].  
Some families of growth factors different from the FGF one, have been shown to 
demonstrate differential binding to perlecan HS with one such example being the VEGFs 
[Whiterlock et al., 2008]. One of the longer isoforms, VEGF189, which contains exon 6 that encodes 
a basic stretch of amino acids and which has been shown to be responsible for matrix localization, 
binds to perlecan HS derived from endothelial cells whereas the shorter and more highly expressed 
VEGF165 does not. Interestingly, a fraction that included both the secreted and cell surface HSPGs 
from fibroblasts was shown to bind VEGF165. This would support the idea that perlecan localizes 
the larger forms of VEGF to the matrix but does not sequester the shorter forms, enabling them to 
diffuse through the pericellular matrix and bind to the cell surface HSPGs where they can activate 
the signal cascade. An elegant study in Zebrafish conducted by Whiterlock et al., shows that the 
localization of VEGF in the matrix was disturbed by the knockdown of the expression of the 
enzyme 6-O-sulfotransferase which affects the levels of sulfation present within HSPGs. Cell 
proliferation occurs satisfactorily but the process of branching morphogenesis is severely retarded. 
It is possible that the perlecan produced by endothelial cells undergoing angiogenesis would have 
low amounts of 6-O-sulfate and if it produced a perlecan that had a high proportion of these sulfate 
groups, it would prevent angiogenesis by hindering the diffusion of VEGF: this may be a process 
that cells use to modulate the response of the endothelial cells to VEGFs produced in the 
pericellular environment [Whiterlock et al., 2008]. Perlecan is largely expressed in the stroma of 
different type of tumors and it might directly contribute to the scaffolding of angiogenic blood 
vessels binding bFGF via the GAG chains and functioning as a low-affinity coreceptor for this 
factor, and for this reason perlecan become an important component in the process of bFGF-tumor 
angiogenesis [Iozzo and Murdoch, 1996]. The knockdown of perlecan in metastatic prostate cancer 
cells  reduces the responses to FGF2 and VEGF and in vivo tumor growth. This PG colocalizes with 
sonic hedgehog in aggressive prostate carcinomas and its knockdown in these cells leads to an 
attenuation of cell proliferation and Shh signaling [Bix and Iozzo, 2008]. Increased perlecan in 
breast and colon carcinomas correlates with enhanced metastatic potential [Bix and Iozzo, 2008]. 
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Collectively, by binding and protecting these various growth factors from degradation and 
misfolding, perlecan could modulate angiogenesis and tumor growth [Bix and Iozzo, 2008]. 
Notably, antisense targeting of endogenous perlecan in a variety of transformed cells including 
colon carcinoma and melanoma cells causes a significant inhibition of tumor growth and 
angiogenesis [Whiterlock et al., 2008]. Seemingly, colon carcinoma cells with a somatic cell 
mutation leading to a perlecan null phenotype show growth retardation and minimal angiogenesis in 
tumor xenografts. The central role of perlecan in angiogenesis is further confirmed by genetic 
manipulation leading to complete ablation of the perlecan gene [Whiterlock et al., 2008]. A 
significant proportion of perlecan-null mice develop numerous vascular anomalies including 
transposition of the great arteries and abnormal coronary arteries. In an animal model expressing a 
mutated form of perlecan lacking the glycosaminoglycan attachment site, and thus lacking HS side 
chains, there is impaired angiogenesis and retarded tumor growth [Whiterlock et al., 2008].  
Using a murine oxygen induced retinopathy model, it was discovered that opticin possesses 
anti-angiogenic activity. Using an ex vivo chick chorioallantoic membrane assay, it was shown that 
opticin inhibits angiogenesis when stimulated by a range of growth factors. It suppresses capillary 
morphogenesis, inhibits endothelial invasion, and promotes capillary network regression in three-
dimensional matrices of collagen and Matrigel. It is then shown that opticin binds to collagen and 
thereby competitively inhibits endothelial cell interactions with collagen via α1β1 and α2β1 
integrins, thereby preventing the strong adhesion that is required for proangiogenic signaling via 
these integrins. 
1.10. Coagulation 
ONLY CORE PROTEIN 
Bikunin is a proteinases inhibitor present in plasma and urine. It can inhibit trypsin, 
chymotrypsin, granulocyte elastase, plasmin, cathepsin G and acrosin. However, bikunin binds 
these enzymes less avidly than other, more abundant proteinase inhibitors in plasma, making the 
physiological function of bikunin unclear. The amino acid residue in the binding site of the C-
terminal domain (domain II) is Arginine, a residue which seems to be conserved among mammals. 
The construction of different modified bikunin molecule makes possible to assign the binding 
capacity of this PG to its core protein domain II. Domain I is involved only in some of the total 
activity against cathepsin G and granulocyte elastase [Fries and Blom, 2000]. 
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COOPERATION 
Thrombomodulin inhibits thrombin-induced fibrinogen clotting and promotes inactivation of 
thrombin by binding antithrombin through both the CS chains and one of the EGF- like region 
(EGF 5-6) of the core protein [Hardingham and Fosang, 1992; Koutsi et al., 2007]. 
Thrombomodulin may also bind and activate zymogen form of the anticoagulant protein C and this 
function is not related to the chains but it depends only on core protein. For this reason if it is 
possible to say that the major anticoagulant activity of thrombomodulin is due to its core protein, 
however GAG chains are important for the modulation of this function [Hardingham and Fosang, 
1992]. Thrombomodulin is present on the surface of endothelial cells and its EGF-like domain 
(EGF 4-6) bind with high affinity to thrombin that is generated close to intact endothelium. This 
binding determines the loss of the procoagulant activity of thrombin and the gain of the ability to 
activate protein C [Anastasiou et al., 2012]. The high concentration of circulating thrombomodulin 
in the microcirculation is crucial for local protein C activation and blood anticoagulation 
[Anastasiou et al., 2012]. Despite the binding is due to one of the PG core protein domain, once 
modified with the CS, thrombomodulin enhances the PC activity, accelerates the neutralization of 
thrombin by heparin-antithrombin and by the PC inhibitor and facilitates binding of platelet factor-4 
to PC to accelerate its activation [Anastasiou et al., 2012; Koutsi et al., 2007]. Different in vivo 
experiments confirm the important function of thrombomodulin in the coagulation process. 
Transgenic mice with single nucleotide modification leading to Glu387Pro substitution (TMPro) in 
the thrombomodulin gene, show a mild hypercoagulable state associated with vascular bed-specific 
fibrin deposition, moderately accelerated platelet thrombus formation and a strong predilection for 
stasis-induced thrombosis. TMPro animals do not develop spontaneous thrombosis [Anastasiou et 
al., 2012]. Moreover, in the thrombomodulin-deficient TM -/- chimeric mice, the fibrin deposits 
were largely restricted to pulmonary vessels, suggesting that localized thrombomodulin deficiency, 
as it occurs for example in atherosclerosis lesions or iatrogenic endothelial cell damage, triggers 
localized coagulation and thrombosis [Anastasiou et al., 2012].  
1.11. Immune response 
ONLY CORE PROTEIN 
Thrombomodulin controls the complement arm of the innate immune system in a thrombin-
dependent manner through activation of the TAFI that binds the EGF-like repeats 3-6 domains of 
thrombomodulin core protein. An intact thrombin-thrombomodulin complex is required for TAFI to 
suppress complement activation [Anastasiou et al., 2012; Koutsi et al., 2007]. When associated with 
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thrombomodulin, the pro-inflammatory properties of thrombin are abrogated and in this way 
thrombomodulin become an indirect anti-inflammatory molecule. Instead the N-terminal C-type 
lectin-like domain of thrombomodulin has direct anti-inflammatory properties by mediating signals 
that interfere with MAPK and NFkB pathway [Anastasiou et al., 2012; Koutsi et al., 2007]. The 
complement control may happen also in a thrombin-independent constitutive manner via 
thrombomodulin lectin-like extracellular domain [Anastasiou et al., 2012].  
PRELP play a foundamental role in immunological disease as modulator of the immune 
response. For example in rheumatoid arthritis, the cartilage tissue is destroyed and fragmented 
molecules, including PRELP, are released into the synovial fluid where they may interact with 
components of the complement system. In different studies PRELP is found to interact with the 
complement inhibitor C4-BP, which is suggested to locally down-regulate complement activation in 
joints during rheumatoid arthritis. It is shown that PRELP directly inhibits all pathways of 
complement by binding C9 and thereby prevents the formation of the membrane attack complex. 
PRELP does not interfere with the interaction between C9 and already formed C5-8, but inhibits C9 
polymerization thereby preventing formation of the lytic pore. The alternative pathway is moreover 
inhibited already at the level of C3-convertase formation due to an interaction between PRELP and 
C3. This suggests that PRELP may downregulate complement attack at basement membranes and 
on damaged cartilage and it therefore limit pathological complement activation in inflammatory 
disease such as rheumatoid arthritis. 
ONLY GAG CHAINS 
After the generation of serglycin knockout mouse models it become easy to study the role of 
this PG in immune system and, in particular, in the process of granulopoiesis. In the knockout 
model, the generation of secretory granules in mast cells shows to be compromised and there is a 
reduction of several important proteases, histamine and serotonin [Kolset and Tveit, 2008, Kolset 
and Pejler, 2011]. It is clear that also secretory granules of cytotoxic T lymphocytes, mast cells, 
neutrophils and platelets are compromised in knockout mice [Kolset and Tveit, 2008]. It is 
important to underline that granzyme A and B are not affected by the lack of serglycin, more 
precisely the storage of granzyme B but not A is affected rather than protease mRNA expression. 
The same effect showed in serglycin knockout mice is seen also in NDST-2 knockout mice that lack 
the enzymes involved in GAG chains production. For this reason is possible to conclude that all the 
effect of serglycin on the granule storage may be attributed to GAG chains presence and binding 
[Kolset and Tveit, 2008; Kolset and Pejler, 2011]. In neutrophils only one type of granules, the 
azurophil ones, is affected in knockout models. Studies on Gram-negative bacteria infection of 
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serglycin knockout mice and control mice, show that the first one model seems to be more 
susceptible to the infection, because the lack of serglycin may affect immune defence [Kolset et 
Tveit, 2008]. Serglycin is shown to bind some proteases, like tryptases, forming tetramers complex, 
and it covalently binds also MMP9 as it is demonstrated in monocyte-like THP-1 cells [Kolset and 
Tveit, 2008]. Interacting with them, serglycin is involved in the retention of proteases in storage 
granules in mast cells. Not all the granule components depend on serglycin presence, in fact 
granzyme A and cathepsin G are not affected by the lack of this PG [Kolset and Tveit, 2008]. 
Complexes of serglycin and proteases are released from mast cells and serglycin is implicated in the 
secretion of different granule molecules, like TNF-α from macrophages, MMP9 from monocytes or 
chemokines from HIV-infected T cells. So it is possible to conclude that serglycin is essential for 
the regulation of the secretion of an impressive repertoire of molecules important in inflammatory 
reactions [Kolset and Tveit, 2008]. The secretion of the serglycin-ligand complexes is linked to the 
cell activation. After secretion, the change in microenvironment pH conditions causes the release of 
serglycin partner molecules [Kolset and Tveit, 2008; Kolset and Pejler, 2011]. So it is clear that 
serglycin has also important roles after immune cell secretion. In particular its heparin chains are 
important for the protection of enzymes inactivation because protease inhibitors are not able to bind 
heparin. Moreover heparin chains may mediate encounter between proteases and their substrates 
and are involved in activation and processing of proteases. Serglycin is also necessary to protect its 
partner molecules during their transport, for example proteases are only released to perform its 
function when the complex has reached its final destination [Kolset and Tveit, 2008; Kolset and 
Pejler, 2011]. Thanks to studies on serglycin knockout mice and NDST-2 knockout mice, it is clear 
that GAG chains linked to serglycin core protein are cell type-dependent. In particular in connective 
tissue-type mast cells serglycin bind prevalently heparin chains and this is the only cell type capable 
to synthesize the highly sulfated GAG heparin whereas a multitude of other cells like macrophages 
synthesize HS. The mucosal mast cells subtype produce serglycin binding CS chains, carrying O-
sulfate groups at the 4- and 6-position. In cell type other than mast cells, for example in T 
lymphocytes, lower sulphated GAG species of CS type are predominantly attached to serglycin 
[Kolset and Pejler, 2011]. The composition of serglycin structure and the GAG chain type attached 
may depend on immunological signals. In fact it is shown that in eosinophils serglycin carries 
prevalently CS-4 sulfated chains after stimulation of cells with IL-3 or GM-CSF [Kolset and Pejler, 
2011]. Serglycin is involved in granules control in most hematopoietic malignancies where its 
aggregation with the partner molecules may prevent extensive diffusion outside inflamed tissues. In 
human multiple myeloma is demonstrated an high cell surface localization of serglycin that binds 
cell surface by its GAG chains [Kolset and Tveit, 2008; Kolset and Pejler, 2011]. Myeloma-derived 
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serglycin interfered with bone mineralization providing a possible explanation for osteoporosis 
commonly in multiple myeloma patients. Serglycin is highly produced in acute myeloid leukemia 
but not in acute lymphoblastic leukemia [Kolset and Pejler, 2011]. 
Syndecans are able to bind most chemokines and participate in immune responses. In 
particular syndecans 1 is directly involved in inflammation as suggested by increased leukocyte-
endothelial interactions in syndecans 1 null mice. It also has an important role in forming complex 
with IL-8, that control syndecans 1 shedding, and in chemokine gradient formation for trans-
endothelial and trans-epithelial migration of neutrophils [Tkachenko et al., 2005]. For example, 
syndecan-1 binds through its heparan sulfate chains to the CC chemokines CCL7, CCL11, and 
CCL17 implicated in allergic diseases, resulting in inhibition of CC chemokine mediated T cell 
migration and suppression of allergen induced accumulation of Th2 cells in the lung [Choi et al., 
2011]. Syndecan 1 and syndecan 4 bind the chemokine RANTES on monocyte derived 
macrophages, facilitating the subsequent interaction of RANTES with its receptor CCR5. The 
interaction of syndecans with chemokines play a pivotal role in cell survival. For example SDF-1 
associates with chemokine (C-X-C motif) receptor 4 (CXCR4) and syndecan 4 at the plasma 
membrane of Huh7 cells, inducing the growth of Huh7 cells by promoting their entry into the cell 
cycle and inhibiting tumor necrosis factor-α-mediated apoptosis [Choi et al., 2011]. Syndecans 
possess the unique ability to interact with pathogens. All members of the syndecan family possess 
similar capacities to interact with HIV-1. Enzymatic removal of the heparan sulfate chains 
abrogates the ability of syndecans to capture HIV-1, indicating the importance of the linear anionic 
heparan sulfate chains for HIV-1 binding [Choi et al., 2011]. Like HIV-1, a great number of other 
pathogens use syndecans as attachment receptors to facilitate either entry into host cells or 
persistence in the hostile host environment [Choi et al., 2011]. 
COOPERATION 
T-cell activation during immune response not only requires the recognition of antigen-
loaded major histocompatibility complex by the T-cell receptor, but also the interaction of 
additional surface receptors expressed by T-cells with their corresponding counter-receptors on 
APC cells. Agrin is one of these important additional receptors and it tooks part in the T-cell-APC 
cells interaction, inducing the cluster of the surface receptors [Bezakova et al., 2003; Jury and 
Kabouridis, 2010]. Its splicing at the amino N-terminus produces either secreted or membrane-
anchored proteins, whereas splicing at two additional sites closer to the carboxy C-terminal, named 
y and z in the mammalian system, produces proteins that either lack or include two small exons. On 
the T-cells only the transmembrane agrin isoform is expressed, it accumulates to distinct areas of 
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the cell membrane and T-cell activation causes its redistribution post-translationally modification to 
a form with an increased ability to aggregate receptors on T-cells. Although if the nature of this 
modification is unknown, it is shown that glycosylated agrin is dominant in resting lymphocytes 
and deglycosylation form is present in activated lymphocytes [Bezakova et al., 2003; Jury and 
Kabouridis, 2010].  
Collagen type IX NC4 domain binds both C4-BP and factor H. C4-BP is the major soluble 
inhibitor of the classical and lectin pathway for the complement activation; factor H inhibits the 
alternative route. Binding these two molecules, collagen type IX play an important role in degrading 
C4b and C3b activating complement factors slowing down the complement activation process 
[Kalchishkova et al., 2011]; NC4 domain can inactivate complement directly inhibiting C9 
polymerization and membrane attack complex formation [Kalchishkova et al., 2011]. 
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                                2.  MATERIAL AND METHODS 
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2.1. RNA extraction and reverse transcription-polymerase chain reaction (RT-
PCR) 
Total RNA from different sarcoma cells was prepared by using Trizol
®
 (Life Technology 
Corporation, California, US) according to the manufacturer’s instructions and RNA quality was 
checked by Biophotometer (Eppendorf AG, Germany) and 1% agarose RNase free TAE agarose gel 
electrophoresis. Total RNA (1μg) was reverse-transcribed with the QuantiTect® Reverse 
Transcription Kit (Qiagen, Netherlands) according to the manufacturer’s instructions. Qualitative 
RT-PCR was performed at the beginning to check the presence of glypicans and syndecans (GPC1, 
GPC2, GPC3, GPC4, GPC5, GPC6, SDC1, SDC2, SDC3, and SDC4) mRNA in cells and it was 
amplified, as internal control, RLP41 housekeeping gene to test the integrity and functionality of 
cDNA from cells. To control the absence of DNA contamination it was performed a PCR with 
primers for RLP41 on reverse-transcribed without RNA as substrate. To quantify the exactly 
amount of each gene expressed in all the sample tested, it was performed a quantitative Real-Time 
PCR using TaqMan Low-Density Arrays (TLDA). Gene expression was normalized to endogenous 
housekeeping gene 18S rRNA and it was chosen cDNA of human mesenchymal stem cells (hMSC) 
as sample calibrator, because all sarcomas analyzed came from mesenchymal cells. An equal 
amount of input cDNA (100 ng) was used per reaction and loaded in one of the eight sample-
loading port of the card. Results were analyzed using ABI PRISM 7900HT Sequence Detection 
System (ABI), and changes in gene expression levels were calculated using the “relative 
quantification method" based on the expression levels of a target gene versus a reference gene in 
each sample in comparison to a sample. 
Total RNA from tumoral tissue biospies were prepared by using alone or in combination Trizol
®
 
(Life Technology) and RNeasy Plus Mini Kit (Qiagen) according to the manufacturer’s instructions 
and RNA quality was checked by Biophotometer (Eppendorf) and 1% agarose RNase free TAE 
agarose gel electrophoresis. Total RNA (1μg) was reverse-transcribed with the QuantiTect® 
Reverse Transcription Kit (Qiagen) according to the manufacturer’s instructions. Qualitative RT-
PCR was performed at the beginning to check the integrity and functionality of the cDNAs, and it 
was amplified human RLP41 (FWD: 5’-GGAGGCCACAGGAGCAGAAA-3’; REV: 5’-
TGTCACAGGTCCAGGGCAGA-3’) and mouse RPL27 (FWD: 5’-CAAGAAGAAGATCGCCAAGC-3’ and REV: 
5’-TCGCTCCTCAAACTTGACCT-3’) housekeeping genes mRNA. To verify the presence of GPC5 
gene transcript, it were used specific primers for human and mouse glypican 5 mRNA: (hFWD) 5’-
TATCCGGTCGTTGGAAGAAC-3’; (hREV) 5’-GGTGGTCTTCATTCCATGCT-3’; (msFWD) 5’-
CCGAGGATGGATGCCCGCAC-3’; (msREV) 5’-CTTCGCAGCTCTCCACGCCC-3’. qPCR on 143B GPC5+ 
clones were done using the human RPL41 and human GPC5 primers previously mentioned and  by 
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SYBR Green technology (Takara Bio Inc., Japan) and all samples were runned on OpticonMJ Real-
Time (Bio-Rad Laboratories Headquarters, California, US) 
 
2.2. Purification of HSs 
Bovine liver was homogenized in ice-cold acetone and lyophilized. The acetone powder was 
digested with actinase E, treated with 5% trichloroacetic acid, and the polysaccharides were 
precipitated with 80% ethanol as previously described [Yamada et al., 2002]. The resultant 
precipitate was subjected to DEAE-cellulose column chromatography using stepwise elution with a 
0.05 M sodium acetate buffer, pH 4.0, containing 0.15, 1.0, and 2.0 M LiCl. Each fraction was 
desalted by ethanol precipitation and the precipitates were dissolved in water. 
Bovine kidney HS, porcine intestine HS, and bovine liver GAG preparations were digested with a 
mixture of heparinases I and III [Ueno et al., 2001]. Each digestion was labeled with a fluorophore 
2-aminobenzeamide and subjected to anion exchange HPLC on an amino-bound silica PA-03 
column (YMC Co., Japan) as previously reported [Kinoshita et al., 1999]. Identification and 
quantification of the resulting disaccharides were achieved by comparison with HS-derived 
authentic unsaturated disaccharides. 
2.3. Cell culture and transfection 
143B human osteosarcoma cells were transfected with pDisplay expression vector containing ORF 
cDNA of glypican 5 HA-tagged (Fig. 1) or glypican-6 HA-tagged and pDisplay empty expression 
vector as control (143B mock). The expression vector pDisplay containing ORF cDNA of GPC5 
was gently provided by Guido David (University of Leuven-CME) and containing the box for G418 
(Geneticin) resistance (Geneticin/Neomycin). The transfections were done using Metafectene™ Pro 
Reagent (Biontex, Germany) in condition predetermined to obtain maximum efficiency of 
transfection; briefly, Solution A (0.8 μg of vector DNA in 50 μl medium free of serum and 
antibiotics) and Solution B (8 μl of Metafectene™ Pro transfection reagent in 50 μl medium free of 
serum and antibiotics) were applied on 60-70% cell confluence and for 143B GPC5 transfected 
were performed an antibiotic monoclonal clones selection by G418 at concentration of 500 µg/ml, 
that is, after 48 h from the transfection, the cells were seeded at high dilution (6000 cells/100 mm 
dish) until formation of single clones, the individual clones were expanded and cells from each 
clones were screened by RT-PCR for presence of GPC5 mRNA. Positive clones were expanded and 
it was chosen the clone with the major level of glypican 5 expression revealed by quantitative Real-
Time PCR.  
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143B cells were routinely grown in monolayer cultures and maintained at 37°C in an atmosphere of 
5% CO2, in DMEM (Sigma Aldrich, Missouri, US) with low Glucose (1.0 g/L), 25 mM HEPES 
Buffer supplemented with 100 U/ml penicillin, 100U/ml streptomycin, 2 mM L-Glutamine and 
10% (v/v) FBS. 
4D1 and 373 E1 mouse hybridoma cells, kindly provided by the National Cancer Institute of 
Aviano (Italy) were cultured at 6x10
5
 cells/ml DMEM culture medium with 4,5 g/L of glucose 
containing 20% FBS, 100 mg/ml of L-Glutamine, 100 U/ml of penicillin/streptamicin and 0,01 
mg/ml of HybriMax (Sigma Aldrich) and incubated at 37 °C in a 5% CO2 incubator. After 18 or 40 
hours of cultivation, the culture supernatants were harvested. Cells and debris were removed by 
centrifugation at 550 g for 5 minutes. Ascites are provided from the National Cancer Institute of 
Aviano. 
                                                                                                                                                                                                                                                               
                                      
Fig.1: (A): schematic representation of the pDisplay vector used for 143B trasfection; (B): 143B wild type 
(143B WT) compared with 143B trasfected cells ( 143B 5+).         
 
 
 
A 
B 
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2.4. ECM molecules-cell adhesion   
ECM molecules were diluted in bicarbonate buffer at the final concentration of 20 µg/ml and then 
distributed 50 ul per well in a 96 multiwell plate. In the control well 50 µl of 2% casein solution in 
PBS 1X were added. All wells were incubated at 4°C over night (O.N.) After the incubation, the 
excess solution were eliminated and wells were blocked with 100 µl per well of 2% casein solution 
in PBS 1X, for 30’ at 37°C. 2% Casein blocking solution was eliminated and wells were gently 
washed. Both 143B WT and 5+ cells were growtn in DMEM with 0,5% of FBS and seeded in 
quadruplicate at a density of 1,5 X 10
5
 cells/well at 37°C with 5% of CO2. After drying and gently 
washing the wells, 120 ul of MTS (Cell Titer 96 A Queous One Solution, Promega Corporation, 
Wisconsin, US) solution in DMEM with 0,5% of FBS were added to each well for 3 h. Wells were 
read with a microplate reader (Multiskan ex, Thermo Fisher Scientific Inc., California, US) To 
correlate the absorbance value with a cell number, a standard curve was prepared with the same 
protocol.  
2.5. Flow cytometry 
To confirm the GPC5 ectopic expression on 143B selected clones, 500.000 expressing GPC5 cells 
(143B 5+) and control cells (143B mock) were collected and incubated with 250 ng of direct PE-
labeled monoclonal antibody anti-human/mouse GPC5 (clone 297716, R&D System, Minneapolis, 
US) on ice and then washed and resuspended in PBS1X (final concentration NaCl 137 mM, KCl 
2.7 mM, Na2HPO4 4.3 mM, KH2PO41.47 mM, adjust to a final pH of 7.4) for the analysis. As a 
control, the same cells were treated with PE-labeled mouse IgG2A isotype control (clone HOPC-1, 
SouthernBiotech, Birmingham, US) antibody in separate tube. All samples were analyzed on 
fluorescence activated cell sorter (Coulter EPICS XL-MCL Flow Cytometer). 
2.6. Western blotting 
Total protein cell extracts were prepared by lysing the cell for 10 min on ice in RIPA lysis buffer 
(final concentration Tris-HCl, pH 7.4, 50 mM, NaCl 150 mM, P-40 1%, Na-deoxycholate 0.5%, 
SDS 0.1%, EDTA 2 mM, leupeptin 50 µM, aprotinin 2 µg/ml, soybean trypsin inhibitor 2 µg/ml, 
pepstatin Na3VO4 1 µg/ml, NaF 1 mM, Pefabloc SC 0.8 mM) after collection from a 100 mm dish 
and double washing with PBS1X. Protein concentration was measured by Bradford method. 
Supernatant of stable cell lines were collected after 24 hours of culture incubation in DMEM serum 
free and concentrated utilizing methanol protocol: 400 μl of supernatants were mixed with 2.5 
volumes of cool 100% methanol, incubated overnight at -20°C, washed the precipitate with cool 
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100% acetone, the pellet recovered were dissolved in sterile water and 20µl of concentrated media 
were denatured with 2X sample buffer (final concentration Tris-HCl ,pH 7.4, 0.065 M, Glycerol 
10.5%, SDS(10%) 21%, Bromophenol Blue (0.05%) 6.5% ). Protein extract diluited in 2X sample 
buffer and concentrated media were resolved on 8% SDS-PAGE and transferred to Hybond-P 
membranes (GE Healthcare Life Science, Sweden) over day. Western blot analysis were performed 
using the following primary antibodies: anti-HA High Affinity (3F10, Roche Diagnostics, 
Switzerland) used 1:2000 in TBS with 0.1% Tween
®
 and 5% skim milk, anti-human Glypican 5 
(R&D) used 1:500 in TBS with 0.1% Tween®, anti-actin (Sigma Aldrich) used 1:3000 in TBS with 
0.1% Tween
®
 and 1% skim milk as control. After incubation with the primary antibody, the blots 
were washed and incubated for 1 hour with the appropriate HRP-conjugated secondary antibody; 
labeled proteins were detected with an ECL-Plus detection system (GE Healthcare). 
2.7. ELISA 
ELISA 96-well plates (Nunc Maxisorp) were coated with the different purified PGs diluted to 10-20 
mg/ml in 0.05 M bicarbonate buffer, pH 9.6, overnight at 4°C. Wells were extensively washed, 
saturated with 2% BSA in the same buffer for 1-2 hours at room temperature and incubated with 
primary antibodies as described below. GAG preparations, in their intact or chemically modified 
form, were biotinylated as previously described [Deepa et al., 2002] and 0.5 μg/well in PBS1X 
were added to streptavidin-coated 96-well Iduron plates which were then incubated overnight at 
4°C. After extensive washing with PBS containing 0.05% Tween-20, blocking with 1% BSA in 
PBS1X at 37 
o
C for 1 hour, plates were incubated with mAb 4D1 (1:100 dilution), mAb 10E4 
(1:1,000 dilution), or mAb HepSS1 (1:1,000 dilution), in PBS1X at 37
o 
C for 2 hours. Wells were 
further extensively washed with 10 mM Tris-HCl buffer, pH 8.0, containing 0.05% Tween 20 and 
0.15 M NaCl and incubated with polyvalent alkaline phosphatase-linked anti-mouse secondary 
antibodies (diluted 1:3,000) at 37
o 
C for 2 hours. After washing the plates with the above indicated 
Tris-HCl buffer, antibody binding was detected by adding 50 μl of p-nitrophenyl phosphate in 0.1 
M sodium carbonate buffer, pH 9.8 and adsorbance reading. Alternatively, non-biotinylated GAGs 
were coated onto Iduron plates (Iduron, UK) by overnight incubation at 4°C after saturation with 
2% BSA, and processed for antibody binding as described above. Competition experiments were 
performed by pre-mixing for 15 min at room temperature mAb 4D1 with 3-10 µg each of HS 
oligosaccharides ranging from 4-18-mers or biotinylated heparin (4 µg) digested with 0.5 mU of 
heparinase I, II, or III in a total volume of 10 ul of 20 mM acetate buffer (pH 7.0) containing 2 mM 
calcium acetate at 37° C for 30 min. The reaction was terminated by boiling at 100°C for 1 min. 
Alternatively, an aliquot of the digest was directly immobilized onto streptavidin-coated plates in 
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PBS1X and plates were processed as above. In some cases heparinases I or III, or a mixture of the 
two enzymes, was added to wells with immobilized biotinylated heparin and incubated at 37
o 
C for 
1 hour to digest the GAG in situ.  
2.8. Immunofluorescence and confocal microscopy 
Immunocytochemistry was done on the transfected cells to confirm the presence of GPC5 protein 
expression and to determine its cellular localization. 30.000 cells seeded on each coverslips were 
fixed after 24 hours using 4% paraformaldehyde; coverslips were washed in PBS1X and if 
necessary permeabilized using 0.1% Triton; coverslips were then incubated with primary antibody 
diluted in a mixture that included 10% NGS and PBS1X. After overnight incubation at 4°C with the 
corresponding primary antibody, cells were incubated for 1 hour at room temperature with the 
secondary appropriate antibody as shown in the table below in a mix with 10% NGS and PBS1X. 
Nuclei were revealed with a 20 minute incubation of coverslips with Hoechst 33258 staining and 
then the coverslips were mounted and observed under epifluorescence Nikon eclipse E600 
microscope connected with a Nikon DXM1200 camera. For confocal microscopy, cells were 
prepared with the same protocol shown previously and stained with the same primary and 
secondary antibodies. Samples were observed in confocal microscopy by LSM 510 meta (Zeiss) 
microscope and analyzed with dedicated software. 
Primary antibody Secondary antibody Permeabilization 
Ms anti-hu/ms GPC5                  
IgG2a (R&D System)               
dilution 1:200 
Anti-ms IgG Alexa Fluor 488    
(Life Technology)                      
dilution 1:200 
None 
Rat anti-HA tag                           
IgG1 (Roche )                            
dilution 1:200 
Anti-rat IgG  Alexa Fluor 488  
(Life Technology)                      
dilution 1:200 
None 
Phalloidin-TRITC conjugated 
(Sigma Aldrich)                          
diluted 1:1000 
None PBS+0,1% Triton 
X100, 30’ RT* 
Ms anti-ms FAK                              
IgG1 (BD Bioscience)                 
dilution 1:100 
Anti-ms IgG1 FITC                
(Sigma Aldrich)                       
dilution 1:50 
PBS+0,1%  Triton 
X100, 30’ RT 
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Rb anti-rb P-Pax (Tyr118)          
(Cell Signaling)                           
dilution 1:20 
Anti-Rb FITC                         
(Sigma Aldrich)                      
dilution 1:50 
PBS+0,3% Triton 
X100, 30’ RT 
*RT: Room Temperature 
 
2.9. In vitro proliferation assays 
Viable cell were seeded in quadruplicate in 96-well culture plates at a density of 3x10
3 
cells/well in 
DMEM with 10%, starvated overnight in 0,5% of FBS, if required, in three independent 
experiments. At different time points cells were stained with a DMEM solution containing Hoechst 
33342 at final concentration of 10 µM, incubated 1 hour at 37°C with 5% CO2 and immediately 
scanned by a triple laser imaging cytometer Acumen® eX3 (TTP LabTech Ltd, UK). The number 
of viable cells were counted and analyzed by dedicated software and a growth curve (cell number) 
was established. To asses if cells were reactive to different growth factors, after starvation as 
previously described the cells were incubated with 10 ng/ml and 25 ng/ml of BMP2, BMP4 or  
BMP7 (Milteny Biotec, Germany), 5ng/ml, 10ng/ml or 50ng/ml of Wnt1A (Sigma-Aldrich), 
5ng/ml, 10ng/ml or 50ng/ml of bFGF (Peprotech, New York, US), 50ng/ml and 100ng/ml  of Shh 
(Sigma-Aldrich), 25 ng/ml, 50 ng/ml and 100 ng/ml of HGF (Sigma-Aldrich), 25 ng/ml, 50 ng/ml 
and 100 ng/ml of IGF (Sigma-Aldrich) and finally with 10 ng/ml and 25 ng/ml of VEGF165aa 
(Milteny Biotec) in 0,5% of FBS cell culture medium. Data are expressed as mean ±SE.                    
 
2.10. Anchorage-independent growth assay 
Anchorage-independent growth assay was done using 35 mm Petri plates. Each plate contained 2 
ml of 0.6% low-melting agarose in complete medium as the bottom layer and 5000 cells in 
complete medium containing 0.3% low-melting agarose were seeded as top layer. Cultures were 
maintained under standard culture conditions for 15 days and the number of colonies was 
determined with an inverted phase-contrast microscope at X100 magnification. A group of >10 
cells was counted as a colony. The data are shown as mean number of colonies per field ± SD. The 
assay was repeated thrice with 3 replicates each time. 
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2.11. In vivo tumorigenesis 
Housing, treatment and sacrifice of animals followed national legislative provisions (Italian law No. 
116 of 27 January, 1992) for the protection of animals used for scientific purposes. Athymic nude 
female mice (Harlan UK) were purchased at 5 weeks of age given at least 1 week to adapt to their 
new environment prior to the treatments. The mice were fed ad libitum. Animals were housed in 
animal care facility of the National Institute for Cancer Research, Genoa, Italy. All manipulations 
on the animals were performed under controlled conditions and all animals were subjected to 
regular health checks. 
For the in vivo experiments, 10×10
6
 143B cells, both 143B 5+ and 143B control, were resuspended 
in a matrigel solution with a 4:1 ratio and then injected subcutaneously into the flank of 8 to 10-
week-old Hsd:Athymic Nude-nu mice. 22 and 37 mice were respectively inoculated with 143B 
mock and 143B 5+ cells. As control, 6 mice were injected with the same protocol with 143B 6+ 
cells.     
The tumor dimensions were measured every 5 days and the volume (V) was calculated as 
V=(d)
2
×D×0.52, where d and D are the short and long dimensions (centimetres) of the tumour, 
respectively, measured with a caliper. The mice were sacrificed by CO2 inhalation when the tumors 
reached a volume of about 1.5 cm
3
. Primary tumors from the flank were excised and the tumors 
were weighed, fixed with 10% formalin and paraffin-embedded. Three tumor masses from three 
different mice representative of all the mice experimental groups were split and used for both 
immunostaining and RNA isolation.  
The statistical significance of the results was determined using the non-parametric Mann–Whitney 
test. The tumor doubling time during the log phase of growth was calculated using the following 
equation: t = (log2)/slope of the log of tumor volume vs. days. 
To analyze the ability of glypican 5 positive cells to form lung metastasis, 8 mice for cell clones 
were caudal intravenous injected with 2,5 X 10
5
, 5 X 10
5  
or
 
 1 X 10
6 
in a physiological solution. 30 
days after inoculation, mice were suppressed and a first evaluation of the formation of metastases in 
the lung was detected by gross observation and histopathological assessment. Briefly, visible tumor 
nodules (macrometastases) were counted immediately after post-mortem lungs explantation. After 
the animal suppression, lungs were explanted, fixed in 4% paraformaldehyde, processed and 
paraffin-embedded. The sample were then sectioned in 5 um sections, every 10
th
 section stained 
with hematoxylin and eosin (H&E), and analyzed for the presence of not visibly detectable 
micrometastases. Five sections of each tissue were examined. Each stained section was examined 
microscopically under low power (12.5X) to visualize approximately 50% of the lung section per 
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microscopic field. The total number of metastases per lung section was counted and the average was 
calculated. 
2.12. Immunohistochemistry 
 
Paraffin on tissue samples were dissolved incubating slides in xylene for 20 minutes; then the 
sections were rehydrated using a decreasing-graded ethanol series (Ethanol 100%, Ethanol 96%, 
Ethanol 80%, Ethanol 75% and Ethanol 50%, for 5 minutes each one). After washing with tap 
water, tissue slides were dipped in TBS1X with 1% Tween (TBST).  
The immunohistochemistry protocols were set up to optimize each antibody staining, as shown in 
the table below, using appropriate Antigen Retrieval techniques for each antibody. TUNEL assay 
(DeadEnd Colorimetric Apoptosis Detection System, Promega) was made according to the 
manufacturer’s instructions. 
The slides were then incubated with 3% H2O2 for 10 minutes at room temperature (RT), washed 
with TBST1X, incubate for 30 minutes at room temperature (RT) with PBST1X with specific sera 
solutions to block unspecific antibody binding sites. Samples were incubated  with primary 
antibodies appropriately diluted in PBS1X with 1% Triton X-100 (PBST). After a wash in PBST 
1X for 30 minutes to remove any primary antibody nonspecific reaction, slides were treated for 1 
hour at RT with secondary antibody conjugated with an enzyme-labeled polymer, according to 
manufacturer’s recommended protocol (Ultra Vision LP Detection System-HRP Polymer, Thermo 
Scientific). The immunoreactivity was detected  with 3,3'-diaminobenzidine solution (Liquid DAB 
Substrate, Chromogen System, DakoCytomation, DK). Samples were counterstained with Harris’ 
haematoxylin solution (Sigma-Aldrich) for 15 seconds, washed with tap water and dipped in 
ammoniacal ethanol for 2 seconds. After several washes in deionized water, slides were mounted 
using an aqueous mounting medium. The detection of the immunolabeling was done using  a light 
microscope ZENITH microscope with OPTIKAM 3 digital camera.  
Specimen and human healthy tissues were kindly received from Dr. Gaetano Magro (Section of 
Anatomic Pathology, Department of G.F. Ingrassia, University of Catania, Italy). Deparaffinized 
TMAs were incubated with 3% H2O2 for 10 minutes at room temperature to quench endogenous 
peroxidise activity, further incubated with Ultra V Block according to manufacturer’s instructions 
to block non-specific antibody binding sites and then incubated with anti-HS antibodies diluted in 
PBS1X for 1 hr at 37°C or overnight at 4°C: mAb 4D1 (ascites fluid, 1:75 dilution; supernatant, 
1:50 dilution), 10E4 (USBiological, Massachusetts, US., 1:100 dilution); 3G10 (USBiological, 
1:100 dilution) and HepSS1 (USBiological, 1:100 dilution). The same protocol was applied for 
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373E1 immunohistochemistry assays. MAbs 373E1 and BCD4 (Seikagaku, Japan) were diluted 
respectively 1:5 and 1:75 in PBS1X with 2% of BSA. After washing with PBS1X, the slides were 
incubated with the UltraVision LP Detection System, washed and developed for 1-5 minutes with
 
Liquid DAB Substrate Chromogen System and counterstained with Harris’ haematoxylin solution 
for 15 seconds. Slides were washed with tap water and dipped in ammoniacal ethanol for 2 seconds. 
For antigen retrieval, prior to the endogenous peroxidase blocking step, sections were dipped in 
citrate buffer, pH 6.0, and subsequently heated to 85°C for 60 minutes. After treatment with H2O2 to 
quench endogenous peroxidase activity, some sections were digested with the different heparinases 
(heparinases I-III, diluted in 50 mM of Tris-Acetate buffer, pH 7.0), used at the concentration of 
0.05 mU/ml, for 60 min at room temperature. In some control experiments, mAb 4D1 was diluted at 
the optimal working dilution, pre-incubated with heparin (EPSOCLAR, used at the concentration of 
5000 U/ml) for 30 minutes at room temperature and the mixture was then added to the tissue 
sections. In other cases, sections were treated with DNAse I (Promega) at the dilution of 5 U/ml and 
incubated for 30 minutes at room temperature before addition of primary antibodies. 
 
Primary antibody Secondary antibody Antigen retrieval Serum block 
Ms anti-hu/ms GPC5      
IgG2a (R&D System)               
dilution 1:450 
Anti-ms IgG HRP 
(Sigma Aldrich)     
dilution 1:500 
Tris EDTA 10 mM 
buffer*,    30’ 95°C  
5%NGS+5%BSA 
30’ RT 
Sh anti-HA tag                    
IgG (AbCAM)               
dilution 1:1000 
Anti-sh IgG HRP 
(Sigma Aldrich) 
dilution 1:500 
none 5%ShS+5%BSA  
30’ RT 
Rb anti-hu CENPA             
IgG (AbCAM)               
dilution 1:50 
Anti-rb IgG HRP 
(Life Techmology)   
dilution 1:600 
Tris EDTA 10 mM 
buffer*,    30’ 95°C 
5%NGS+5%BSA 
30’ RT 
Rb anti-hu Ki67                  
IgG (AbCAM)               
dilution 1:100 
Anti-rb IgG HRP 
(Life Technology)   
dilution 1:600 
Tris EDTA 10 mM 
buffer*,    30’ 95°C 
5%NGS+5%BSA 
30’ RT 
Rat anti-ms Ki67             
IgG2a (Dako)                 
dilution 1:20 
Anti-rat IgG HRP 
(Life Technology)    
dilution 1:500 
Tris EDTA 10 Mm 
buffer, 30’ RT 
5%NGS+5%BSA  
30’ RT 
Rb anti-ms NG2                  
IgG (AbCAM)               
dilution 1:3000 
Anti-rb IgG HRP 
(Life Technology)   
dilution 1:600 
Tris EDTA 10 mM 
buffer,    30’ 95°C 
5%NGS+5%BSA 
30’ RT 
Rat anti-ms CD31           
IgG2a (AbCAM)            
Anti-rat IgG HRP 
(Life Technology)    
Proteinase K solution in 
Tris EDTA 50 mM 
5%NGS+5%BSA  
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dilution 1:100 dilution 1:500 buffer
#
 ,  30’ RT 30’ RT 
* Tris-EDTA Buffer (10mM Tris Base, 1mM EDTA Solution, 0.05% Tween 20, pH 9.0)  
#
 Proteinase K Solution: 20 μg/ml in TE Buffer (50mM Tris Base, 1mM EDTA, 0.5%  
Triton X-100, pH 8.0)  
 
2.13. Vessel density and perfusion 
To measure perfusion, mice were injected with Dextran 70kDa-FITC (Life Technology; 360 
μmol/L, 50 μL/mouse) 3 min before sacrifice. Perfused vessels were visualized by fluorescent 
microscopy using DM LB2 microscope (Leica). Vascularization tumors was evaluated by anti-
CD31 (Sigma Aldrich) staining. Microvessels vascular density (MVD) or percentage of perfusion 
was quantified by screening for the areas of highest vascularity or perfused vessels; for each 
sample, 10 representative fields at 200X magnification were counted. Confocal laser scanning 
microscopy was carried out with a Zeiss LSM 510 microscope using argon (488 nm) and helium-
neon (543–633 nm) laser sources, depending on the size of tumor sections; images were collected at 
a magnification of 200X. 
2.14. Data and statistical analysis 
In all the experiments, if not differently specified, the results were expressed as the mean ± SEM 
and Student's t-test was used for statistical analysis to determine the statistical significance. 
Significance was defined as a *= P<0.01. 
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                                                              3. RESULTS 
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3.1. Glypican 5 control of cancer growth and dissemination 
3.1.1. Proteoglycan surface pattern in sarcoma cells 
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HT1080
NTI-LS-4
NTI-LMS-5
NTI-FS-1
SW982
NTI-PNS-1
NTI-LMS-3
SK-LMS-1
GCT
RD
NTI-LMS-6
NTI-LMS-8 MES-SASK-UT-1
NTI-LS-3
NTI-MFH-3
A204
SW872
NTI-LS-1
NTI-LS-5
MG63
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Fig.2. Surface PG expression pattern of different sarcoma models. 
RT-PCR and TaqMan Low Density Array results allowed as to define a PG expression panel where 
it was possible to distinguish 24 different cellular PG models at the transcriptional level (Fig.2) with 
discrete surface PG pattern available for subsequent molecular manipulation, as gene transduction. 
Some sarcoma cells, even if belonging to different hystotype, may present the same PGs pattern 
expression. On the base of these patterns, it was decided to use an osteosarcoma model, 143B cells, 
to de novo express GPC5 because these cells have a rather complex pattern of PGs expression. In 
particular this cell line express on its surface all the syndecans, the glypicans 1, 2 and 4, NG2 and a 
low expression of GPC6. This can allowed us to performe different in vitro and in vivo techniques, 
SDC-3 
SDC-4 
GPC-6   
GPC-5   GPC-3   
GPC-4   GPC-2   
GPC-1   SDC-1 
SDC-2 
  
  
  
  
NG2 
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analyzing also the possibility of a GPC interaction as mechanisms to compensate the different 
GPC5 expression. 
These cells were subjected to the trasfection for the production of GPC5 and then tested for the cell 
surface PG expression. Wild type cells were used as control, in parallel with 143B cells trasfected 
with an empty vector (143B mock). There were generated more than one clone expressing GPC5 
and we chose the higher expressing one, named 143B 5+, that was used for in vitro and in vivo 
assays. Flow cytometry (Fig.3,A), immunofluorescence staining with an antibody that specifically 
recognizes GPC5 (Fig.3,B) and western blot analysis (Fig.3,C) showed the de novo expression of 
GPC5 in about 90% of the transfected cells respect to 143B mock. 143B cells were also transfected 
with a pDisplay-GPC6 vector to obtain the clone 143B 6+ that overexpress this PG and that was 
used as an additional control to asses the specificity of GPC5 function. 
                       
Fig. 3. (A): flow cytometry of 143B mock and trasfected cells; (B): immunofluorescence staining of 143B 
5+ cells. The GPC5 distribution on cell membrane corresponds to green spots and nuclei are stained with 
Hoechst (blu). Magnification 100X. (C) Western blot detection of GPC5 de novo expressed in 143B 5+ and 
control cells. It is present a nonspecific band of about 60 kDa (*)                  
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3.1.2. GPC5 distribution on cell surface 
                     
Fig. 4. Confocal sequences analysis of 143B mock immunolabeled with a human/mouse anti-GPC5 antibody 
(green). A little positivity may be due to the antibody crossreaction with cytoplasmic molecules. Microscope 
objective 63X.  
                 
Fig. 5. Confocal sequences analysis of 143B 5+ immunolabeled with a human/mouse anti-GP5 antibody 
(green). Microscope objective 63X. 
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GPC5 expressing cells show a proteoglycan distribution that is different from that of control cells. 
More deeply, in 143B mock cells, GPC5-positivity seems to have a perinuclear distribution, 
probably related with an antibody cross reaction with endoplasmic reticulum and/or Golgi 
subcellular compartments molecules. In these cells GPC5 is completely absent from the cell surface 
(Fig. 4). Instead, 143B 5+ cells show a marked membrane distribution of GPC5 that appear to be 
concentrated in particular local areas of reinforcement probably corresponding with the lipid rafts 
(Fig.5). In particular GPC5 positive membrane domains seem to localize in particular cell 
extroflections, the filopodia, produced by cell during its movement. There is a close relationship 
between plasma membrane domains like the lipid rafts and actin filaments. Immunostaining with 
phalloidin-TRITC conjugated allow us to relate GPC5 distribution and actin citoskeletal 
conformation. Confocal analysis of double immunofluorescence staining suggest that in 143B 5+ 
cells, GPC5 colocalize with the membrane portion in which actin forms structural reinforcement 
(Fig.6, 7 and 8). These high positive membrane spots seems to correspond with the presence of 
focal adhesion molecules, such FAK or paxillin (Pax) in the activated phosphorilated form (P-Pax) 
(phosphorilation on Tyr118). Immunostaining shows that GPC5 may colocalize with these adhesion 
complexes, probably partecipating to their stability and biological functions (Fig.9).  
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Fig. 6. Double immunofluorescence confocal analysis using phalloidin-TRITC conjugated (red) and the anti-
human/mouse GPC5 antibody (green) on 143B WT fixed cells.The image sequence start from the basal cell 
surface. Microscope objective 40X.  
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Fig. 7. Double immunofluorescence confocal analysis using phalloidin-TRITC conjugated (red) and the anti-
human/mouse GPC5 antibody (green) on 143B mock fixed cells.The image sequence start from the basal cell 
surface. Microscope objective 40X. 
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Fig. 8. Double immunofluorescence confocal analysis using phalloidin-TRITC conjugated (red) and the anti-
human/mouse GPC5 antibody (green) on 143B 5+ fixed cells.The image sequence start from the basal cell 
surface. Microscope objective 40X. 
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Fig. 9. double immunofluorescence staining on 143B WT and 5+ cells. In left panel, cells are stained with 
antibody anti-GPC5 (green) and anti-FAK (red). In the right panel the same cells are stained with antibody 
anti-GPC5 (green) and anti-P-Pax (red). In both immunostaining merges, the colocalization of GPC5 with 
the respective adhesion molecule is shown as yellow spots. Microscope objective 60X.  
 
3.1.3. GPC5 influences cell adhesion and proliferation 
The evaluation of the proliferation rate in a 0,3% FBS growth condition suggested us that 143B 5+ 
and mock cells have a comparable growth curve within the 24 hours after the seeding. These data 
allowed us to performe all the assays excluding the possibility that differences in the cell 
proliferation may affect the results. After 24 hours it is evident that both 143B 5+ and mock cells  
show a pushed growth rate in optimal growth conditions respect to nutrient deficiency conditions 
(Fig.10,A). Moreover it seems that the presence of GPC5 on the cell surface may negatively affect 
the cell proliferation capacity. 
Cells expressing GPC5 demonstrate a different ability to adhere to different ECM molecules respect 
to wild type cells. In particular their adhesion capacity is suppressed on collagen type III-, collagen 
type VI-, fibronectin- and vitronectin-coated substrates (Fig.10,B). On un-coated plastic wells, both 
143B 5+ and 143B wild type cells show the same anchorage ability, while no cell adhesion was 
seen on the casein block solution. The cell anchorage capacity is monitored after 1 hour after 
seeding.  
We have also examined GPC5+ transfected cells capacity to growth in an anchorage-independent 
condition by a soft-agar assay. It is shown a significant decreased ability of GPC5 positive cells to 
growth without any adhesion to the substrate respect to wild-type control cells, while 143B 6+ 
ability to growth without any anchorage is comparable with that of control cells (Fig.10,C).  
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143B cell models were cultured in the presence of different growth factors. This assay suggest that 
the GPC5 expression on these cells may influence their response to some of these growth factors. In 
particular in fig. 11 A and D, are shown the most significative results obtained. In the graphs it is 
possible to see that in the presence of VEGF 165aa and HGF, 143B 5+ cells show a decreased 
proliferation rate respect to control cells, in particular 48 hours after the seeding. The same 
response, but not so evident  extent, is obtained traiting cells with Wnt1 (Fig.11,C). In the graph B 
in fig.11, are reported the results of the same assay in presence of the IGF factor. In this case the 
presence of GPC5 on the cell surface seems to enanche the cell proliferation ability respect to 
control cells. 
         
Fig 10. (A): growth curve of 143B mock and 143B 5+ cells in optimal (DMEM added with 10% of FBS) and 
wanting (DMEM added with 0,3% of FBS) gowth conditions. Data are expressed as the means ± SE. (B): 
trasfected 143B cells show a different ability to adhere to different  ECM molecules respect to control cells. 
Cell number is calculated from values of MTS absorbance at 490 nm and interpolation on standard curve. 
Data are expressed as means ± SD. (C): Anchorage-indipendent growth ability of 143B WT, 143B 5+ and 
143B 6+ cells. It was considered a colony an aggregation of more than 10 cells and were counted 10 field in 
each replicate.  Data are expressed as means ± SD. 
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Fig. 11. Growth factor responsiveness: 143B 5+ and control cells were treated with (A): VEGF 165aa at the 
concentration of 25 ng/ml; (B): IGF at the concentration of 25 ng/ml; (C): Wnt1 at the concentration of 10 
ng/ml and (D): HGF at the concentration of 25 ng/ml. 
 
3.1.4. Inhibition of in vivo tumor formation 
To investigate the role of GPC5 in in vivo tumour cell growth, nude mice were injected 
subcutaneously with respectively 143B WT, 143B 5+ and 143B 6+ cells. None of the mice showed 
any obvious clinical signs of tumor development during the first 12 days of observation following 
cancer cell injection. After this period, same mice showed small subcutaneous tumor masses 
(Fig,12) and they displayed morbidities such as hunched posture, inactivity, and shortness of breath; 
33 days after the inculation, all mice showed tumor masses and were suppressed. The analysis of 
tumor mass volumes, suggest that the presence of GPC5 on the surface of injected cells may reduce 
their capacity to induce tumor cell proliferation in vivo respect to controls (Fig.13,A). This ability 
may be specifically attributed to GPC5 expression because  143B 6+ control mice show a behaviour 
comparable to 143B WT. 
In 143B 5+-induced tumors the number of vessels was significantly decrease more than 30% in 
comparison to CTRL tumors, while the percentage of vessel perfusion wasn’t statistically different 
(Fig.13,B) suggesting a normal vessel structure and perfusion with a reduction in vascularization. 
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Fig. 12. Exemple of nude mice after the sacrifice; mice are injected respectively with 143B WT, 143B 5+ 
and 143B 6+ cell into subcutaneous space of the right flank 
 
 
Fig.13. (A): growth curves of tumor volumes. The tumor dimensions were measured every 5 days, and the 
volume (V) was calculated as V=(d)
2
×D×0.52, where d and D are respectively the short and long dimensions 
(centimetres) of the tumour, measured with a caliper.(B): Mann-Whitney statistical test was applied and 
values are mean ± SE. In B panel is shown an immunofluorescence labelling example of anti-CD31 and 
Dextrane-FITC in vivo staining on 143B 5+ induced tumor mass OCT section by confocal microscopy; 
magnification 200X 
 
After the explantation, tumor masses were treated and included in paraffin for the 
immunohistochemistry analysis. Immunostaining with the anti-human-GPC5 antibody (Fig.14) 
showed GPC5-positive cells in tumor obtained from the inoculation of 143B 5+ cells. These cells 
are characterized by a strong membrane positivity probably corresponding with the lipid rafts. It is 
also possible to recognize same positive citosolic structure probably corresponding to the endocytic 
vescicles, containing GPC5 molecules. GPC5 negative masses do not present any membrane 
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positivity but in these masses it is possible to see a nuclear positivity, probably due to athypic 
mitosis that are frequent in tumor cells.The presence of human GPC5+ cells is confirmed also by 
the staining of tumor masses with an anti-HA tag antibody. GPC5+ masses show single cell surface 
positive cells instead control masses are completely negative (Fig.15), conferming the anti-GPC5 
staining. The presence of human cells within the tumor masses was investigated using an antibody 
that specifically recognizes a component of human nuclei, CENPA, that is a centromere protein 
component of nucleosomes. Both GPC5+ and control masses show a limited presence of human 
cells, without any particular difference between the two samples (Fig.16). We investigated more 
deeply the growth and apoptotic rate of cells within the tumors. In particular we started 
investigating the cell proliferation using two antibodies that specifically recognize human and murin 
Ki67. Ki67 is used as proliferation marker because it is a nuclear antigen present only in 
proliferating cells. In the second and third panels of figure 16 is possible to see that both samples 
show a low rate of proliferating cells (less than 10%), in either human and murine cells. To evaluate 
the apoptosis rate of tumors, it was used the TUNEL assay to misure the nuclear DNA 
fragmentation. Positive DNase treated and negative controls were used. As for proliferation marker, 
also in this case the immunostaining show single nuclear positive cells but no differences are 
detected between the GPC5+ and the control tumors (Fig.17). Another aspect that may influence the 
tumor development is the presence of a developed vascular network. For this reason we decided to 
evaluate the vessel organization using two different markers: CD31 and NG2 (Fig.18). CD31 is 
largely expressed on endothelial cells instead NG2 is expressed by pericytes and it may be 
considered a marker of the more mature vessels. For both the vascular immunostainings there were 
no particular structural differences between GPC5+ and control tumor masses. 
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Fig.14. Light micrograph of mouse 
tumor tissues (DAB, brown): 
immunostaining with anti-hu/ms 
GPC5 antibody reveals the presence 
of nuclear crossreaction in control 
masses (first panel) and the 
presence of specific citoplasmic and 
cell surface strong positivity in 
GPC5+ masses (second panel).  
Microscope objective 100X     
 
 
 
 
 
 
  
 
Fig.15.  Light micrograph of mouse 
tumor tissues (DAB, brown): 
immunostaining with an anti-HA 
antibody confirms the presence of 
single positive cells in the GPC5+ 
tumors.. Control masses appears 
completely negative for the staining.  
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Fig.16.  Light micrograph of mouse tumor tissues (DAB, brown): immunostainings with an anti-human 
CENPA (first panel), anti-human (second panel)  and murine (third panel) Ki67 show no particular 
differences between tumor induced by 143B 5+ and 143B WT cells. 10 field per sample are analyzed 
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Fig.17. Light micrograph of mouse tumor tissues (DAB, brown): for the detection of apoptotic cells it is used 
the DeadEnd
TM
 Colorimtric TUNEL System. In both GPC5+ and control masses it is possible to see positive 
cells but there are no differences between the two masses. For negative control no antibody is used and for 
positive control samples were treated with DNase before the antbody incubation. 10 field per sample are 
analyzed. 
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Fig.18. Light micrograph of mouse tumor tissues (DAB,brown): in the first panel it is shown the 
immunostaining of GPC5+ and control masses with anti-CD31 antibody. In the second panel it is shown the 
immunostaining with anti-NG2 antibody.  
 
 
To evaluate the capacity of 143B 5+ cells to induce a distal metastasis, nude mice were subjected to 
intravenous inocula of 143B 5+. Three different experimental groups were inoculated with 2,5x10
5
, 
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5x10
5 
and
 
1x10
6
 cells respectively. Mice lungs were analized for the detection of both macro and 
micro nodule formation. The simple observation of explanted lungs, showed no macronodules 
presence in both 2,5x10
5
 and 5x10
5 
 inocula of 143B 5+ cells. The cellular organization of the lung 
of these mice seems to be not disturbed and the data were confermed also by H&E staining of serial 
lung samples. As shown in figure 19, the immunostaining does not reveal any presence of 
metastatic formation. Differently, animals injected with 1x10
6
 cells, show visibile lung 
macronodules masses (not shown). 
                  
Fig.19. Example of H&E staining on a paraffin-embedded serie of sections of the lung from mice injected 
with 2,5X10
5 
143B 5+ cells. Microscope objective 10X 
 
 
To detect the presence of human and murine GPC5 in tumor masses, RNA was extracted, retro-
transcribed and amplified by PCR, using specific primers. Amplification products were visualized 
by 1% agarose gel electrophoresis. As controls, human RPL41 and murine rpl27bis housekeeping 
genes were amplified. In panels A and B of the figure 20 it is shown the detection of the two control 
genes. In panel C it is possible to see a weak presence of the transcript of human GPC5 
amplification in all the three tumor masses analized; no amplifications are visible when it is used a 
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murine gpc5 specific primer (Fig. 20, panel D). In all the amplifications, negative and positive 
controls are used.  
 
                           
                     
Fig. 20. Detection of GPC5 trascript in tumor masses. a: negative control lane; b,c and d: cDNA extracted 
from control masses; e: marker lane; f,g and h: cDNA extracted from 143B 5+ cell induced masses; i: 
positive control lane.  
 
 
 
 
 
 
 
 
 
A B 
C D 
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3.2. Immunomapping of highly sulfated heparan moieties in human 
tissues 
3.2.1. Specificity of antibody 4D1 
Antibody 4D1 was not found to react with CS-, DS- or KS-substituted PGs from a variety tissue 
sources and species (not shown), while combined ELISA and Western blotting indicated that it 
recognized a GAG chain-associated, rather than core protein-associated epitope. To ascertain this 
reactivity, mAb 4D1 was further screened against a panel of sulfated GAGs, including CS-A, 
chondroitin prepared by chemical desulfation of CS-A, DS, CS-C, CS-D, CS-E, a DS preparation 
particularly rich in IdoAα1-3GalNAc (4,6-O-disulfate), one rich in IdoA(2-O-sulfate)α1-
3GalNAc(6-O-sulfate) and untreated low and high molecular weight and heparin treated with HNO2 
at pH 1,5 or at pH 3,9. MAb 4D1 was found to display a specific reactivity against HSs, with the 
highest affinity detected against intact heparin (Fig.21,A). A further comparison of the levels of 
reactivity of mAb 4D1 against HS variants with distinct sequences and sulfation degrees (Tab.6) 
showed that the antibody preferentially recognized HS chains containing highly sulfated domains 
(Fig.21,B) and accordingly failed to recognize both murine and human HSs perlecan (data not 
shown). This finding was confirmed by the loss of immunoreactivity seen against heparin digested 
with heparinase I or II (Fig.21,C) and partially or entirely desulfated heparin (Fig.21,D). Further 
hints about the structural requirements of epitope binding were provided by experiments with N-
acetylated heparin (Fig.21,D). Comprehensively, these findings suggested that 2-N-, 2-O-, and 6-O-
sulfate groups of the GAG were all indispensable for antigen binding and that the recognized epitope 
appeared to be a unique heparin/HS sequence composed of trisulfated disaccharide units of the 
HexUA(2S)-GlcN(NS, 6S) type.  
3.2.2. The epitope of mAb 4D1 encompasses a highly sulfated tetrasaccharide 
repeat  
To highlight its uniqueness, the specificity of mAb 4D1 was compared with that of the previously 
described anti-HS antibodies 10E4 and HepSS-1 using the set of diversely sulfated HS preparations. 
MAb 10E4 bound to all tested HS preparations and HepSS-1 preferentially reacted with HS 
preparations derived from the EHS tumour and characterized by a lower sulfation degree 
(Fig.21,B). The reactivity pattern of mAb 4D1 markedly differed from that of these mAbs since it 
only react with highly sulfated HS species (Fig.21,F). Interestingly, optimal recognition of such 
GAGs required their integrity, as shown by loss of reactivity upon heparinase fragmentation of high 
molecular weight heparin (Fig.21,C). Whereas HepSS-1 retained some ability to bind to completely 
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de-acetylated N-desulfated heparin and mAb 10E4 bound equally well to intact and 6-O-desulfated 
heparin, mAb 4D1 entirely failed to recognize de-acetylated/de-sulfated heparins. (Fig.21,D). We 
have comparatively assayed mAbs 4D1, 10E4 and HepSS-1 against chemically modified heparin 
preparations. Finally, to narrow down the mAb 4D1 epitope, we carried out competition ELISAs 
using immobilized heparin and a panel of HS oligosaccharide fragments of defined, progressively 
decreasing sizes as competitors (Fig.21,E). In agreement with the reactivity pattern observed 
following heparinase digestion of heparin, binding of mAb 4D1 to HS fragments was reduced by 
more than 50%. However, a certain inhibition of binding to intact high molecular weight heparin, 
could be seen with fragments encompassing a tetrasaccharide unit minimal, suggesting that the 
epitope required may be a tri- or tetrasaccharide and that optimal antibody recognition of 
HS/heparin requires a repeating highly sulfated unit of that size. 
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   Table 6. Disaccharide composition of HS and heparin preparations (%) 
 
Major disaccharide unit
1
 
 
HS-BK
 
 
HS-PI 
 
HS-BL 
(1M) 
 
HS-BL 
(2M) 
 
HS EHS 
 
Human- 
perlecan 
HS 
 
Murine- 
perlecan 
HS 
 
Heparin  
PI 
 
Heparin 
BL 
 
ΔHexUA-GlcNAc 
ΔHexUA-GlcNAc(6S) 
ΔHexUA-GlcN(NS) 
ΔHexUA-GlcN(NS,6S) 
ΔHexUA(2S)-GlcN(NS) 
ΔHexUA(2S)-GlcNAc(6S) 
ΔHexUA(2S)-GlcN(NS,6S) 
 
54 
12 
21 
5 
4 
0 
4 
 
47 
12 
32 
3 
2 
0 
4 
 
38 
9 
23 
6 
3 
0 
21 
 
0 
2 
11 
10 
4 
6 
67 
 
30 
0 
67 
1 
2 
0 
0 
 
55 
6 
31 
2 
4 
0 
2 
 
60 
10 
17 
5 
3 
0 
5 
 
5 
4 
5 
15 
4 
0 
67 
 
3 
4 
3 
11 
10 
0 
69 
      Abbreviations: ΔHexUA, unsaturated hexuronic acid; GlcNAc, N-acetyl-D-glucosamine; GlcN, D-glucosamine; 2S, 6S and NS, 
      2-O-sulfate, 6-O-sulfate and 2-N-sulfate; HS-BK, bovine kidney HS; HS-PI, porcine intestinal HS; HS-BL, bovine liver HS
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Fig.21. Reactivity of antibodies toward various GAG preparations. 
Reactivity of mAb 4D1 toward various GAG preparations using an Iduron plate: chondroitin prepared by 
chemical desulfation of CS A (Chn); chondroitin sulphate A from whale cartilage (CS-A), dermatan sulphate 
from pig skin (CS-B), chondroitin sulphate C from shark cartilage (CS-C), chondroitin sulphate D fromshark 
fin cartilage (CS-D), chondroitin sulphate E from squid cartilage (CS-E), dermatan sulphate from hag fish 
notochord rich in IdoAα1-3GalNAc (4,6-O-disulfate) units (iE), dermatan sulfate from Ascidia nigra rich in 
IdoA(2-O-sulfate)α1-3GalNAc(6-O-sulfate) units (iD), heparin treated with HNO2 at pH 1,5 and at pH 3,9 
(A); reactivity of the antibodies 4D1, 10E4, and HepSS1 toward HS/Hep preparations. Closed, open, and 
hatched columns show the reactivity of 4D1, 10E4, and HepSS-1, respectively. Bovine kidney heparan 
sulfate (BKHS), porcine intestine heparan sulfate (PIHS), bovine liver 1 M and 2 M HS was purified by an 
anion-exchange chromatography eluted with 1 M and 2 M LiCl, respectively, EHS 1 M HS and 2 M HS was 
purified from chondrosarcoma by an anion-exchange chromatography eluted with 1 M and 2 M LiCl, 
respectively (B); reactivity of mAb 4D1 toward the enzymatic digestion of heparin with Hep lyases (C); 
reactivity of the the antibodies 4D1, 10EA and HepSS-1 toward various chemically modified Hep 
preparations. CDNS, CDNA, and NDNA represent completely desulfated N-acetylated heparin, completely 
desulfated N-sulfated heparin, and N-desulfated N-acetylated heparin, respectively. 2ODS and 6ODS stand 
for 2-O-desulfated heparin and 6-O-desulfated heparin, respectively (D); inhibition of the reactivity of mAb 
4D1 toward biotinylated heparin by heparin oligosaccharides at the concentration of 100 ug (E); binding site 
of different anti-HS antibodies (F). The results are expressed as means ± SD. 
 
3.2.3. Distribution of mAb 4D1-reactive HS chains in human adult tissues     
To approach the tissue distribution of the HS species recognized by mAb 4D1 in the human body, 
we performed immunohistochemical stainings of TMAs encompassing a representation of more than 
30 human tissues/organs (Fig.22) and compared these stainings with those obtained with the three 
previously described anti-HS antibodies, mAbs 10E4, HepSS1 and 3G10. The outcome of these 
mapping studies is summarized in tables 7 and 8.  
Epithelia: stratified squamous epithelia of skin (Fig.22,A and 22,A), epithelia of esophagus 
(Fig.23,G) and cervix (data not shown) were intensly stained with mAb 4D1 and with 
immunoreactivity being particularly enriched in the luminal layers. The pseudo-stratified epithelium 
lining the bronchi (Fig.23,C) showed a prevalent positivity at the apical side, whereas glandular 
(secretory) elements of resting mammary glands (Fig.22,D), hepatocytes (Fig.23,E) and gastric 
mucosa shared a diffuse cytoplasmic staining. Absorptive cells of the colon had a prevalent luminal 
distribution of 4D1-reactive HS chains (Fig.22,G), whereas glandular epithelium of the uterus, the 
epithelium of the prostate, podocytes attached to glomerular capillaries of the kidney, and lung 
epithelium showed a weak immunoreactivity. Mucous cells and basement membranes were 
consistently negative in all tissues analyzed. The immunoreactive pattern of mAb 4D1 largely 
mirrored that of mAb 10E4 (Tab.9), which strongly labelled basement membranes, but failed to 
label the epithelial cells themselves (Fig.22,B). 
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Vascular structures: the endothelial cells of vascular structure resulted strongly positive (Fig.26) 
while they appeared no or weakly positive for the immunostaining with mAb 10E4 (data not 
shown). 
Connective tissues: In dense connective tissues of both regular, such as that of the resting mammary 
gland (Fig.22,D), and irregular type, such as those of the skin, a marked positivity was noted for 
mAb 4D1, while mAb 10E4 more electively stained fibroblasts (Fig.22,E). In loose connective 
tissues, such as for example that surrounding mucous glands in the bronchus, there was similarly an 
intense expression of 4D1-reactive HS variants and a lack of 10E4-reactive ones.  
Muscle tissues: In skeletal muscle and dermis mAbs 10E4 and HepSS1 gave weaker and less 
diffuse staining patterns than mAb 4D1 and the same applied to mAb HepSS1 in irregular dense 
connective tissues. Notable was also the weak (skeletal muscle) to absent staining (cardiac and 
smooth muscle) for mAb 4D1 of muscle fibers, whereas mAbs 10E4, and HepSS1 gave both 
positive reactions in these tissue structures. The smooth muscle of arteries showed a marked 
positivity for mAb 4D1 (Fig. 22,N) and a basal membrane positivity for mAb 10E4 (Fig. 22,O). 
Nervous and endocrine tissues: In the CNS there was a very weak staining for mAb 4D1 in the grey 
and white matters (Fig.24,A) of the cortex and only a nuclear positivity in the granular layer of 
cerebellum was noted as exclusive of this antibody since it was not seen with other anti-HS mAbs. 
Purkinje fibers (Fig.24,B) and peripheral nerve (Fig.24,G). Endocrine cells, connective tissues of 
neuroendocrine glands, adrenal glands and thyroid, showed a weak positivity, whereas in the 
pancreas both exocrine and endocrine (Fig.24,D) components exhibited an intense 
immunolabelling. No such staining patterns were observed with mAbs 10E4 and HepSS-1. Finally, 
lymph nodes and spleen had many 4D1-positive cells showing a preferential nuclear staining. While 
connective tissue of the spleen showed some weak 4D1 positivity, it was much more intensely 
labeled by mAbs HepSS1 and 10E4.  
Specificity of mAb 4D1 in situ staining: To ascertain the nuclear specificity of the staining (i.e. 
whether it was due to an unspecific binding of the antibody to DNA) we predigested sections with 
DNase I. No difference was observed with and without pre-digestion (Fig.24,A and B). Finally we 
used competition experiments to confirm the immunostaining data; for this purpose we preincubate 
samples with heparin. As expected there was no staining (Fig.24,C and D). 
97 
 
Consistently with the solid-phase binding data (Fig.21,C), all observed in situ staining patterns were 
strongly susceptible to pre-digestion of the sections with heparinase I and II, but were unaffected by 
heparinase III digestion (Fig.23) 
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A
B
C
D
E
F
G
H
I
J
K
1    2    3    4    5    6   7    8    9 
A1,A2,A3: brain (gray matter);           A4,A5,A6: brain (white matter);            A7,A8,A9: cerebellum;
B1,B2,B3: adrenal gland;                   B4,B5,B6: ovary;                                   B7,B8,B9: pancreas; 
C1,C2,C3: parathyroid gland;            C4,C5,C6: hypophysis;                         C7,C8,C9: testis; 
D1,D2,D3: thyroid;                              D4,D5,D6: breast;                                 D7,D8,D9: spleen; 
E1,E2,E3: tonsil;                                 E4,E5,E6: thymus gland;                      E7,E8,E9: bone marrow; 
F1,F2,F3: lung;                                   F4,F5,F6: cardiac muscle;                    F7,F8,F9: esophagus; 
G1,G2,G3: stomach;                          G4,G5,G6: intestine;                              G7,G8,G9: colon; 
H1,H2,H3: liver;                                  H4,H5,H6: salivery gland;                     H7,H8,H9: kidney;
I1,I2,I3: prostate;                                 I4,I5,I6: endometrium;                           I7,I8,I9: uterine cervix; 
J1,J2,J3: skeletal muscle;                  J4,J5,J6: skin;                                       J7,J8,J9: peripheral nerve; 
K1,K2,K3: mesothelial ;                      K4,K5,K6: cornea;                                K7,K8,K9: larynx .
A CB
D E F
NML
H
O
IG
 
Fig.22. light micrographs of tissue microarray-Immunohistochemical assay (DAB, brown), X400.  
Human normal organ TMAs (Biomax, Inc., Rockville, US). (A): keratinized stratified squamous epithelia of 
the skin with mAb 4D1, (B) with mAb 10E4 and (C)with mAb HepSS1; (D): regular dense connective of 
resting mammary glands with mAb 4D1, (E) with mAb 10E4 and (F) with mAb HepSS1; (G): absorptive 
and goblet cells (arrow) of colon with mAb 4D1, (H) with mAb 10E4 and (I)with mAb 3G10; (L): smooth 
muscle cells under the vascular endothelium with 4D1 and (M)with 10E4; (N): glandular elements of resting 
mammary glands with mAb 4D1 and (O)with mAb 10E4.  
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Fig.23. light micrographs of  tumoral tissue microarray-  Immunohistochemical assay with mAb 4D1(DAB, 
brown), X400. 
(A): keratinized stratified squamous epithelia of the skin without any treatment and (B)after digestion with 
Heparinase III; (C): pseudo-stratified epithelium lining of bronchus without any treatment and (D)after 
digestion with Heparinase II; (E): hepatocytes of liver without any treatment and (F)after digestion with 
Heparinase I; (G): stratified squamous epithelium lining of esophagus without any treatment and (H)after 
digestion with Heparinase I  
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Fig. 24. light micrographs of tissue microarray -  Immunohistochemical assay with mAb 4D1 (DAB, brown), 
X100. 
(A): cerebral white matter; (B): purkinje fibers; (C): ovarian follicles; (D): endocrine cells of pancreas; (E): 
bone marrow; (F): salivary gland; (G): peripheral nerve; (H): cornea. 
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Fig.25. light micrographs of tissue microarray- immunohystochemical assay with mAb 4D1 (DAB, brown), 
X400. 
(A): stratified squamous epithelium lining of esophagus without any treatment and (B) with DNAse; (C): 
absorptive and globlet cells of colon with mAb 4D1 and (D)with  mAb 4D1 diluted in presence of heparin.
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Fig.26. light micrographs of blood vessels- immunohystochemical assay with mAb 4D1 (DAB, 
brown),X400. 
(A): capillaris of  uterine cervix; (B): hepatic artery and portal vein of portal canal; (C): medium-size venules 
of parathyroid; (D): capillaries and a small arteriola of spleen; (E): arteriola of scheletal muscle; (F): a small 
artery. 
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*): number of cell types with expression/staining compared to the total number of analyzed cell types; 
#
): colour coding indicating staining intensity defined as:   
                                                                                                 
                                                                                              
Organ Number of elements*
 
       Staining intensity
# 
Central nervous system 6  
Hematopoietic 4  
Liver and pancreas 3  
Digestive tract 13  
Respiratory system 5  
Cardiovascular system 2  
Female tissues 8  
Male tissues 5  
Urinary tract 4  
Skin and soft tissues 5  
Endocrine tissues 4  
Special senses 2  
Table 7. Comprehensive distribution map of HSs recognized by mAb 4D1 in healthy tissues 
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Tissue/organ 
Antibody 
4D1 10E4 HepSS-1 3G10 
Staining 
intensity
 
Cellular 
localization
 
Staining 
intensity 
Cellular 
localization 
Staining 
intensity 
Cellular 
localization 
Staining 
intensity 
Cellular 
localization 
 
Cerebral cortex: 
              white matter 
                gray matter 
 
Cerebellar cortex: 
               granular layer 
               Purkinje cell layer 
               molecular layer 
 
Peripheral nerves 
 
Cardiac muscle 
 
Blood vessels 
 
Spleen 
 
Lung 
 
Larynx: 
               mucous secreting cells 
               epithelium 
 
 
+ 
+ 
 
 
+/++ 
+/++ 
+ 
 
++/+++ 
 
++ 
 
+++ 
 
++/+++ 
 
+/++ 
 
 
- 
++/+++ 
 
 
C 
C 
 
 
C 
C 
C 
 
C/N 
 
C 
 
C/N 
 
C 
 
C/N 
 
 
n.a. 
C/N 
 
 
- 
- 
 
 
- 
- 
- 
 
n.a. 
 
-/++ 
 
+++ 
 
- 
 
- 
 
 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
n.a. 
 
n.a. 
 
BM 
 
C 
 
n.a. 
 
n.a. 
 
 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
n.a. 
 
n.a. 
 
n.a. 
 
++ 
 
+ 
 
n.a. 
 
 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
n.a. 
 
n.a. 
 
         n.a. 
 
n.a. 
 
C/N 
 
n.a. 
 
 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
n.a. 
 
n.a. 
 
n.a. 
 
++/+++ 
 
n.a. 
 
n.a. 
 
 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
n.a. 
 
n.a. 
 
n.a. 
 
C 
 
n.a. 
 
n.a. 
 
 
n.a. 
n.a. 
Table 8. Comparison of the immunoreactivity patterns of mAbs 4D1, 10E4, HepSS-1 and 3G10 on human normal tissues 
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               submucosa 
               cartilage 
 
 
Salivary gland: 
               mucous secretory unit 
               serous secretory unit 
 
Esophagus: 
               epithelium 
               basal lamina 
               muscolaris mucosa 
 
Stomach: 
               epithelium 
               mucosa 
               sub mucosa 
 
Small intestine: 
               epithelium 
               sub mucosa                
               muscolaris  mucosa 
 
Colon: 
               epithelium 
               lamina propria 
 
Liver: 
               hepatocytes 
               intralobular structures 
 
Pancreas 
 
Kidney: 
++/+++ 
- 
 
 
 
- 
++ 
 
 
++ 
- 
+/++ 
 
 
++ 
-/+ 
++ 
 
 
++ 
+ 
+ 
 
 
++/+++ 
+ 
 
 
+++ 
+++ 
 
+++ 
 
 
C 
n.a. 
 
 
 
n.a. 
C/N 
 
 
C 
n.a. 
N 
 
 
C/N 
C 
C 
 
 
C/N 
C 
C 
 
 
C/N 
C 
 
 
C/N 
C 
 
C 
 
 
n.a. 
n.a. 
 
 
 
- 
- 
 
 
- 
+ 
- 
 
 
- 
++ 
++ 
 
 
- 
++ 
- 
 
 
+++ 
+++ 
 
 
- 
- 
 
+++ 
 
 
n.a. 
n.a. 
 
 
 
n.a. 
n.a. 
 
 
n.a. 
BM 
n.a. 
 
 
n.a. 
BM 
BM 
 
 
n.a. 
C 
n.a. 
 
 
C 
C 
 
 
n.a. 
n.a. 
 
BM 
 
 
n.a. 
n.a. 
 
 
 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
n.a. 
 
n.a. 
n.a. 
 
n.a. 
 
 
n.a. 
n.a. 
 
 
 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
n.a. 
 
n.a. 
n.a. 
 
n.a. 
 
 
n.a. 
n.a. 
 
 
 
n.a. 
n.a. 
 
 
+++ 
- 
++ 
 
 
++ 
++ 
n.a. 
 
 
+++ 
- 
- 
 
 
+++ 
++/+++ 
 
 
++ 
+++ 
 
++/+++ 
 
 
n.a. 
n.a. 
 
 
 
n.a. 
n.a. 
 
 
C 
n.a. 
C 
 
 
C 
C 
n.a. 
 
 
C 
n.a. 
n.a. 
 
 
C/N 
C/N 
 
 
C 
C 
 
C 
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               renal glomeruli 
               podocytes 
               Bowman’s capsule 
               ducts 
 
Testis: 
               Leydig’s cells 
               seminiferous tubule 
 
Prostate gland: 
               mucosal gland 
               mast cells 
               connective capsule 
 
Ovary: 
               follicle 
               stromal cells 
 
Uterus: 
               endometrium 
               submucosa 
               muscolaris mucosa 
               uterine cervix 
 
Breast: 
               fibroblasts 
               connective tissue 
 
C-cells of thyroid gland 
                
Parathyroid gland 
 
Thymus 
 
- 
-/+ 
- 
++ 
 
 
++/+++ 
++ 
 
 
++ 
+++ 
++ 
 
 
+++ 
++ 
 
 
++/+++ 
++ 
++ 
++/+++ 
 
 
+++ 
++/+++ 
 
+++ 
 
+++ 
 
-/+++ 
 
n.a. 
C/N 
n.a. 
C 
 
 
C 
C 
 
 
C 
C 
C 
 
 
N 
N 
 
 
C 
C 
C 
C 
 
 
C 
C/N 
 
N 
 
C/N 
 
C 
 
- 
- 
- 
- 
 
 
++ 
++ 
 
 
- 
- 
- 
 
 
- 
- 
 
 
- 
++ 
+ 
n.a. 
 
 
+++ 
+++ 
 
n.a. 
 
n.a. 
 
n.a. 
 
n.a. 
n.a. 
n.a. 
n.a. 
 
 
C 
C 
 
 
n.a. 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
 
 
n.a. 
BM 
BM 
n.a. 
 
 
C/N 
BM 
 
n.a. 
 
n.a. 
 
n.a. 
 
++ 
+++ 
+++ 
+++ 
 
 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
n.a. 
 
 
- 
+ 
 
 
n.a. 
n.a. 
n.a. 
n.a. 
 
 
+++ 
- 
 
++ 
 
n.a. 
 
n.a. 
 
C/N 
C/N 
C/N 
C/N 
 
 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
n.a. 
 
 
n.a. 
N 
 
 
n.a. 
n.a. 
n.a. 
n.a. 
 
 
N 
n.a. 
 
N 
 
n.a. 
 
n.a. 
 
n.a. 
n.a. 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
 
n.a. 
 
n.a. 
 
n.a. 
 
n.a. 
n.a. 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
n.a. 
n.a. 
 
 
n.a. 
n.a. 
 
n.a. 
 
n.a. 
 
n.a. 
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Tonsil 
 
Hypophysis 
 
Adrenal gland 
 
 
Skin: 
               epidermis 
               dermis 
               fibroblasts 
 
Smooth muscle 
 
Skeletal muscle 
 
Bone marrow 
 
Eye: 
               epithelium 
               connective tissue 
-/+++ 
 
-/++ 
 
+++ 
 
 
 
++ 
- 
           - 
 
+/++ 
 
+/++ 
 
++/+++ 
 
 
+++ 
- 
 
C/N 
 
C 
 
C 
 
 
 
C 
n.a. 
n.a. 
 
C 
 
C/N 
 
C 
 
 
N 
n.a. 
 
n.a. 
 
n.a. 
 
+++ 
 
 
 
n.a. 
n.a. 
- 
 
n.a. 
 
- 
 
n.a. 
 
 
n.a. 
n.a. 
 
n.a. 
 
n.a. 
 
C/N 
 
 
 
n.a. 
n.a. 
n.a. 
 
n.a. 
 
n.a. 
 
n.a. 
 
 
n.a. 
n.a. 
 
n.a. 
 
n.a. 
 
n.a. 
 
 
 
+++ 
- 
+++ 
 
n.a. 
 
+++ 
 
n.a. 
 
 
n.a. 
n.a. 
n.a. 
 
n.a. 
 
n.a. 
 
 
 
C 
n.a. 
N 
 
n.a. 
 
C/N 
 
n.a. 
 
 
n.a. 
n.a. 
n.a. 
 
n.a. 
 
n.a. 
 
 
 
n.a. 
n.a. 
n.a. 
 
n.a. 
 
n.a. 
 
n.a. 
 
 
n.a. 
n.a. 
 
n.a. 
 
n.a. 
 
n.a. 
 
 
 
n.a. 
n.a. 
n.a. 
 
n.a. 
 
n.a. 
 
n.a. 
 
 
n.a. 
n.a. 
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3.3. Immunomapping of keratan sulphates  
In collaboration with the group Seikagaku biobusiness corporation LAL & Biochemicals Marketing 
Department and Research we studied the characteristic of KS linked to aggrecan, through SDS 
techniques (Fig.27,A and B) and we evaluated the linkage of the monoclonal antibody 373E1 with 
KS through TEM photograph (Fig.27,C). Studies on this mAb was performed in comparison with 
those of another specific known antibody against intact keratan sulphate chains, mAb BCD4 
(Seikagaku). 
                   
Fig.27. (A): run on a 5% agaros gel of KS moieties without digestion and after digestion with Keratanase 
II;enzimatic digestion degrades all KS moieties; (B): SDS-PAGE on gel with gradient of 3%-8% of KS 
moieties without digestion and after two different enzimatic digestion: with Endo-β.galactosidase and with 
Chondroitinase ABC. Gel gradient detain all big moieties like no-digested aggrecan, while Endo-
β.galactosidase cut all moieties. Cheratanase ABC is used for a control digestion; (C): molecules of aggrecan 
showed by TEM. The core of aggrecan is compounded of uronic acid while KS-regions they are presents 
toward the outside of aggreacan. Arrows indicate the 373E1 moieties; part of them are linked to KS-regions 
while an other part of them are not-linked  
 
3.3.1. Definition of the specificity of the anti-KS mAb 373E1 
Characterization of mAb 373E1 was performed. Primarely 373E1 and BCD4 reactivity was tested 
on different GAG preparation, suggesting that both the antibodies specifically recognize KS 
moieties (Fig.28,A). The specificity of binding was examine by digestion of biotinylated-KS with 
Keratanase II (Fig.28,B). MAb 373E1 bound to non-treated biotinylated-KS and did not bind to 
digested-biotinylated-KS the same as mAb BCD4. These data confirmed that 373E1 specifically 
recognized KS. Reactivity of 373E1 and BCD4 to keratan sulphate from bovine cornea (KS(BC)) 
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and keratan polysulphate from shark (KPS-1) were compared with inhibition assay. BCD4 reacted 
stronger with KPS-1 than KS(BC) (Fig.28,D). On the other hand, 373E1 reacted stronger with 
KS(BC) than KPS-1(Fig.28,C) and reactivity of 373E1 to KPS-1 was very weak. Reactivity of 
373E1 and BCD4 to some NaCl-eluted fractions of anion-exchange column chromatography in 
KS(BC) and KPS-1 were compared in the same as above. BCD4 basically reacted stronger with 
higher NaCl fraction in KPS-1 and KS(BC). It is thought from these results that activity of BCD4 is 
mainly dependent on sulphation in KS. On the other hand, 373E1 did not react with any KPS 
fractions and react with higher salt fractions of KS(BC). It is presumed from these results that 
activity of 373E1 is dependent on not only sulphation but also structures in KS and 373E1 may 
strictly recognize any unique structures in KS. 
      
Fig.28. (A): binding test for 373E1 and BCD4 to various GAG preparations, HA: Hyarulonic acid Ch: 
Chondroitin CSA, (W): Chondroitin sulfate A from whale cartilage, CSC: Chondroitin sulfate C from shark 
cartilage, CSD: Chondroitin sulfate D from shark cartilage, CSE: Chondroitin sulfate E from squid cartilage, 
HS: Heparan sulfate from bovine kidney, HEP: Heparin from pig intestine. (B): specificity of the binding of 
373E1 and BCD4 with and without digestion of Bi-KS with Keratanase III. (C): inhibition assays of NaCl-
eluted fractions of KS(BC) and KPS in anion-exchange column chromatography for mAb 373E1. (D): 
inhibition assays of NaCl-eluted fractions of KS(BC) and KPS in anion-exchange column chromatography 
for mAb BCD4.  
KS(BC): keratan sulfate from bovine cornea; KPS-1: keratan polysulphate from shark. 
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3.3.2. Immunohistochemical staining patterns  
MAb 373E1 may be used for both immunochemical and immunofluorescence staining (Fig. 29), but 
we performed the KS mapping throught the classical immunohistochemical staining. The assays 
were performed to evaluate the distribution pattern of both mAbs 373E1 and BCD4. Tissue 
microarray were employed to evaluate the immunostaining of antibodies in many human normal 
tissues  
Epithelial tissues: immunohistochemistry of epithelial tissues with mAb 373E1 (Fig.30) revealed 
that pseudo-stratified epithelium (Fig. 30,A) was negative instead a very weak positivity of the 
apical portion of the cells. Both absorptive and goblet cells of colon (Fig. 30,B) and the gastric 
mucosa (Fig. 30,C) showed a more intense cytoplasmatic expression for the epitope recognized by 
the mAb; mucus resulted always negative. Stratified squamous epithelia, for example those of the 
skin, of the esophagus or of the cervix (data not shown). and basal membrane (data not shown), 
were also negative. Epithelial cells of the liver (Fig. 30,E), lung (Fig. 30,F), prostatic and uterine 
glandular epithelium, and podocytes of  kidney (Fig. 30,D), showed a weak immunoexpression. 
The immunoexpression of mAb BCD4 (Fig. 31) was positive in stratified squamous epithelia of the 
skin (Fig. 30,A) and in absorptive and goblet cells of colon (Fig. 30,B). In colon mocous was 
negative while lumen of mucosal cells were positive. Glandular epithelium of uterus (Fig. 30,C) 
showed a strong coloration on the apical layer, and the same is for cuboidal cells that forms kidney 
proximal ducts (Fig. 30,D), while the rest resulted negative.  
Connectival tissues: Both dense and loose connective (Fig.32) showed a weak diffuse positivity 
with mAb 373E1, as shown in of dense regular connective of resting mammary gland (Fig. 32,A) 
and loose connective surrounding mucous glands of the bronchus (Fig. 32,C). 
Immunoexpression for BCD4 in connectival tissues was the same showed for 373E1 (Fig. 32.) with 
a weak diffuse positivity both in dense (Fig. 32,B) and loose (Fig. 32,D) connective.  
Muscolar tissues: In figure 32, microphotographs shows a very pale immunoexpression in a skeletal 
muscle (Fig. 32,E). All the other muscular tissues, smooth and cardiac, resulted completely negative 
for this antibody (data not shown).  
Immunoexpression of muscle tissues was a little more intense for mAb BCD4 (Fig32,F) compared 
to that for mAb 373E1. As for 373E1 this positivity is diffused and is the same for all types of 
muscle (in figure 32, F is shown the skeletal muscle while the cardiac and smooth muscle are not 
shown) 
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Nervous tissues: Both white matter (Fig.33,A) and grey matter (Fig.33,C) of cerebellum were 
negative for 373E1, while immunoexpression of BCD4 in nervous tissues (Fig.33,B and D) was 
very strong.  
Endocrine tissue: microphotographs in figure 33, E showed a pale immunoexpression for mAb 
373E1 in pancreatic cells, while the same cells resulted negative for mAb BCD4 (data not shown). 
The other neuro-endocrine tissues, such as thyroid and adrenal gland resulted negative with both 
antibodies (data not shown). 
Enzimatic digestion: enzymatic digestion of different tissues with Endo-β-galactosidase and 
Keratanase II demonstrated different results. In some tissues the enzimatic digestion eliminated 
totally the immunoexpression, while in other tissues the immunopositivity was not completely 
eliminated. The studies about this treatment will be continue to have more precise data.                       
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 Fig. 29. light micrographs of tissue microarray with mAb 373E1.  
Immunohistochemical staining of (A) human adult cartilage and (B)fetal pancreas, immunofluorescence 
staining of (C)human adult duct of kidney and (D)a glomerulus.  
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Fig.30. light micrographs of tissue microarray-Immunohistochemical assay with mAb 373E1 (DAB, brown), 
X400. 
(A): pseudo-stratified epithelium lining of bronchus;(B): absorptive and goblet cells of colon;(C): gastric 
mucosa; (D):glomerulus and podocytes attached to glomerular capillaries;(E): hepatocytes separated by 
hepatic sinusoids: (F): cuboidal alveolar cells of lung. 
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 Fig.31. light micrographs of tissue microarray-Immunohistochemical assay with mAb BCD4 (DAB, brown), 
X400. 
(A): keratinized stratified squamous epithelia of the skin; (B): absorptive and goblet cells of colon;( C): 
glandular epithelium of uterus;(D): glomerulus and podocytes  attached to glomerular capillaries and cuboidal 
cell of kidney duct (arrow). 
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Fig.32. light micrographs of tissue microarray-Immunohistochemical assay with mAb 373E1 and mAb BCD4 
(DAB, brown), X400. 
(A): regular dense connective of resting mammary glands, mAb 373E1; (B): regular dense connective of 
resting mammary glands, with mAb BCD4 (C):  loose connective that surround a mucousal gland associated 
with bronchus with mAb 373E1; (D):  loose connective of esophagus with mAb BCD4 ( E):  muscle skeletal 
fibers grouped into fascicles running longitudinally through the section with mAb 373E1; (F):  muscle 
skeletal fibers grouped into fascicles running longitudinally through the section with mAb BCD-4. 
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Fig. 33. light micrographs of tissue microarray-Immunohistochemical assay with mAb 373E1 and mAb 
BCD4 (DAB, brown), X400. 
 (A): white matter of cerebellum with mAb 373E1; (B): white and grey matter of cerebellum with mAb 
BCD4; (C): grey matter of cerebrum with mAb 373E1; (D): grey matter of cerebrum with mAb BCD4. (E): 
endocrine cells of pancreas with mAb 373E1. 
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The recent literature underlines as PGs may directly influence different cell functions, in 
normal as well as in pathological conditions. In particular recent works put the attention on the PGs 
involvement in the process of neoplastic transformation. Also if some PGs are well known to inhibit 
or to promote malignant transformation and tumor growth, others show a dual and controversal 
role: this is the case of the glypicans family. For example the inactivation of GPC3 and GPC5 genes 
seems to be related with an higly incidences of lung and breast carcinomas, mesothelioma and 
gastric cancer [Lin et al., 2012; Murthy et al., 2000; Xiang et al., 2001; Zhang et al., 2011; Zhu et 
al., 2002] while on the other hand genomic amplification of the 13q31.3 chromosome are suggested 
to be correlated with lymphomas [Yu et al., 2003] and rhabdomyosarcomas [Li et al., 2011; 
Williamson et al., 2007]. For this reason get off the hypothesis that role of GPCs in the 
tumorigenesis process may be specifically tumor-type correlated and may be influenced by their 
interactions with different ligands.  
Glypicans are expressed in particular during development, suggesting that they play a central role in 
cell proliferation and morphogenesis and in regulating different heparin-binding growth factors in a 
tissue- and cell-specific manner. Among glypicans, GPC5 is the less well known, both for its 
involvement in normal and pathological conditions. Different studies correlated GPC5 expression 
modification with tumor progression [Li et al., 2011; Williamson et al., 2007; Yu et al., 2003; 
Zhang et al., 2011]. In this work we wanted to investigate the GPC5 role in the particular context of 
the soft tissue sarcomas, about that there are very few informations. After a deep study of the cell 
surface PG expression patterns of different sarcoma cell lines, we have identified a particular 
osteosarcoma cell line, 143B cells, characterized by a rather complex pattern of PG expression. We 
started with the construction of a cell model obtained by de novo surface expression of GPC5 and 
called 143B 5+. First we investigated the GPC5 cell surface localization by immunofluorescence 
and confocal analysis. The microscopic evaluation of GPC5 expressing cells suggest that the GPC5 
localizes in particular cell surface regions that may correspond with reinforcement areas 
prevalentely located on filopodia. This allow us to advance the hypothesis that GPC5 may be 
involved in cell adhesion and motility. The first evidence of this is the correlation between 
citoskeletal organization and GPC5 localization. The study of the actin filaments network suggests 
that GPC5 is mainly distributed in specific membrane areas where actin forms reinforcing structures 
and that it may be involved in the cytoskeletal reorganization during cell movement. The 
investigation of GPC5-focal adhesion plaques correlation seems to support this hypothesis. We 
could observe that different focal adhesion molecules seems to colocalize with GPC5 and may be 
influenced by the presence of the PG. To deepen investigate the GPC5 involvement in the cell 
adhesion phenomena, we evaluate the ability of 143B 5+ cells to adhere on different ECM matrices 
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or in a anchorage-independent way. Our data suggest that GPC5 may affect cell ability to adhere on 
ECM components, such as collagene type III, collagene type VI, fibronectin and vitronectin. 
Probably GPC5 is involved in the interaction with particular integrin moieties that are related with 
the cell adhesion to these specific ECM matrices. In condition of anchorage independence, the 
presence of GPC5 on the cell surface seems to inhibit the cell growth capacity, prompting an 
inhibition influence of GPC5 on the survival of circulating cancer cells. Cell proliferation assays 
suggest us that GPC5 may be involved also in the proliferation capacity of 143B cells. More deeply, 
when GPC5 is expressed on the membrane, cells undergo a sensibly reducing in their proliferation 
rate, also in presence of growth factor such as VEGF, HGF or Wnt1. All these data support the idea 
that GPC5 may affect cell survival and proliferation, becaming a good candidate as tumor 
suppressor.  
De novo expression of GPC5 was also tested in in vivo mouse models to investigate the influence of 
GPC5 on the whole tumor mass. The first important result obtained from in vivo inoculation of 
143B 5+ and control cells, was that the presence of GPC5 on the injected cells seems to inhibit the 
tumor mass growth. Conseguentely vascolarization of masses GPC5 positive results reduced respect 
to control, but the vascular perfusion does not appear altered suggesting that GPC5 does not 
influence the tumor vascular compartement. Immunostaining of the vascular network with marker 
for both endothelial and pericyte compartements, confirms that GPC5 probably does not influences 
the tumor vasculogenesis. To understand what is the basis of this anti-tumoral capacity, we 
investigated different aspect of tumorigenesis throughout imunostaining of the tumors masses. We 
observed that the human 143B 5+ cells injected in mouse have the possibility to survive in the 
murine environment and they may be observed within the murine masses. These cells seem to retain 
the same GPC5 membrane localization observed in in vitro assays. This data is confermed also by 
gene transcript analysis. Interestingly, investigations on the proliferation rate of both human and 
murine cells and on the apoptotic rate do not show any particular differences between tumor masses 
obtained from 143B 5+ and control inocula. 
Osteosarcoma cells transfected to over-express GPC6 show a behavior that is similar to what 
observed for control cells. 
These data permits us to specifically ascribe to GPC5 expression all the characteristics of 143B 5+ 
cells. 
We have therefore raised a unique anti-HS antibody denoted 4D1 that reacts with high 
affinity with heparin and highly sulfated HS variants and permits the immunolocalization of unique 
HS moieties in cells and tissues. The structural requirements of mAb 4D1 for antigen recognition 
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appear clearly distinct from those of several of the previously described anti-HS antibodies, 
including 10E4, 3G10, and HepSS1, although some overlapping traits were noted. Divergency for 
optimal antigen binding was observed with regard to sulfation degree, considering both 2-O- and 6-
O-sulfation, and N-acetylation. The use of a panel of oligosaccharides of defined sizes and sulfation 
patterns further allowed us to establish that the epitope of mAb 4D1 must be contained within a 
tetrasaccharide HS unit. These observations lends further support to the notion that the epitope may 
be different than those recognized by the above previously described anti-HS antibodies, as well as 
by a number of phage display-generated anti-HS antibodies that have been published over the years 
[Lensen et al., 2005; Kurup et al., 2007; Smits et al., 2006; Thompson et al., 2009; van de Westerlo 
et al., 2002]. In accordance with its diverse epitope recognition, mAb 4D1 detected in a 
differentiated manner specific HS variants in healthy adult human tissues and its immunoreactive 
pattern was markedly different than that previously documented for other anti-HS antibodies. A first 
striking difference was the lack of mAb 4D1-reactive HS variants in basement membranes of 
epithelial tissues composing the majority of the organs of the body. This finding is consistent with 
the preferential staining of basement membranes by mAb 10E4 reported in previous investigations 
[David et al., 1992; van der Born et al., 2005] and further documented in this study. Why basement 
membranes would benefit from HSs with a lower sulfation degree remains an enigma. This in 
particular in light of the fact that no differences in the staining patterns of mAb 10E4 and 4D1 were 
observed in vascular structures; although light microscopy may not provide a sufficient high 
resolution for determining this aspect, it would appear that basement membranes of endothelial cells 
may contain HS with a spectrum of sulfation degrees. Differential expression of mAb 10E4- and 
HepSS1-reactive HS variants in basement membranes versus cell surfaces has also been 
documented in previous studies and parallels the analogous differential expression observed here 
between mAb 4D1 and mAb 10E4. Which cell surface-associated HSPGs actually carry the more 
highly sulfated HS moieties in different epithelial tissues remains to be further established. On the 
other hand it is likely that more sulfated HS chains may more effectively engage in growth factor 
sequestering on the cell membrane and optimally contribute to ternary complexes between these 
factors and their cognate receptors [Ashikari-Hada et al., 2004; Deakin et al., 2009; Guglier et al., 
2008; Jastrebova et al., 2006; Jastrebova et al., 2010].    
In parallel with mAb 4D1, a unique anti-KS was raised and called 373E1. This monoclonal 
antibody specifically react with a particular KS chemical structure. Thanks to the work of our 
collaborators of the Seikagaku biobusiness corporation, it is shown that this particular structure is 
characterized by an high concentration of sialic acid and fucose. The epitope necessary for 373E1 
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binding appear clearly distinct from those recognized from previously described anti-KS antibodies, 
such as BCD4. The differences in the binding site appear to involve the chemical structure of KS 
moiety. The distribution pattern of these particular KS structures generally results overlapping with 
that of KS recognized by BCD4. MAb 373E1 immunoreactivity appear to be intense in colon and 
intestine tissues and weakly in all the other tissues. Moreover 373E1-binding KS seems to be 
completely absent from all types of nervous tissues, suggesting that this mAb does not recognizes 
KS type III that is specifically distributed in all the nervous system. As KS is one of the most 
heterogeneous and less studied GAG moieties [Funderburgh, 2002], the characterization of these 
mAb may provide an additional tool for the study of this moiety. 
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